<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004923" GROUP_ID="BREASTCA" ID="999103101721162268" MERGED_FROM="" MODIFIED="2010-08-03 01:37:23 +0200" MODIFIED_BY="Melina Willson" REVIEW_NO="60" REVMAN_SUB_VERSION="5.0.24" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2010-08-03 09:02:24 +1000" MODIFIED_BY="Melina Willson">
<TITLE MODIFIED="2010-07-25 21:57:34 +1000" MODIFIED_BY="[Empty name]">Non-hormonal interventions for hot flushes in women with a history of breast cancer</TITLE>
<CONTACT>
<PERSON ID="521BCAC782E26AA2019829A90CCF351D" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Gabriel</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Rada</LAST_NAME>
<SUFFIX/>
<POSITION>Assistant Professor</POSITION>
<EMAIL_1>radagabriel@hotmail.com</EMAIL_1>
<EMAIL_2>umbeuc@med.puc.cl</EMAIL_2>
<URL>http://www.umbeuc.cl</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Internal Medicine, Evidence Based Health Care Program</DEPARTMENT>
<ORGANISATION>Faculty of Medicine, Pontificia Universidad Católica de Chile</ORGANISATION>
<ADDRESS_1>Lira 44, Decanato Primer piso</ADDRESS_1>
<ADDRESS_2/>
<CITY>Santiago</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="CL">Chile</COUNTRY>
<PHONE_1>+56 2 354 3030</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2010-08-03 09:02:24 +1000" MODIFIED_BY="Melina Willson">
<PERSON ID="521BCAC782E26AA2019829A90CCF351D" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Gabriel</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Rada</LAST_NAME>
<SUFFIX/>
<POSITION>Assistant Professor</POSITION>
<EMAIL_1>radagabriel@hotmail.com</EMAIL_1>
<EMAIL_2>umbeuc@med.puc.cl</EMAIL_2>
<URL>http://www.umbeuc.cl</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Internal Medicine, Evidence Based Health Care Program</DEPARTMENT>
<ORGANISATION>Faculty of Medicine, Pontificia Universidad Católica de Chile</ORGANISATION>
<ADDRESS_1>Lira 44, Decanato Primer piso</ADDRESS_1>
<ADDRESS_2/>
<CITY>Santiago</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="CL">Chile</COUNTRY>
<PHONE_1>+56 2 354 3030</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="18195" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Daniel</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Capurro</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>dcapurro@med.puc.cl</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Internal Medicine, Evidence Based Health Care Program</DEPARTMENT>
<ORGANISATION>Faculty of Medicine, Pontificia Universidad Católica de Chile</ORGANISATION>
<ADDRESS_1>Lira 44 Decanato Primer piso</ADDRESS_1>
<ADDRESS_2/>
<CITY>Santiago</CITY>
<ZIP/>
<REGION>Región Metropolitana</REGION>
<COUNTRY CODE="CL">Chile</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="17015" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Tomas</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Pantoja</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>tpantoja@med.puc.cl</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Family Medicine, Evidence Based Health Care Program, Faculty of Medicine</DEPARTMENT>
<ORGANISATION>Pontificia Universidad Católica de Chile</ORGANISATION>
<ADDRESS_1>Lira 44. Edificio Decanato. Primer Piso</ADDRESS_1>
<ADDRESS_2/>
<CITY>Santiago</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="CL">Chile</COUNTRY>
<PHONE_1>+56 2 3548111</PHONE_1>
<PHONE_2>+56 2 3548688</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="18197" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Javiera</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Corbalán</LAST_NAME>
<SUFFIX/>
<POSITION>Resident</POSITION>
<EMAIL_1>jicorbal@puc.cl</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Family Medicine, Evidence Based Health Care Program, Faculty of Medicine</DEPARTMENT>
<ORGANISATION>Pontificia Universidad Católica de Chile</ORGANISATION>
<ADDRESS_1>Lira 44, Decanato Primer piso</ADDRESS_1>
<ADDRESS_2/>
<CITY>Santiago</CITY>
<ZIP/>
<REGION>Región Metropolitana</REGION>
<COUNTRY CODE="CL">Chile</COUNTRY>
<PHONE_1>+56 2 3548688</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="18202" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Gladys</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Moreno</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor</POSITION>
<EMAIL_1>gmoreno@med.puc.cl</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Family Medicine, Evidence Based Health Care Program, Faculty of Medicine</DEPARTMENT>
<ORGANISATION>Pontificia Universidad Católica de Chile</ORGANISATION>
<ADDRESS_1>Lira 44, Decanto Medicina</ADDRESS_1>
<ADDRESS_2/>
<CITY>Santiago</CITY>
<ZIP/>
<REGION>Metropolitana</REGION>
<COUNTRY CODE="CL">Chile</COUNTRY>
<PHONE_1>+56 2 3548688</PHONE_1>
<PHONE_2>+56 2 3548111</PHONE_2>
<FAX_1>+56 2 6645408</FAX_1>
<FAX_2>+56 2 5186760</FAX_2>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="18198" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Luz</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Letelier</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor</POSITION>
<EMAIL_1>lmletel@med.puc.cl</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Internal Medicine, Evidence Based Health Care Program</DEPARTMENT>
<ORGANISATION>Faculty of Medicine, Pontificia Universidad Católica de Chile</ORGANISATION>
<ADDRESS_1>Lira 44 Decanato Primer piso</ADDRESS_1>
<ADDRESS_2/>
<CITY>Santiago</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="CL">Chile</COUNTRY>
<PHONE_1>56 2 3543030</PHONE_1>
<PHONE_2>56 2 2880965</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="17379" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Claudio</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Vera</LAST_NAME>
<SUFFIX>MSc</SUFFIX>
<POSITION>Instructor Asociado</POSITION>
<EMAIL_1>cmverapg@med.puc.cl</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Obstetrics and Gynecology,Evidence Based Health Care Program</DEPARTMENT>
<ORGANISATION>Faculty of Medicine, Pontificia Universidad Católica de Chile</ORGANISATION>
<ADDRESS_1>Lira 85 5to piso</ADDRESS_1>
<ADDRESS_2/>
<CITY>Santiago</CITY>
<ZIP/>
<REGION>RM</REGION>
<COUNTRY CODE="CL">Chile</COUNTRY>
<PHONE_1>+56 2 686 3034</PHONE_1>
<PHONE_2/>
<FAX_1>+56 2 6333 1457</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2010-08-02 16:30:15 +1000" MODIFIED_BY="Melina Willson">
<UP_TO_DATE>
<DATE DAY="22" MONTH="8" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="22" MONTH="8" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="23" MONTH="8" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2004"/>
</DATES>
<WHATS_NEW MODIFIED="2010-06-04 10:35:12 +1000" MODIFIED_BY="Melina Willson"/>
<HISTORY MODIFIED="2010-07-26 12:24:33 +1000" MODIFIED_BY="Melina Willson"/>
<SOURCES_OF_SUPPORT MODIFIED="2008-10-06 05:57:37 +1100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2008-10-06 05:54:48 +1100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2008-10-06 05:54:48 +1100" MODIFIED_BY="[Empty name]">
<NAME>Pontificia Universidad Católica de Chile</NAME>
<COUNTRY CODE="CL">Chile</COUNTRY>
<DESCRIPTION>
<P>The University did not provide a specific support for the development of the review, but all the authors receive a fixed salary from the institution.</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2008-10-06 05:57:37 +1100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2008-10-06 05:57:37 +1100" MODIFIED_BY="[Empty name]">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-07-26 12:30:05 +1000" MODIFIED_BY="Melina Willson">
<SUMMARY MODIFIED="2010-06-24 17:10:27 +1000" MODIFIED_BY="Melina Willson">
<TITLE MODIFIED="2010-06-21 12:48:23 +1000" MODIFIED_BY="[Empty name]">Non-hormonal interventions for reducing hot flushes in women with a history of breast cancer</TITLE>
<SUMMARY_BODY MODIFIED="2010-06-24 17:10:27 +1000" MODIFIED_BY="Melina Willson">
<P>Breast cancer is one of the most frequent cancers worldwide and its treatment can produce disturbing symptoms including hot flushes, the sudden feeling of heat in the face, neck and chest. Hormonal treatments are used to control such symptoms in postmenopausal women but for women with a history of breast cancer these are not recommended as they can induce cancer growth. The aim of this review is to evaluate the efficacy of non-hormonal interventions in treating hot flushes in such women.<BR/>
<BR/>We found 10 randomised controlled studies assessing pharmacological therapies and six assessing non-pharmacological treatments (complementary or alternative therapies). The 10 studies on pharmacological therapies included two on clonidine (an antihypertensive that stimulates a norepinephrine receptor implicated in the initiation of flushes), one on gabapentin (an anticonvulsant that diminishes hot flushes through an unknown mechanism), six on selective serotonin or serotonin-norepinephrine reuptake inhibitors (antidepressants that increase the levels of serotonin and norepinephrine, both implicated in the generation of hot flushes) particularly venlafaxine, paroxetine, sertraline and fluoxetine, and one on vitamin E (mechanism unknown).</P>
<P>Clonidine, antidepressants and gabapentin reduced the number and severity of hot flushes. Vitamin E did not reduce the number or severity of hot flushes.</P>
<P>Of the six studies evaluating non-pharmacological therapies, two were on homeopathy (one evaluated a single homeopathic remedy in a group and the Hyland's menopause formula in a second group; and the other study evaluated homeopathic medicines in tablet, granule or liquid form, prepared by a single pharmacy), two on relaxation therapy (occupational therapist-guided relaxation consisting in stress management, written information about stress, deep breathing techniques, muscle relaxation and guided imagery), one on acupuncture (eight treatment sessions, 19 acupuncture points) and one on magnetic therapy (magnetic devices attached to participants' skin, placed over acupuncture or acupressure sites).</P>
<P>In the studies on non-pharmacological therapies, relaxation therapy was the only one that probably reduced the frequency and severity of hot flushes. Homeopathy, acupuncture and magnetic therapy may not lead to any differences in the number and severity of hot flushes.</P>
<P>One limitation of our review is that it is not possible to say if some treatments are better than others. Another limitation is that adverse effects were not clearly reported in all studies.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-07-12 11:31:31 +1000" MODIFIED_BY="Melina Willson">
<ABS_BACKGROUND MODIFIED="2010-06-21 12:41:38 +1000" MODIFIED_BY="[Empty name]">
<P>Hot flushes are common in women with a history of breast cancer. Hormonal therapies are known to reduce these symptoms but are not recommended in women with a history of breast cancer due to their potential adverse effects. The efficacy of non-hormonal therapies is still uncertain.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-05-14 14:28:10 +1000" MODIFIED_BY="Melina Willson">
<P>To assess the efficacy of non-hormonal therapies in reducing hot flushes in women with a history of breast cancer.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-07-12 11:31:31 +1000" MODIFIED_BY="Melina Willson">
<P>We searched the Cochrane Breast Cancer Group Specialised Register, CENTRAL (<I>The Cochrane Library</I>), MEDLINE, EMBASE, LILACS, CINAHL, PsycINFO (August 2008) and WHO ICTRP Search Portal. We handsearched reference lists of reviews and included articles, reviewed conference proceedings and contacted experts.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-05-14 14:29:08 +1000" MODIFIED_BY="Melina Willson">
<P>Randomized controlled trials (RCTs) comparing non-hormonal therapies with placebo or no therapy for reducing hot flushes in women with a history of breast cancer.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-06-21 12:42:23 +1000" MODIFIED_BY="[Empty name]">
<P>Two authors independently selected potentially relevant studies, decided upon their inclusion and extracted data on participant characteristics, interventions, outcomes and the risk of bias of included studies.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-06-21 12:48:03 +1000" MODIFIED_BY="[Empty name]">
<P>Sixteen RCTs met our inclusion criteria. We included six studies on selective serotonin (SSRI) and serotonin-norepinephrine (SNRI) reuptake inhibitors, two on clonidine, one on gabapentin, two each on relaxation therapy and homeopathy, and one each on vitamin E, magnetic devices and acupuncture. The risk of bias of most studies was rated as low or moderate. Data on continuous outcomes were presented inconsistently among studies, which precluded the possibility of pooling the results. Three pharmacological treatments (SSRIs and SNRIs, clonidine and gabapentin) reduced the number and severity of hot flushes. One study assessing vitamin E did not show any beneficial effect. One of two studies on relaxation therapy showed a significant benefit. None of the other non-pharmacological therapies had a significant benefit. Side-effects were inconsistently reported.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-06-20 19:48:33 +1000" MODIFIED_BY="[Empty name]">
<P>Clonidine, SSRIs and SNRIs, gabapentin and relaxation therapy showed a mild to moderate effect on reducing hot flushes in women with a history of breast cancer.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-07-26 12:30:05 +1000" MODIFIED_BY="Melina Willson">
<BACKGROUND MODIFIED="2010-07-26 12:25:11 +1000" MODIFIED_BY="Melina Willson">
<CONDITION MODIFIED="2010-07-26 12:25:11 +1000" MODIFIED_BY="Melina Willson">
<P>Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer-related mortality in women, worldwide. Annually, more than a million women are diagnosed with this condition and over 411,000 die (<LINK REF="REF-Ferlay-2004" TYPE="REFERENCE">Ferlay 2004</LINK>). Over 4.4 million women diagnosed with breast cancer in the last five years are currently alive, making breast cancer the most prevalent cancer (<LINK REF="REF-Parkin-2005" TYPE="REFERENCE">Parkin 2005</LINK>).</P>
<P>Women with breast cancer can experience climacteric symptoms, because of natural menopause but also as a consequence of the treatment they receive. Some breast cancer treatments target estrogen production which is known to impact on the growth of breast cancer (e.g. the endocrine therapies tamoxifen and aromatase inhibitors) and others impact on the natural function of the ovaries (chemotherapy) and cause premature menopause. One of the most common treatment-related symptoms is hot flushes (i.e. the sudden feeling of heat in the face, neck and chest) (<LINK REF="REF-WHO-1996" TYPE="REFERENCE">WHO 1996</LINK>), which occur more frequently and with more intensity in breast cancer treated women than in postmenopausal women (<LINK REF="REF-Gupta-2006" TYPE="REFERENCE">Gupta 2006;</LINK> <LINK REF="REF-McPhail-2000" TYPE="REFERENCE">McPhail 2000</LINK>). Hot flushes may interfere with normal habits, disrupt sleep and compromise quality of life (<LINK REF="REF-Carpenter-1998" TYPE="REFERENCE">Carpenter 1998</LINK>; <LINK REF="REF-Gupta-2006" TYPE="REFERENCE">Gupta 2006</LINK>; <LINK REF="REF-Stein-2000" TYPE="REFERENCE">Stein 2000</LINK>). Additionally, they may decrease long-term compliance with breast cancer therapy (<LINK REF="REF-Cella-2008" TYPE="REFERENCE">Cella 2008</LINK>).</P>
<P>The pathophysiology of hot flushes is still uncertain but is probably caused by an exaggerated response of the thermoregulatory centre in the hypothalamus that is induced by decreased estrogen and progesterone levels (<LINK REF="REF-Freedman-2005" TYPE="REFERENCE">Freedman 2005</LINK>). Another possible mechanism is sympathetic activation of central &#945;2-adrenergic receptors, which modulate the core temperature threshold needed for widespread cutaneous vasodilation and profuse upper body sweating.</P>
</CONDITION>
<INTERVENTION MODIFIED="2010-07-12 11:33:52 +1000" MODIFIED_BY="Melina Willson">
<P>For women without a history of breast cancer, hormone therapy with estrogen or combined estrogen and progestogen is highly effective for the treatment of hot flushes (<LINK REF="REF-MacLennan-2004" TYPE="REFERENCE">MacLennan 2004</LINK>), but their long term use increases the risk of various conditions, such as venous thromboembolism, cardiovascular diseases, dementia, gallbladder disease and breast cancer (<LINK REF="REF-Farquhar-2005" TYPE="REFERENCE">Farquhar 2005</LINK>). The trade-off between the potential benefit of alleviating symptoms with hormones and the increased risk of these conditions is still a matter of debate, but there is consensus that their use should be limited to the shortest possible period (<LINK REF="REF-Beral-2003" TYPE="REFERENCE">Beral 2003</LINK>; <LINK REF="REF-Chlebowski-2003" TYPE="REFERENCE">Chlebowski 2003</LINK>; <LINK REF="REF-Rossouw-2002" TYPE="REFERENCE">Rossouw 2002</LINK>).</P>
<P>Hormonal therapy is usually contraindicated in women with a history of breast cancer. Estrogen and progesterone promote epithelial growth and differentiation of breast cancer cells. Cellular concentrations of estrogen receptor or progesterone receptor are demonstrated in approximately 60% of breast cancer tumors and these are therefore considered to be hormonally responsive (<LINK REF="REF-Allegra-1980" TYPE="REFERENCE">Allegra 1980</LINK>). Confirming the latter, a recent randomized trial showed that treatment with a estrogen and progestogen combination more than doubled the risk of breast cancer recurrence after a median follow up of four years (<LINK REF="REF-Holmberg-2008" TYPE="REFERENCE">Holmberg 2008</LINK>). Additionally, women with breast cancer have an increased risk of thrombosis as a consequence of the disease itself or from treatments employed for long-term secondary prevention (for example tamoxifen). This, added to the well demonstrated risk of thrombosis associated with hormonal therapies, constitutes another reason to avoid hormonal therapies in this group of patients (<LINK REF="REF-Deitcher-2004" TYPE="REFERENCE">Deitcher 2004</LINK>; <LINK REF="REF-Rossouw-2002" TYPE="REFERENCE">Rossouw 2002</LINK>).</P>
<P>Progestational agents alone are effective in relieving hot flushes (<LINK REF="REF-Goodwin-2008" TYPE="REFERENCE">Goodwin 2008</LINK>) but theoretical concerns and in vitro data suggest they may unfavourably affect prognosis (<LINK REF="REF-Hofseth-1999" TYPE="REFERENCE">Hofseth 1999</LINK>). Observations from the Women's Health Initiative trial (WHI) also cast doubts on the long-term effects of progestational agents since an increase in breast cancer risk was observed in women enrolled in the estrogen-progestin arm of the study but not in the estrogen alone arm (<LINK REF="REF-Anderson-2004" TYPE="REFERENCE">Anderson 2004</LINK>; <LINK REF="REF-Rossouw-2002" TYPE="REFERENCE">Rossouw 2002</LINK>).</P>
<P>Other commonly employed options for hormone therapy are black cohosh, phytoestrogens and tibolone. All of these demonstrate possible estrogenic action, so their use in women with breast cancer is generally not recommended (<LINK REF="REF-Grady-2006" TYPE="REFERENCE">Grady 2006</LINK>; <LINK REF="REF-Sturdee-2008" TYPE="REFERENCE">Sturdee 2008</LINK>).</P>
<P>All these reasons have prompted the search for safer alternatives to treat hot flushes in women with a history of breast cancer. The concept of non-hormonal therapy has emerged and includes any treatment which is known not to have proven or supposed hormonal activity (to be estrogen-like).</P>
</INTERVENTION>
<THEORY MODIFIED="2010-06-21 13:48:49 +1000" MODIFIED_BY="[Empty name]">
<P>Anecdotal reports initially drew attention to the use of new generation antidepressants, selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), as a method of treating hot flushes (<LINK REF="REF-Loprinzi-2009" TYPE="REFERENCE">Loprinzi 2009</LINK>). Even though their mechanism of action is not widely understood, serotonin and noradrenaline (norepinephrine) act at various levels in the regulation of body temperature and the initiation of hot flushes (<LINK REF="REF-Sturdee-2008" TYPE="REFERENCE">Sturdee 2008</LINK>). A systematic review evaluating the effects of non-hormonal therapies in both postmenopausal and breast cancer related hot flushes identified six studies of SSRIs and SNRIs. This review concluded that there was some evidence for efficacy, but most studies had methodological deficiencies (<LINK REF="REF-Nelson-2006" TYPE="REFERENCE">Nelson 2006</LINK>).</P>
<P>Given the role of norepinephrine in the initiation of hot flushes, the &#945;2-adrenergic agonists clonidine and methyldopa have also been evaluated. The review by Nelson (<LINK REF="REF-Nelson-2006" TYPE="REFERENCE">Nelson 2006</LINK>) identified 10 and three studies respectively, and concluded that there was some benefit for clonidine in relieving hot flushes but adverse effects were frequent, whereas methyldopa was probably not effective.</P>
<P>Other options assessed for treating hot flushes include the anticonvulsant gabapentin and vitamin E (<LINK REF="STD-Barton-1998" TYPE="STUDY">Barton 1998</LINK>; <LINK REF="STD-Pandya-2005" TYPE="STUDY">Pandya 2005</LINK>). Their mechanisms of action are unknown.</P>
<P>Psychological factors may contribute to hot flushes. Some situations such as those causing embarrassment and stress can trigger hot flushes, probably through sympathetic activation. Interventions aimed at managing these aspects (<LINK REF="REF-Freedman-2005" TYPE="REFERENCE">Freedman 2005</LINK>) such as relaxation-based procedures, exercise and other non-pharmacological therapies have been investigated in postmenopausal women but with inconclusive results (<LINK REF="REF-Daley-2007" TYPE="REFERENCE">Daley 2007</LINK>; <LINK REF="REF-Loprinzi-2008" TYPE="REFERENCE">Loprinzi 2008</LINK>; <LINK REF="REF-Sturdee-2008" TYPE="REFERENCE">Sturdee 2008</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2010-06-21 13:51:34 +1000" MODIFIED_BY="[Empty name]">
<P>Current evidence does not support the safety of any hormonal therapy for women with a history of breast cancer. Therefore, a rigorous evaluation of non-hormonal alternatives is highly relevant.</P>
<P>The review by Nelson (<LINK REF="REF-Nelson-2006" TYPE="REFERENCE">Nelson 2006)</LINK> did not find clear evidence of a different effect of therapies between postmenopausal women and women receiving tamoxifen. However, this conclusion was based on few studies with important methodological limitations.</P>
<P>Considering the different physiology underlying hot flushes in women with breast cancer, it is important to evaluate this group separately. Based on the current available information it is premature to assume that effective therapies in postmenopausal women will have the same effect in women with a history of breast cancer.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-06-21 13:51:43 +1000" MODIFIED_BY="[Empty name]">
<P>The aim of this review was to assess the efficacy of non-hormonal interventions for the treatment of hot flushes in women with a history of breast cancer.</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-07-26 12:29:14 +1000" MODIFIED_BY="Melina Willson">
<SELECTION_CRITERIA MODIFIED="2010-07-26 12:28:07 +1000" MODIFIED_BY="Melina Willson">
<CRIT_STUDIES MODIFIED="2010-06-21 13:52:02 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled clinical trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-06-21 13:53:09 +1000" MODIFIED_BY="[Empty name]">
<P>Women of any age experiencing any of the following.</P>
<P>1. Hot flushes due to endocrine therapy for breast cancer treatment. Endocrine therapy includes:</P>
<UL>
<LI>surgical removal of the ovaries;</LI>
<LI>hormonal manipulation leading to symptoms of estrogen deficiency (such as with tamoxifen, fulvestrant or aromatase inhibitors).</LI>
</UL>
<P>2. Hot flushes due to menopause secondary to treatment for breast cancer (chemotherapy or radiation therapy) and with or without concomitant endocrine therapy.</P>
<P>3. Hot flushes due to menopause in women with a history of breast cancer.</P>
<P>We included studies that evaluated a combination of women with a history of breast cancer and perimenopausal women if data from the breast cancer patients were presented separately or &gt; 80% of participants had the above-mentioned criteria.<BR/>
<BR/>
</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-06-21 13:55:57 +1000" MODIFIED_BY="[Empty name]">
<P>Any trial assessing a non-hormonal therapy compared to placebo or a non-treated control group.</P>
<P>Non-hormonal therapy was defined as any treatment which is known not to have proven or supposed hormonal activity (not estrogen-like).</P>
<P>We included the following.</P>
<UL>
<LI>Pharmacological agents such as: vitamin E, clonidine, ergotamine-phenobarbital-belladona, gabapentin, veralipride, SSRIs and SNRIs (venlafaxine, paroxetine, sertraline, fluoxetine, mirtazapine, trazodone).</LI>
</UL>
<UL>
<LI>Non-pharmacological therapies such as: meditation, yoga, ayurveda, aromatherapy, acupuncture, magnetic therapy, applied relaxation, biofeedback, hypnosis, behavioural treatments (breathing exercises like paced respiration, aerobic exercise).</LI>
</UL>
<P>We excluded studies evaluating the following compounds because they have proven or possible estrogen-like mechanisms:<BR/>
</P>
<UL>
<LI>plant phytoestrogens (i.e. isoflavones that are derived from soy or red clover);</LI>
<LI>black cohosh, or <I>Cimicifuga racemosa (</I>
<LINK REF="REF-Fitzpatrick-2003" TYPE="REFERENCE">Fitzpatrick 2003</LINK>);</LI>
<LI>tibolone.</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-07-26 12:28:07 +1000" MODIFIED_BY="Melina Willson">
<P>Hot flushes were defined as a sudden sensation of heat or sweat centered on the face and upper chest.<BR/>
</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2010-07-26 12:28:04 +1000" MODIFIED_BY="Melina Willson">
<UL>
<LI>Frequency of hot flushes.</LI>
<LI>Severity of hot flushes as reported through validated instruments such as patient diaries or other well-validated methods.</LI>
<LI>Hot flushes scores were considered if they included frequency and severity of hot flushes.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2010-07-26 12:28:07 +1000" MODIFIED_BY="Melina Willson">
<UL>
<LI>Recurrence of breast cancer or survival, or both.</LI>
<LI>Any side-effects of non-hormonal therapies or any effect not listed as an outcome and reported as a side-effect by the authors.</LI>
<LI>Health-related quality of life as measured by any validated generic or condition-specific instrument.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-07-26 12:28:24 +1000" MODIFIED_BY="Melina Willson">
<ELECTRONIC_SEARCHES MODIFIED="2010-07-26 10:01:52 +1000" MODIFIED_BY="Melina Willson">
<P>1) The following electronic databases were searched with no language or publication restrictions.</P>
<P>(a) Cochrane Breast Cancer Group Specialised Register (22 August 2008). Details of the search strategy used by the Group for the identification of studies for the Register, and the procedure used to code references, are outlined in the Group's module (<A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/BREASTCA/frame.html">www.mrw.interscience.wiley.com/cochrane/clabout/articles/BREASTCA/frame.html</A>). Studies with any of the keywords 'hot flush', 'hot flushes', 'hot flash', 'hot flashes', 'vasomotor symptoms', 'non-hormonal therapy', 'non hormonal therapy', 'selective serotonin reuptake inhibitors' or 'SSRI' were extracted for consideration.</P>
<P>(b) Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2008, Issue 3), <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>(c) CINAHL (1982 to August 2008), <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<P>(d) PsycINFO (1887 to August 2008), <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>.</P>
<P>(e) LILACS (1986 to August 2008), <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>.</P>
<P>(f) Considering that CENTRAL includes MEDLINE and EMBASE, we only made supplementary searches in these databases as old articles may not be well indexed (MEDLINE: January 1966 to December 2005, <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>; EMBASE: 1974 to April 2005, <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>).</P>
<P>(g) WHO International Clinical Trials Registry Platform (ICTRP) Search Portal (performed search 21 May 2010) (http://apps.who.int/trialsearch/), <LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2010-07-26 12:28:24 +1000" MODIFIED_BY="Melina Willson">
<P>2) Grey literature.</P>
<P>In order to identify articles potentially missed through the electronic searches, grey literature and unpublished studies, an expanded search was performed that included the following strategies:</P>
<P>(a) handsearching of reference lists of all retrieved articles, texts and other reviews on the topic;<BR/>(b) handsearching of conference proceedings of the ASCO Annual Meeting (2000 to 2004); and<BR/>(c) contacting experts for further information: the Cochrane Breast Cancer Review Group and key authors of publications included in this review.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-07-26 12:29:14 +1000" MODIFIED_BY="Melina Willson">
<P>We performed the analysis in accordance with the guidelines published in the Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (<LINK REF="REF-Cochrane-Handbook" TYPE="REFERENCE">Cochrane Handbook</LINK>).<BR/>
</P>
<STUDY_SELECTION MODIFIED="2010-07-26 12:28:55 +1000" MODIFIED_BY="Melina Willson">
<P>Titles and abstracts identified through the search strategy were scanned independently by two authors (GM and JC). If no abstract was available the full-text paper was obtained for detailed evaluation. Two authors (DC and GR) then independently assessed the full text of all potentially eligible trials against the above mentioned criteria for inclusion in the review.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-07-26 12:29:14 +1000" MODIFIED_BY="Melina Willson">
<P>Two authors (DC and GR) independently extracted data using forms designed for this review. Extracted data included: number of participants allocated to each group, losses to follow up, exclusions and the reasons, number of participant centres, study setting, baseline characteristics of patients (i.e. age, breast cancer status, tamoxifen use), intervention characteristics (i.e. dose and duration), frequency of hot flushes, severity, score, quality of life and adverse effects.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-06-21 14:04:26 +1000" MODIFIED_BY="[Empty name]">
<P>The risk of bias of the included studies was assessed by two authors (DC and GR) using the criteria established in the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Cochrane-Handbook" TYPE="REFERENCE">Cochrane Handbook</LINK>). A third author (TP) resolved any discrepancies.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-06-25 12:08:28 +1000" MODIFIED_BY="Melina Willson">
<P>Most outcomes were presented as continuous data. For the majority of studies it was not possible to directly obtain the standard deviations of the outcomes from the study reports, since there was great inconsistency in the way data were presented. We tried to calculate standard deviations from standard errors, confidence intervals or P values. When it was not possible, we contacted authors in order to obtain suitable data for meta-analysis.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2010-06-21 14:06:08 +1000" MODIFIED_BY="[Empty name]">
<P>We included both parallel and cross-over randomized controlled trials. In cross-over studies we included data from both the first period and the cross-over period since a carry-over effect was not demonstrated in any of the studies.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2010-06-21 14:06:30 +1000" MODIFIED_BY="[Empty name]">
<P>We analysed only the available data and addressed the potential impact of missing data on the findings of the review in the <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK> section. We did not conduct other approaches in order to handle missing data.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2010-06-21 14:10:16 +1000" MODIFIED_BY="[Empty name]">
<P>We planned to qualitatively examine heterogeneity between studies for the treatment effect of each intervention by inspecting the distribution of point estimates for the effect measure and the overlap in their confidence intervals on a forest plot. Quantitatively, we considered that a Chi<SUP>2</SUP> statistic (Q statistic) with P &lt; 0.10 or the inconsistency between studies (I<SUP>2 </SUP>statistic) greater than 40% as evidence of relevant heterogeneity.<BR/>
</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2010-06-21 14:10:42 +1000" MODIFIED_BY="[Empty name]">
<P>Due to the small number of studies included in each category, funnel plots or other ways of investigating publication bias were not performed. Considering that all the studies reported the main outcomes there was little reason to suspect selective reporting.<BR/>
</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-06-21 14:12:28 +1000" MODIFIED_BY="[Empty name]">
<P>When applicable, we carried out meta-analysis of outcome measurements made on the same scale and considered the measure as a mean difference (MD) with 95% confidence interval (CI). We used the fixed-effect inverse variance model to estimate the pooled measure of treatment effect.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2010-01-27 05:30:45 +1100" MODIFIED_BY="[Empty name]">
<P>Since we were unable to pool the results, we could not perform subgroup analyses. </P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2010-06-21 14:13:19 +1000" MODIFIED_BY="[Empty name]">
<P>We did not perform sensitivity analyses due to the small number of studies included in each group and the impossibility of pooling results.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-07-25 22:52:18 +1000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2010-07-25 21:57:48 +1000" MODIFIED_BY="[Empty name]">
<P>See: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>
</P>
<SEARCH_RESULTS MODIFIED="2010-07-25 21:57:48 +1000" MODIFIED_BY="[Empty name]">
<P>The comprehensive literature search retrieved 1012 references that were subsequently screened. Of these, 126 were potentially eligible and the full-text reports were evaluated. We excluded 101 papers that did not meet our inclusion criteria for reasons detailed in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and considered for inclusion a total of 25 references reporting on trials. Seven references corresponded to preliminary results of included studies or duplicate publications. We excluded two trials that initially met our criteria, for reasons detailed in the table of <LINK TAG="EXCLUDED_STUDIES_DESCR" TYPE="SECTION">Excluded studies</LINK>. Therefore, the review included 16 studies reported in 15 references. For a detailed description of the search process see the QUORUM flow diagram (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-07-12 11:39:58 +1000" MODIFIED_BY="Melina Willson">
<P>Two studies did not address the proportion of women with a history of breast cancer, so it was not possible to be certain if our criterion of at least 80% of participants having breast cancer history was met (<LINK REF="STD-Loprinzi-2000" TYPE="STUDY">Loprinzi 2000</LINK>; <LINK REF="STD-Loprinzi-2002" TYPE="STUDY">Loprinzi 2002</LINK>). The author of both studies was contacted and confirmed that breast cancer status was not assessed, however a substantial proportion of patients received tamoxifen (54% and 69%). Therefore, it was likely that women with a history of breast cancer constituted the majority of the included participants. Since our criterion was an arbitrary limit we decided to include both studies, as opposed to the guidelines provided by the recent version of the Cochrane Handbook (<LINK REF="REF-Cochrane-Handbook-5.0.2" TYPE="REFERENCE">Cochrane Handbook 5.0.2</LINK>).</P>
<P>Of the included studies, six evaluated the SSRI and SNRI antidepressants fluoxetine (<LINK REF="STD-Loprinzi-2002" TYPE="STUDY">Loprinzi 2002</LINK>), paroxetine (<LINK REF="STD-Stearns-2005" TYPE="STUDY">Stearns 2005</LINK>), sertraline (<LINK REF="STD-Kimmick-2006" TYPE="STUDY">Kimmick 2006</LINK>) and venlafaxine (<LINK REF="STD-Carpenter-2007a" TYPE="STUDY">Carpenter 2007a</LINK>; <LINK REF="STD-Carpenter-2007b" TYPE="STUDY">Carpenter 2007b</LINK>; <LINK REF="STD-Loprinzi-2000" TYPE="STUDY">Loprinzi 2000</LINK>); two studies evaluated clonidine, one using a transdermal patch (<LINK REF="STD-Goldberg-1994" TYPE="STUDY">Goldberg 1994</LINK>) and the other an oral formulation (<LINK REF="STD-Pandya-2000" TYPE="STUDY">Pandya 2000</LINK>); one study evaluated gabapentin (<LINK REF="STD-Pandya-2005" TYPE="STUDY">Pandya 2005</LINK>); and one vitamin E tablets (<LINK REF="STD-Barton-1998" TYPE="STUDY">Barton 1998</LINK>). Six studies tested non-pharmacological interventions: one study evaluated magnetic therapy (six magnetic devices attached to participant's skin, placed over acupuncture or acupressure sites) (<LINK REF="STD-Carpenter-2002" TYPE="STUDY">Carpenter 2002</LINK>); two assessed relaxation therapies (occupational therapist-guided relaxation consisting of stress management, written information about stress, deep breathing techniques, muscle relaxation and guided imagery) (<LINK REF="STD-Fenlon-1999" TYPE="STUDY">Fenlon 1999</LINK>; <LINK REF="STD-Fenlon-2008" TYPE="STUDY">Fenlon 2008</LINK>); one acupuncture (eight treatment sessions, 19 acupuncture points) (<LINK REF="STD-Deng-2007" TYPE="STUDY">Deng 2007</LINK>); and two homeopathy (one study evaluated a single homeopathic remedy in one group and Hyland's menopause formula in a second group, and the other study evaluated homeopathic medicines in tablet, granule or liquid form, prepared by a single pharmacy) (<LINK REF="STD-Jacobs-2005" TYPE="STUDY">Jacobs 2005</LINK>; <LINK REF="STD-Thompson-2005" TYPE="STUDY">Thompson 2005</LINK>).</P>
<P>Four studies included more than one active treatment arm (<LINK REF="STD-Jacobs-2005" TYPE="STUDY">Jacobs 2005</LINK>; <LINK REF="STD-Loprinzi-2000" TYPE="STUDY">Loprinzi 2000</LINK>; <LINK REF="STD-Pandya-2005" TYPE="STUDY">Pandya 2005</LINK>; <LINK REF="STD-Stearns-2005" TYPE="STUDY">Stearns 2005</LINK>). Nine studies had a cross-over design (<LINK REF="STD-Barton-1998" TYPE="STUDY">Barton 1998</LINK>; <LINK REF="STD-Carpenter-2002" TYPE="STUDY">Carpenter 2002</LINK>; <LINK REF="STD-Carpenter-2007a" TYPE="STUDY">Carpenter 2007a</LINK>; <LINK REF="STD-Carpenter-2007b" TYPE="STUDY">Carpenter 2007b</LINK>; <LINK REF="STD-Deng-2007" TYPE="STUDY">Deng 2007</LINK>; <LINK REF="STD-Goldberg-1994" TYPE="STUDY">Goldberg 1994</LINK>; <LINK REF="STD-Kimmick-2006" TYPE="STUDY">Kimmick 2006</LINK>; <LINK REF="STD-Loprinzi-2002" TYPE="STUDY">Loprinzi 2002</LINK>; <LINK REF="STD-Stearns-2005" TYPE="STUDY">Stearns 2005</LINK>).</P>
<P>The number of participants per study ranged from a minimum of 15 to a maximum of 420, with a median of 85. Thirteen studies included exclusively women with a history of breast cancer (<LINK REF="STD-Barton-1998" TYPE="STUDY">Barton 1998</LINK>; <LINK REF="STD-Carpenter-2002" TYPE="STUDY">Carpenter 2002</LINK>; <LINK REF="STD-Carpenter-2007a" TYPE="STUDY">Carpenter 2007a</LINK>; <LINK REF="STD-Carpenter-2007b" TYPE="STUDY">Carpenter 2007b</LINK>; <LINK REF="STD-Deng-2007" TYPE="STUDY">Deng 2007</LINK>; <LINK REF="STD-Fenlon-1999" TYPE="STUDY">Fenlon 1999</LINK>; <LINK REF="STD-Fenlon-2008" TYPE="STUDY">Fenlon 2008</LINK>; <LINK REF="STD-Goldberg-1994" TYPE="STUDY">Goldberg 1994</LINK>; <LINK REF="STD-Jacobs-2005" TYPE="STUDY">Jacobs 2005</LINK>; <LINK REF="STD-Kimmick-2006" TYPE="STUDY">Kimmick 2006</LINK>; <LINK REF="STD-Pandya-2000" TYPE="STUDY">Pandya 2000</LINK>; <LINK REF="STD-Pandya-2005" TYPE="STUDY">Pandya 2005</LINK>; <LINK REF="STD-Thompson-2005" TYPE="STUDY">Thompson 2005</LINK>) and three included both women with a history of breast cancer, women at high risk of breast cancer or had concerns about breast cancer (<LINK REF="STD-Loprinzi-2000" TYPE="STUDY">Loprinzi 2000</LINK>; <LINK REF="STD-Loprinzi-2002" TYPE="STUDY">Loprinzi 2002</LINK>; <LINK REF="STD-Stearns-2005" TYPE="STUDY">Stearns 2005</LINK>). Three studies included only women using tamoxifen (<LINK REF="STD-Goldberg-1994" TYPE="STUDY">Goldberg 1994</LINK>; <LINK REF="STD-Kimmick-2006" TYPE="STUDY">Kimmick 2006</LINK>; <LINK REF="STD-Pandya-2000" TYPE="STUDY">Pandya 2000</LINK>). In the remaining studies, tamoxifen use ranged from 51% to 80% of women. Aromatase inhibitors use was reported in only two studies, where it ranged from 6% to 23% (<LINK REF="STD-Deng-2007" TYPE="STUDY">Deng 2007</LINK>; <LINK REF="STD-Stearns-2005" TYPE="STUDY">Stearns 2005</LINK>). In seven studies the setting was not clearly reported (<LINK REF="STD-Barton-1998" TYPE="STUDY">Barton 1998</LINK>; <LINK REF="STD-Carpenter-2002" TYPE="STUDY">Carpenter 2002</LINK>; <LINK REF="STD-Goldberg-1994" TYPE="STUDY">Goldberg 1994</LINK>; <LINK REF="STD-Jacobs-2005" TYPE="STUDY">Jacobs 2005</LINK>; <LINK REF="STD-Kimmick-2006" TYPE="STUDY">Kimmick 2006</LINK>; <LINK REF="STD-Loprinzi-2000" TYPE="STUDY">Loprinzi 2000</LINK>; <LINK REF="STD-Loprinzi-2002" TYPE="STUDY">Loprinzi 2002</LINK>). The rest of the studies were performed mainly in oncology or breast cancer referral clinics. One study was conducted in the outpatient department of an homeopathic hospital (<LINK REF="STD-Jacobs-2005" TYPE="STUDY">Jacobs 2005</LINK>). The duration of the studies ranged from three days to one year.</P>
<P>All studies reported on frequency (mostly number of hot flushes per day) and some numeric measure of severity of hot flushes with the exception of one study that reported on frequency only (<LINK REF="STD-Deng-2007" TYPE="STUDY">Deng 2007</LINK>). The same hot flush severity score (number of hot flushes per day x severity on a scale of 1 to 4, with 4 the maximum severity) was used in eight studies (<LINK REF="STD-Barton-1998" TYPE="STUDY">Barton 1998</LINK>; <LINK REF="STD-Fenlon-2008" TYPE="STUDY">Fenlon 2008</LINK>; <LINK REF="STD-Goldberg-1994" TYPE="STUDY">Goldberg 1994</LINK>; <LINK REF="STD-Jacobs-2005" TYPE="STUDY">Jacobs 2005</LINK>; <LINK REF="STD-Kimmick-2006" TYPE="STUDY">Kimmick 2006</LINK>; <LINK REF="STD-Loprinzi-2000" TYPE="STUDY">Loprinzi 2000</LINK>; <LINK REF="STD-Pandya-2000" TYPE="STUDY">Pandya 2000</LINK>; <LINK REF="STD-Stearns-2005" TYPE="STUDY">Stearns 2005</LINK>). Quality of life was measured on different scales and was inconsistently reported. The majority of trials did not report on adverse effects in detail.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2010-06-21 14:31:42 +1000" MODIFIED_BY="[Empty name]">
<P>See: the table <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>
<BR/>One study was of a program that included some drugs with possible hormonal action was excluded because data did not allow us to discriminate which participants received the different drugs (<LINK REF="STD-Ganz-2000" TYPE="STUDY">Ganz 2000</LINK>).<BR/>One trial in which women were randomised to Shugan-liangxue compound was excluded because there was too little information on the compound to be sure of its non-hormonal mechanism, and we did not find published literature to support the safety of this compound in women with breast cancer (<LINK REF="STD-Li-2006" TYPE="STUDY">Li 2006</LINK>).<BR/>
</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-07-12 11:41:46 +1000" MODIFIED_BY="Melina Willson">
<P>The 'Risk of bias' tables for each study are given in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<ALLOCATION MODIFIED="2010-07-12 11:41:15 +1000" MODIFIED_BY="Melina Willson">
<P>All studies were randomized but in four the method was not described (<LINK REF="STD-Carpenter-2002" TYPE="STUDY">Carpenter 2002</LINK>; <LINK REF="STD-Fenlon-1999" TYPE="STUDY">Fenlon 1999</LINK>; <LINK REF="STD-Goldberg-1994" TYPE="STUDY">Goldberg 1994</LINK>; <LINK REF="STD-Kimmick-2006" TYPE="STUDY">Kimmick 2006</LINK>).</P>
<P>Concealment was rated as adequate in nine (<LINK REF="STD-Carpenter-2007a" TYPE="STUDY">Carpenter 2007a</LINK>; <LINK REF="STD-Carpenter-2007b" TYPE="STUDY">Carpenter 2007b</LINK>; <LINK REF="STD-Deng-2007" TYPE="STUDY">Deng 2007</LINK>; <LINK REF="STD-Fenlon-1999" TYPE="STUDY">Fenlon 1999</LINK>; <LINK REF="STD-Fenlon-2008" TYPE="STUDY">Fenlon 2008</LINK>; <LINK REF="STD-Jacobs-2005" TYPE="STUDY">Jacobs 2005</LINK>; <LINK REF="STD-Pandya-2000" TYPE="STUDY">Pandya 2000</LINK>; <LINK REF="STD-Stearns-2005" TYPE="STUDY">Stearns 2005</LINK>; <LINK REF="STD-Thompson-2005" TYPE="STUDY">Thompson 2005</LINK>) and unclear in the other seven studies.<BR/>
</P>
</ALLOCATION>
<BLINDING MODIFIED="2010-07-12 11:41:46 +1000" MODIFIED_BY="Melina Willson">
<P>Participants were blinded to the intervention in all but the two studies of relaxation therapy (<LINK REF="STD-Fenlon-1999" TYPE="STUDY">Fenlon 1999</LINK>; <LINK REF="STD-Fenlon-2008" TYPE="STUDY">Fenlon 2008</LINK>). In the study of acupuncture (<LINK REF="STD-Deng-2007" TYPE="STUDY">Deng 2007</LINK>) the acupuncturist was not blinded but the other care givers were. Blinding status of other participants was described in six studies (<LINK REF="STD-Barton-1998" TYPE="STUDY">Barton 1998</LINK>; <LINK REF="STD-Carpenter-2007a" TYPE="STUDY">Carpenter 2007a</LINK>; <LINK REF="STD-Carpenter-2007b" TYPE="STUDY">Carpenter 2007b</LINK>; <LINK REF="STD-Deng-2007" TYPE="STUDY">Deng 2007</LINK>; <LINK REF="STD-Loprinzi-2000" TYPE="STUDY">Loprinzi 2000</LINK>; <LINK REF="STD-Thompson-2005" TYPE="STUDY">Thompson 2005</LINK>). Given that the majority of outcomes were self assessed, we generally considered participants and providers for blinding (instead of recollectors or assessors) in order to develop the judgment on quality in the 'Risk of bias' tables.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2010-06-21 14:34:40 +1000" MODIFIED_BY="[Empty name]">
<P>All studies based their analyses on the patients with complete data by the end of the study. Completeness of follow up ranged from 60% to 97%. Only two studies evaluated the effects of missing data on results (<LINK REF="STD-Loprinzi-2000" TYPE="STUDY">Loprinzi 2000</LINK>; <LINK REF="STD-Pandya-2000" TYPE="STUDY">Pandya 2000</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2010-06-20 21:44:59 +1000" MODIFIED_BY="[Empty name]">
<P>All studies reported the outcomes that we considered most important. There was no reason to suspect selective reporting of outcomes.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2010-06-21 14:35:05 +1000" MODIFIED_BY="[Empty name]">
<P>We did not identify any additional sources of bias.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-07-25 22:52:18 +1000" MODIFIED_BY="[Empty name]">
<P>There was great inconsistency in the way of reporting continuous outcomes. We could not obtain suitable data for meta-analysis from authors so we presented measures of treatment effect using data as reported in the study reports.</P>
<SUBSECTION>
<HEADING LEVEL="4">Effects on hot flushes frequency and severity score</HEADING>
<P>
<B>Clonidine</B>
</P>
<P>We found two studies (252 assessable participants) evaluating a transdermal and an oral formulation of clonidine.<BR/>
<BR/>One study (<LINK REF="STD-Goldberg-1994" TYPE="STUDY">Goldberg 1994</LINK>), including 89 assessable patients, tested a transdermal patch. At week four, the hot flush frequency in the intervention arm, as a median, had a reduction from baseline of 44% compared to the reduction in the placebo arm of 27% (P = 0.04). The median combined severity score decreased 56% from baseline with the intervention and 30% with placebo (P = 0.04). For the effect after cross-over, the difference at week eight was reported as significant for both frequency (P &lt; 0.0001) and the combined severity score (P = 0.0006).<BR/>
</P>
<P>A second study (<LINK REF="STD-Pandya-2000" TYPE="STUDY">Pandya 2000</LINK>) that evaluated an oral formulation included 163 assessable patients. At week eight, the hot flush frequency had a mean reduction from baseline of 38% in the treatment arm compared to 24% with placebo (difference in percentage reduction of means of 14%; 95% CI 3% to 27%; P = 0.006). The severity score was reduced by 45% with clonidine and 26% with placebo (P = 0.006).<BR/>
<BR/>
</P>
<P>
<B>Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) </B>
</P>
<P>Six studies (<LINK REF="STD-Carpenter-2007a" TYPE="STUDY">Carpenter 2007a</LINK>; <LINK REF="STD-Carpenter-2007b" TYPE="STUDY">Carpenter 2007b</LINK>; <LINK REF="STD-Kimmick-2006" TYPE="STUDY">Kimmick 2006</LINK>; <LINK REF="STD-Loprinzi-2000" TYPE="STUDY">Loprinzi 2000</LINK>; <LINK REF="STD-Loprinzi-2002" TYPE="STUDY">Loprinzi 2002</LINK>; <LINK REF="STD-Stearns-2005" TYPE="STUDY">Stearns 2005</LINK>) including 451 assessable women evaluated the effects of different SSRIs and SNRIs (venlafaxine, paroxetine, fluoxetine and sertraline).<BR/>Even though all studies measured the same outcomes, the way of reporting them precluded any possibility of pooling (reasons detailed in <LINK TAG="EFFECT_MEASURES" TYPE="SECTION">Measures of treatment effect</LINK>), and each study was reported separately.</P>
<P>Venlafaxine (extended release formulation) was evaluated in three different doses in three studies.<BR/>
<LINK REF="STD-Loprinzi-2000" TYPE="STUDY">Loprinzi 2000</LINK> included 191 assessable participants who received three different doses (37.5, 75 and 150 mg) of venlafaxine. The placebo group had a median decrease from baseline of 19% in the frequency of hot flushes at week four (95% CI 14 to 28). The three active arms had greater reductions: 30% for the low dose (95% CI 22 to 53; P &lt; 0.001), 46% for the intermediate dose (95% CI 36 to 63; P &lt; 0.001), and 58% for the highest dose of venlafaxine (95% CI 42 to 67; P &lt; 0.001).<BR/>The severity score reduction was also superior in the active arms. The median decrease from baseline was 27% in the placebo group (95% CI 11 to 34), 37% in the low-dose arm (95% CI 26 to 54; P &lt; 0.001), 61% in the intermediate dose arm (95% CI 50 to 68; P &lt; 0.001) and 61% in the high-dose arm (95% CI 48 to 75; P &lt; 0.001) versus placebo.</P>
<P>Another two studies on venlafaxine, reported together in a single paper, evaluated two doses (37.5 and 75 mg) for 12 weeks.<BR/>The low-dose study (<LINK REF="STD-Carpenter-2007a" TYPE="STUDY">Carpenter 2007a</LINK>) included 31 assessable patients. In the treatment group, the mean daily frequency measured by skin conductance monitoring decreased by 1.7 hot flushes per day (22%) compared with baseline whereas in the placebo group no change from baseline was observed (adjusted mean difference P &lt; 0.001). Similar reductions were observed in the frequency measured by written diary entries (mean decrease from baseline 42% with the low dose versus 18% with placebo; P &lt; 0.001) and electronic event markers (mean decrease from baseline 41% with the low dose versus 22% with placebo; P &lt; 0.001). The mean severity decreased 7% from baseline in the treatment group and increased 6% with placebo (P &lt; 0.001).<BR/>The 75 mg venlafaxine study (<LINK REF="STD-Carpenter-2007b" TYPE="STUDY">Carpenter 2007b</LINK>) included 15 assessable patients. Compared with baseline, the mean daily frequency measured by skin conductance monitoring decreased by one hot flush per day (14%) in the treatment group and increased by 1.4 hot flushes per day (13%) in the placebo group (P = 0.013). Frequency measured from written diary entries (mean decrease from baseline 25% versus 4%; P = 0.001) and electronic event markers (mean change from baseline 4% decrease versus 22% increase; P &lt; 0.001) were also lower in the treatment group. The mean severity decreased by 27% from baseline in the treatment group and 5% in the placebo group (P &lt; 0.001).</P>
<P>One study evaluating fluoxetine at a dose of 20 mg versus placebo (<LINK REF="STD-Loprinzi-2002" TYPE="STUDY">Loprinzi 2002</LINK>) included 68 assessable patients in a cross-over trial with two periods of four weeks each. After eight weeks, the active period was superior to the placebo period with a median decrease from baseline of 1.5 hot flushes per day (19%; P = 0.01) and 3.1 score units per day (24%; P = 0.02) compared with placebo.</P>
<P>
<LINK REF="STD-Stearns-2005" TYPE="STUDY">Stearns 2005</LINK> evaluated two different doses of paroxetine for eight weeks compared to placebo in 107 assessable participants in a cross-over trial. In the paroxetine periods hot flushes were reduced from baseline more than in the placebo periods regardless of the dose. In the 10 mg arms, the mean percentage reduction in hot flush frequency was 40.6% in the active period compared with 13.7% in the placebo period (mean difference 27.0%; P = 0.0006). The mean percentage reduction in severity score was 45.6% in the active period compared to 13.7% in the placebo period (P = 0.0008).<BR/>For patients in the 20 mg arm, the mean percentage reduction of hot flush frequency was 51.7% in the active period compared with 26.6% reduction in the placebo period (mean difference 25.2%; P = 0.002). The mean percentage reduction in severity score was 56.1% in the active period compared with 28.5% in the placebo period (P &lt; 0.001).</P>
<P>One study used sertraline 50 mg versus placebo in 39 assessable participants (<LINK REF="STD-Kimmick-2006" TYPE="STUDY">Kimmick 2006</LINK>). The study was powered to evaluate complete resolution of hot flushes at six weeks of treatment. Because there were no cases of complete hot flush resolution the study was underpowered. A second period of six weeks was added to test the cross-over effect, however the dropout rate was high. In the primary analysis at week six, there was no difference in reduction from baseline for sertraline compared to placebo with a mean reduction from baseline of 1.6 daily hot flushes in the sertraline group and 1.5 in the placebo group (P = 0.9). At week 12, no significant differences were found on hot flush frequency or score reductions from baseline. The group that switched to sertraline had a reduction, compared to week six, of 0.9 daily hot flushes; and the arm that switched to placebo had an increase of 1.5 daily hot flushes (P = 0.03). The score was reduced by 3.2 points at week six in the sertraline group and 4.6 points in the placebo group (P = 0.7). At week 12, the group that changed to sertraline had a reduction, compared with week six, of 1.7 points; and the arm that changed to placebo had an increase of 3.4 points (P = 0.03). A mixed model analysis found no carry-over effects for the hot flush frequency (P = 0.25) or score (P = 0.13) and did not find any treatment effects for hot flush frequency (P = 0.73) or hot flush score (P = 0.68).<BR/>
<BR/>
<B>Vitamin E</B>
</P>
<P>One study including 105 assessable participants evaluated vitamin E 800 IU (<LINK REF="STD-Barton-1998" TYPE="STUDY">Barton 1998</LINK>). After four weeks of therapy there was no significant effect on the frequency of hot flushes (mean difference -0.15; 95% CI -2.45 to 2.16; P = 0.90) nor on the severity score (mean difference -0.82; 95% CI -4.68 to 3.05; P = 0.68).</P>
<P>
<B>Gabapentin</B>
</P>
<P>One study including 347 assessable women evaluated two different doses of gabapentin (<LINK REF="STD-Pandya-2005" TYPE="STUDY">Pandya 2005</LINK>). The frequency of hot flushes was reduced with the 900 mg/day dose of gabapentin (mean change -2.1; 95% CI &#8211;2.95 to &#8211;1.23). A lower dose (300 mg/day) did not achieve a significant effect (mean change &#8211;0.8; 95% CI &#8211;1.7 to 0.1). The same effects were observed on severity scores (low dose mean change -1.79; 95% CI &#8211;4.38 to 0.80 and high dose mean change -4.88; 95% CI &#8211;7.23 to &#8211;2.53).<BR/>
<BR/>
<B>Non-pharmacological therapies</B>
</P>
<P>We identified six studies evaluating the effects of non-pharmacological therapies. Homeopathy and relaxation therapy were each evaluated in two studies, and a magnetic device and acupuncture in single studies.</P>
<P>The first study on homeopathy (<LINK REF="STD-Thompson-2005" TYPE="STUDY">Thompson 2005</LINK>) included 45 assessable women who received a tailored homeopathic prescription or placebo. There were no significant effects observed in a four-item profile score that included two self-rated symptom items, an activity of daily living item and a general feeling of well-being item (mean difference -0.10; 95% CI -4.86 to 4.66).</P>
<P>The second study on homeopathy (<LINK REF="STD-Jacobs-2005" TYPE="STUDY">Jacobs 2005</LINK>) compared two forms of homeopathy (single or combination therapy) with placebo in 79 assessable participants. There were no statistical differences among comparisons for the frequency or severity score of hot flushes.</P>
<P>The first study on relaxation therapy (<LINK REF="STD-Fenlon-1999" TYPE="STUDY">Fenlon 1999</LINK>) included 16 women and found no significant differences in the effects of this treatment on the number of hot flushes per day (mean difference 0.50; 95% CI -1.23 to 2.23) nor the severity score (mean difference 0.64; 95% CI -2.10 to 3.38). A larger study by the same author (<LINK REF="STD-Fenlon-2008" TYPE="STUDY">Fenlon 2008</LINK>) included 150 women. The number of hot flushes decreased at one month (median difference 7 hot flushes per week; 95% CI 4 to 7; P &lt; 0.001) but the effect was not significant at three months (median difference 5 hot flushes per week; 95% CI 0 to 10; P &lt; 0.06). Severity of hot flushes was also lower at one month (median difference 0.54; 95% CI 0.11 to 1.01; P = 0.01) but the difference became non-significant at three months (median difference 0.56; 0.02 to 1.18; P = 0.05).</P>
<P>A study including 11 women (<LINK REF="STD-Carpenter-2002" TYPE="STUDY">Carpenter 2002</LINK>) evaluated a magnetic device compared to a placebo device. There was no difference between the arms in terms of number of hot flushes (mean difference 1.63; 95% CI -5.69 to 8.95).</P>
<P>One study with 67 assessable women (<LINK REF="STD-Deng-2007" TYPE="STUDY">Deng 2007</LINK>) evaluated real versus sham acupuncture. There was no difference between the arms in the frequency of hot flushes per day (mean difference -0.10; 95% CI -3.63 to 3.43).</P>
<P>
<BR/>
<B>
<I>Effects on quality of life</I>
</B>
</P>
<P>Twelve of 16 included studies measured quality of life but the quality of reporting was very poor. We were not able to pool these results because the studies used different scales (Hot Flash-related Daily Interference Scale: <LINK REF="STD-Carpenter-2002" TYPE="STUDY">Carpenter 2002</LINK>; General Health Questionnaire of 60 questions: <LINK REF="STD-Fenlon-1999" TYPE="STUDY">Fenlon 1999</LINK>; SF 36 Quality of Life Score: <LINK REF="STD-Jacobs-2005" TYPE="STUDY">Jacobs 2005</LINK>; two single-item global quality-of-life questions: <LINK REF="STD-Loprinzi-2000" TYPE="STUDY">Loprinzi 2000</LINK>; Uniscale global quality-of-life instrument: <LINK REF="STD-Loprinzi-2002" TYPE="STUDY">Loprinzi 2002</LINK>; Single question rating overall QOL from 1 to 10: <LINK REF="STD-Pandya-2000" TYPE="STUDY">Pandya 2000</LINK>; The Center for Epidemiologic Studies Depression Scale, seven anxiety items of the Hospital Anxiety and Depression Scale, the Medical Outcomes Study Sleep Problems Index, MOS Sexual Problems Index and a self-rating questionnaire of overall health-related QOL standardized in the EuroQOL Linear Rating Scale: <LINK REF="STD-Stearns-2005" TYPE="STUDY">Stearns 2005</LINK>; 36-item Medical Outcomes Survey with its eight subscales: <LINK REF="STD-Carpenter-2007a" TYPE="STUDY">Carpenter 2007a</LINK>; <LINK REF="STD-Carpenter-2007b" TYPE="STUDY">Carpenter 2007b</LINK>; European Organization for Research and Treatment of Cancer Quality of Life Questionnaire: <LINK REF="STD-Thompson-2005" TYPE="STUDY">Thompson 2005</LINK>; Functional Assessment of Cancer Therapy-Breast: <LINK REF="STD-Kimmick-2006" TYPE="STUDY">Kimmick 2006</LINK>; Functional Assessment of Cancer Therapy-Endocrine subscale: <LINK REF="STD-Fenlon-2008" TYPE="STUDY">Fenlon 2008</LINK>).</P>
<P>Among the studies that used clonidine, one did not report on quality of life (<LINK REF="STD-Goldberg-1994" TYPE="STUDY">Goldberg 1994</LINK>) and the other found no differences compared with the control group (<LINK REF="STD-Pandya-2000" TYPE="STUDY">Pandya 2000</LINK>). In the six studies using SSRIs and SNRIs, no significant differences in quality of life measures were found except in the study using venlafaxine (<LINK REF="STD-Loprinzi-2000" TYPE="STUDY">Loprinzi 2000</LINK>), where an improvement in quality of life scores was seen among the participants taking the drug; this was independent of the dose. In the two studies evaluating the role of homeopathy, one did not find any differences (<LINK REF="STD-Thompson-2005" TYPE="STUDY">Thompson 2005</LINK>) and the other found an improvement in quality of life scores in women using single or combination homeopathy (<LINK REF="STD-Jacobs-2005" TYPE="STUDY">Jacobs 2005</LINK>). The other non-pharmacological intervention trials (<LINK REF="STD-Carpenter-2002" TYPE="STUDY">Carpenter 2002</LINK>; <LINK REF="STD-Fenlon-1999" TYPE="STUDY">Fenlon 1999</LINK>; <LINK REF="STD-Fenlon-2008" TYPE="STUDY">Fenlon 2008</LINK>) did not find differences between the treatment and control groups. The gabapentin (<LINK REF="STD-Pandya-2005" TYPE="STUDY">Pandya 2005</LINK>), vitamin E (<LINK REF="STD-Barton-1998" TYPE="STUDY">Barton 1998</LINK>) and acupuncture (<LINK REF="STD-Deng-2007" TYPE="STUDY">Deng 2007</LINK>) trials did not report on quality of life outcomes.</P>
<P>
<B>
<I>Effects on patient preferences</I>
</B>
</P>
<P>Five of nine studies with a cross-over design measured patient preference for one or other of the treatments after both periods had been completed (<LINK REF="STD-Barton-1998" TYPE="STUDY">Barton 1998</LINK>; <LINK REF="STD-Goldberg-1994" TYPE="STUDY">Goldberg 1994</LINK>; <LINK REF="STD-Kimmick-2006" TYPE="STUDY">Kimmick 2006</LINK>; <LINK REF="STD-Loprinzi-2002" TYPE="STUDY">Loprinzi 2002</LINK>; <LINK REF="STD-Stearns-2005" TYPE="STUDY">Stearns 2005</LINK>).</P>
<P>The preference for vitamin E or placebo was 32% or 29%, and 38% did not have a preference (<LINK REF="STD-Barton-1998" TYPE="STUDY">Barton 1998</LINK>). Preference for clonidine, placebo or no preference was expressed by 48%, 25% and 27% of women (P = 0.02) in one study (<LINK REF="STD-Goldberg-1994" TYPE="STUDY">Goldberg 1994</LINK>). Sertraline or placebo was preferred by 49% or 11% (P = 0.006); 41% had no preference (<LINK REF="STD-Kimmick-2006" TYPE="STUDY">Kimmick 2006</LINK>). In the case of fluoxetine or placebo or none, the preferences were 47%, 22% or 31% (P = 0.14) (<LINK REF="STD-Loprinzi-2002" TYPE="STUDY">Loprinzi 2002</LINK>). In a study with two doses of paroxetine, 60% of patients wished to continue on the 10 mg per day dose and 46% on the 20 mg per day dose (<LINK REF="STD-Stearns-2005" TYPE="STUDY">Stearns 2005</LINK>).<BR/>
</P>
<P>
<B>
<I>Adverse effects</I>
</B>
</P>
<P>Thirteen of 16 included studies mentioned adverse effects. No major adverse effects were reported. Overall the quality of the adverse effect reporting was low and it was not possible to calculate risk estimates.</P>
<P>The clonidine dermal patch was associated with an increased frequency of dry mouth, constipation, dizziness and itching under the patch (<LINK REF="STD-Goldberg-1994" TYPE="STUDY">Goldberg 1994</LINK>). Clonidine significantly increased sleep disorders (<LINK REF="STD-Pandya-2000" TYPE="STUDY">Pandya 2000</LINK>). Women in the studies evaluating venlafaxine (<LINK REF="STD-Carpenter-2007a" TYPE="STUDY">Carpenter 2007a</LINK>; <LINK REF="STD-Carpenter-2007b" TYPE="STUDY">Carpenter 2007b</LINK>; <LINK REF="STD-Loprinzi-2000" TYPE="STUDY">Loprinzi 2000</LINK>), paroxetine (<LINK REF="STD-Stearns-2005" TYPE="STUDY">Stearns 2005</LINK>) and sertraline (<LINK REF="STD-Kimmick-2006" TYPE="STUDY">Kimmick 2006</LINK>) reported an increased incidence of nausea. Venlafaxine also increased the risk of decreased appetite, mouth dryness and constipation, with a higher incidence in women taking the higher doses. Sertraline was associated with a slight increase in fatigue and malaise, diarrhoea, and anxiety or nervousness. The study that used fluoxetine (<LINK REF="STD-Loprinzi-2002" TYPE="STUDY">Loprinzi 2002</LINK>) did not find differences between groups in the incidence of adverse effects.</P>
<P>The vitamin E study (<LINK REF="STD-Barton-1998" TYPE="STUDY">Barton 1998</LINK>) did not find any differences in adverse effects. Gabapentin caused an increase in sleeping disorders but the study obtained data on adverse effects only if these were the reason for withdrawing, so they are likely to be underestimated (<LINK REF="STD-Pandya-2005" TYPE="STUDY">Pandya 2005</LINK>).</P>
<P>No differences between the different study groups were found for the studies with homeopathy (<LINK REF="STD-Jacobs-2005" TYPE="STUDY">Jacobs 2005</LINK>; <LINK REF="STD-Thompson-2005" TYPE="STUDY">Thompson 2005</LINK>). Acupuncture was associated with minor adverse effects such as slight bleeding or bruising at the needle site (<LINK REF="STD-Deng-2007" TYPE="STUDY">Deng 2007</LINK>).<BR/>Three studies of non-pharmacological interventions (<LINK REF="STD-Carpenter-2002" TYPE="STUDY">Carpenter 2002</LINK>; <LINK REF="STD-Fenlon-1999" TYPE="STUDY">Fenlon 1999</LINK>; <LINK REF="STD-Fenlon-2008" TYPE="STUDY">Fenlon 2008</LINK>) did not report on the occurrence of adverse effects.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-07-12 12:06:18 +1000" MODIFIED_BY="Melina Willson">
<SUMMARY_OF_RESULTS MODIFIED="2010-07-12 12:06:18 +1000" MODIFIED_BY="Melina Willson">
<P>This review shows that some non-hormonal therapies have a mild to moderate effect in reducing the frequency and intensity of hot flushes in women with a history of breast cancer. The 16 included studies assessed eight different interventions (four pharmacological and four non-pharmacological).</P>
<P>Due to the inconsistency in the way data were presented, we were not able to calculate a pooled estimate of the effects of the different interventions and so we do not know the relative magnitude of the benefit for each treatment.<BR/>
<BR/>The evidence on clonidine shows a statistically significant reduction in hot flushes in both studies. Clonidine however also produces frequent adverse effects that may outweigh any benefit.</P>
<P>All the studies on SSRIs and SNRIs had a statistically significant effect favoring the intervention. Even though this response was far from complete, these drugs have only minor adverse effects and their safety profile has been well established from research in other clinical settings (<LINK REF="REF-Gartlehner-2008" TYPE="REFERENCE">Gartlehner 2008</LINK>). Added to their low cost and widespread access, this makes them an attractive alternative for women with a history of breast cancer. It should be noted, however, that paroxetine may interfere with the metabolism of tamoxifen and is not recommended in women taking this drug for their breast cancer (<LINK REF="REF-Jin-2005" TYPE="REFERENCE">Jin 2005</LINK>).</P>
<P>We found one small study of vitamin E that showed no significant effect of this treatment.</P>
<P>The only study of gabapentin evaluated two different doses, with a significant response for the 900 mg/day dose but not for a lower dose. The 900 mg/day dose reduced hot flushes by 2.1 per day. This effect constitutes a greater reduction than the reductions achieved by the other interventions included in this review but no direct comparisons are available.</P>
<P>From the non-pharmacological therapies, two studies on homeopathy, one on magnetic devices and one on acupuncture showed no significant benefit. Two studies evaluating a very similar form of relaxation therapy had different results. One of them, with a small sample size, showed no benefit. The other trial with a bigger sample size demonstrated a reduction of one hot flush per day at one month, but this benefit became non-significant by the third month.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2010-06-21 15:57:30 +1000" MODIFIED_BY="[Empty name]">
<P>It is important to note that our review is not designed to compare the effects of different therapies. Our goal was to determine whether any of these non-hormonal interventions were effective and therefore we did not include studies that directly compared active interventions. Therefore, indirect comparisons from this review must be interpreted with caution.</P>
<P>We found very limited evidence supporting non-pharmacological alternatives such as homeopathy, magnetic devices and acupuncture for the treatment of hot flushes. Even though all of these studies had limited power to show an effect, it is important to note that none of the studies showed a significant benefit.</P>
<P>The applicability of the results of this review is limited in several ways. First, the review did not include direct comparisons between treatments and, as discussed, it is not possible to draw conclusion on which intervention is best or which is the optimum dose for a particular drug. Second, all studies provided information for short periods of follow up (maximum 12 weeks). Therefore, inferences about chronic use of the interventions should be made carefully. Third, the paucity of data on adverse effects makes it difficult to perform an adequate assessment of benefit to risk.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2010-06-21 16:00:15 +1000" MODIFIED_BY="[Empty name]">
<P>The main limitation in the quality of the evidence from this review relates to the loss of follow up, which ranged from 3% to 40% in the included studies. The loss of this data could potentially result in an overestimatation of the true effect, by not considering participants who possibly had less benefit or no benefit at all. Furthermore, losses to follow up were pronounced in those studies evaluating the interventions that appeared to be more effective. For instance, 17% of the participants in the study of gabapentin were not assessable at the end of the study. On the other hand, one point of reassurance is the dose response gradient between low and higher doses, even though more women could not be assessed in the low-dose group. An important number of participants in the SSRI/SNRI studies were also not assessable (range 8% to 40%). The fact that the larger study is the one with better follow up (<LINK REF="STD-Loprinzi-2000" TYPE="STUDY">Loprinzi 2000</LINK>) makes the estimate less prone to bias.</P>
<P>An important limitation of the studies on relaxation therapy is the lack of blinding. The effect of relaxation therapy was mild to moderate and was not maintained at three months. It is very difficult to be certain if the benefit obtained in one of these studies is real or could be explained by its quality limitations, particularly a placebo effect.</P>
</QUALITY_OF_EVIDENCE>
<AGREEMENT MODIFIED="2010-07-12 11:47:03 +1000" MODIFIED_BY="Melina Willson">
<P>We have no knowledge of other systematic reviews evaluating non-hormonal therapies alone in women with a history of breast cancer. Four previous systematic reviews looked at the effects of non-hormonal therapies on hot flushes and included a combination of postmenopausal women and women with a history of breast cancer (<LINK REF="REF-Bordeleau-2007" TYPE="REFERENCE">Bordeleau 2007</LINK>; <LINK REF="REF-Cheema-2007" TYPE="REFERENCE">Cheema 2007</LINK>; <LINK REF="REF-Nedrow-2006" TYPE="REFERENCE">Nedrow 2006</LINK>; <LINK REF="REF-Nelson-2006" TYPE="REFERENCE">Nelson 2006</LINK>). These reviews included some therapies that we consider to be hormonal (for example phytoestrogens, black cohosh, tibolone). The conclusions yielded from these reviews, with a broader question, were similar to those that we obtained, that is a mild to moderate benefit from some pharmacological treatments but little or no effect from non-pharmacological options.<BR/>
<BR/>Although the conclusions from the reviews with a broader question and our review are similar, we think it is premature to assume that hot flushes can be managed in the same way in postmenopausal women and women with a history of breast cancer. Aside from the biological and psychological differences between these two populations, the studies on the latter represent a small proportion of the total and the amount of evidence on each group of interventions is very limited.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-07-26 12:30:05 +1000" MODIFIED_BY="Melina Willson">
<IMPLICATIONS_PRACTICE MODIFIED="2010-06-21 16:10:51 +1000" MODIFIED_BY="[Empty name]">
<P>Based on a limited number of studies, it appears that clonidine has some benefit in relieving hot flushes in women with a history of breast cancer but with side-effects. The epidermal patch, in particular, was associated with dry mouth, constipation, dizziness and itching. Any recommendation for its use would need to consider the impact of hot flushes on quality of life against the potential side-effects for an individual.<BR/>
<BR/>The benefits shown with SSRIs and SNRIs are promising, particularly due to their good safety profile. However, since the absolute benefit is rather small, the costs and each woman's preference should guide recommendations.<BR/>
<BR/>Based on a single study, gabapentin also shows benefit in high doses, but not with lower doses. There is a trade-off between this potentially greater benefit, cost considerations and the need for more frequent administration (three times a day).</P>
<P>Vitamin E was not effective. Considering there is no plausible mechanism for an effect of this treatment on hot flushes, it should not be considered as an alternative therapy for this condition.<BR/>
<BR/>There is little evidence on non-pharmacological therapies and the majority of studies did not show any benefit. The only exception is relaxation therapy, which showed a mild effect in the short term. This benefit was not sustained at three months. The risk of bias of the study showing benefit was high so it is difficult to be certain if there is a real effect.<BR/>
</P>
<P>In summary, the evidence supports three pharmacological and probably one non-pharmacological intervention to reduce the frequency and intensity of hot flushes in women with a history of breast cancer.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-07-26 12:30:05 +1000" MODIFIED_BY="Melina Willson">
<P>In women with breast cancer and hot flushes there are some questions that still remain regarding which class of drugs, and which drug within a class (that is SSRIs and SNRIs) or which dose is more effective.</P>
<P>The effect of combined therapies is also an important factor which should be considered in future research, particularly as none of the evaluated treatments fully resolved symptoms.</P>
<P>Research on other pharmacological and non-pharmacological treatments is clearly needed.</P>
<P>Research on some complementary therapies is also needed. Even though there is some evidence on the potential hormonal mechanism of some agents (e.g. black cohosh, soy products) there is still no consensus regarding their clinical relevance. These agents are widely used in clinical practice.</P>
<P>The following should be included and reported on in future trials.</P>
<UL>
<LI>Validated scores of severity of hot flushes, like the one employed in the majority of trials of pharmacological therapies. Outcomes should be measured in the long term, ideally longer than three months.</LI>
<LI>Numbers of participants developing individually identified adverse effects.</LI>
<LI>Efforts should be made to obtain complete follow-up data. If this is not achieved, losses must be taken into account in the analyses.</LI>
<LI>The method of reporting continuous outcomes is critical for systematic reviews. A consensus in the way of reporting hot flushes is required.</LI>
</UL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-06-21 16:17:19 +1000" MODIFIED_BY="[Empty name]">
<P>We would like to thank Cecilia Pacheco who provided great support and assistance in the development of the search strategies; Dr Charles L Loprinzi who facilitated additional data for two of the included studies; and Sharon Parker and other members of the Cochrane Breast Cancer Group who provided us with invaluable help.<BR/>
<BR/>
</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2010-06-20 17:43:09 +1000" MODIFIED_BY="[Empty name]">
<P>None</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-06-20 22:15:58 +1000" MODIFIED_BY="[Empty name]">
<P>Gabriel Rada: background, criteria for considering studies. Data extraction and quality assessment of included studies. Statistical analyses. Manuscript redaction.</P>
<P>Luz María Letelier: review methods. Discrepancies resolution. Manuscript redaction.</P>
<P>Javiera Corbalán: screening of studies.</P>
<P>Tomás Pantoja: criteria for considering studies, statistical analyses.</P>
<P>Daniel Capurro: criteria for considering studies, review methods. Data extraction and quality assessment of included studies. Manuscript redaction.</P>
<P>Gladys Moreno: screening of studies.</P>
<P>Claudio Vera: statistical analyses. Manuscript redaction.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2010-06-25 12:07:03 +1000" MODIFIED_BY="Melina Willson">
<P>On<I> types of interventions (under 'Criteria for considering studies for this review')</I>
</P>
<P>We decided to include any study independent of the time of follow up, even though we had established that we were going to include "any non-hormonal therapy administered for at least one month". This decision was made before screening for articles so should not have introduced selection bias.</P>
<P>On<I> Search methods for identification of studies</I>
</P>
<P>We did not perform handsearching as we did not identify any relevant journal that was not already included in the Cochrane Breast Cancer Group Specialized Register.</P>
<P>On <I>Assessment of Methodological Quality (under 'Methods of the Review')</I>
</P>
<P>The quality assessment followed the same principles to that stated in the protocol. In order to facilitate the presentation and understanding, they are shown in 'Risk of bias' tables and 'Summary of finding' tables.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-08-03 09:26:23 +1000" MODIFIED_BY="Melina Willson">
<STUDIES MODIFIED="2010-08-03 09:26:23 +1000" MODIFIED_BY="Melina Willson">
<INCLUDED_STUDIES MODIFIED="2010-07-26 12:34:35 +1000" MODIFIED_BY="Melina Willson">
<STUDY DATA_SOURCE="PUB" ID="STD-Barton-1998" MODIFIED="2008-10-06 03:57:07 +1100" MODIFIED_BY="[Empty name]" NAME="Barton 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Barton DL, Loprinzi CL, Quella SK, Sloan JA, Veeder MH, Egner JR</AU>
<TI>Prospective evaluation of vitamin E for hot flashes in breast cancer survivors</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>2</NO>
<PG>495-500</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carpenter-2002" MODIFIED="2010-06-20 17:08:51 +1000" MODIFIED_BY="[Empty name]" NAME="Carpenter 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-06-20 17:08:51 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter JS, Wells N, Lambert B, Watson P, Slayton T, Chak B</AU>
<TI>A pilot study of magnetic therapy for hot flashes after breast cancer</TI>
<SO>Cancer Nursing</SO>
<YR>2002</YR>
<VL>25</VL>
<NO>2</NO>
<PG>104-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carpenter-2007a" MODIFIED="2010-07-26 12:32:54 +1000" MODIFIED_BY="Melina Willson" NAME="Carpenter 2007a" YEAR="2007">
<REFERENCE MODIFIED="2010-07-26 12:32:54 +1000" MODIFIED_BY="Melina Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter JS, Storniolo AM, Johns S, Monahan PO, Azzouz F, Elam JL, et al</AU>
<TI>Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer</TI>
<SO>The Oncologist</SO>
<YR>2007</YR>
<VL>12</VL>
<PG>124-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carpenter-2007b" MODIFIED="2010-07-26 12:33:05 +1000" MODIFIED_BY="Melina Willson" NAME="Carpenter 2007b" YEAR="2007">
<REFERENCE MODIFIED="2010-07-26 12:33:05 +1000" MODIFIED_BY="Melina Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter JS, Storniolo AM, Johns S, Monahan PO, Azzouz F, Elam JL, et al</AU>
<TI>Randomized, Double-Blind, Placebo-Controlled Crossover Trials of Venlafaxine for Hot Flashes After Breast Cancer</TI>
<SO>The Oncologist</SO>
<YR>2007</YR>
<VL>12</VL>
<PG>124-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deng-2007" MODIFIED="2010-07-26 12:33:14 +1000" MODIFIED_BY="Melina Willson" NAME="Deng 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-07-26 12:33:14 +1000" MODIFIED_BY="Melina Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deng G, Vickers AJ, Yeung KS, D&#8217;Andrea GM, Xiao H, Heerdt AS, et al</AU>
<TI>Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>35</NO>
<PG>5584-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fenlon-1999" MODIFIED="2008-10-06 03:57:25 +1100" MODIFIED_BY="[Empty name]" NAME="Fenlon 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fenlon D</AU>
<TI>Relaxation therapy as an intervention for hot flushes in women with breast cancer</TI>
<SO>European Journal of Oncology Nursing</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>4</NO>
<PG>223-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fenlon-2008" MODIFIED="2010-06-20 17:13:33 +1000" MODIFIED_BY="[Empty name]" NAME="Fenlon 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-06-20 17:13:33 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fenlon D, Corner JL, Haviland JS</AU>
<TI>A randomized controlled trial of relaxation training to reduce hot flashes in women with primary breast cancer</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2008</YR>
<VL>35</VL>
<NO>4</NO>
<PG>397-405</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldberg-1994" MODIFIED="2010-07-26 12:33:32 +1000" MODIFIED_BY="Melina Willson" NAME="Goldberg 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-07-26 12:33:32 +1000" MODIFIED_BY="Melina Willson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Goldberg RM, Loprinzi CL, O'Fallon JR, Veeder MH, Miser AW, Mailliard JA, et al</AU>
<TI>Transdermal clonidine for ameliorating tamoxifen-induced hot flashes</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1994</YR>
<VL>12</VL>
<NO>1</NO>
<PG>155-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jacobs-2005" MODIFIED="2010-06-20 17:15:43 +1000" MODIFIED_BY="[Empty name]" NAME="Jacobs 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-03-02 20:10:28 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jacobs J , Dawson P, Bowden R</AU>
<TI>Homeopathy for hot flashes in breast cancer survivors</TI>
<SO>Era of Hope: Department of Defense Breast Cancer Research program meeting</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-06-20 17:15:43 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jacobs J, Herman P, Heron K, Olsen S, Vaughters L</AU>
<TI>Homeopathy for menopausal symptoms in breast cancer survivors: a preliminary randomized controlled trial</TI>
<SO>Journal of Alternative and Complementary Medicine</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>1</NO>
<PG>21-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kimmick-2006" MODIFIED="2010-06-20 17:17:56 +1000" MODIFIED_BY="[Empty name]" NAME="Kimmick 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-06-08 09:15:18 +1000" MODIFIED_BY="Melina Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kimmick GG, Lovato J, McQuellon R, Robinson E, Muss HB</AU>
<TI>Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen</TI>
<SO>The Breast Journal</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>2</NO>
<PG>114-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-06-20 17:17:56 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kimmick GG</AU>
<TI>Randomized, placebo-controlled study of sertraline (Zoloft TM) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen</TI>
<SO>ASCO Annual Meeting</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loprinzi-2000" MODIFIED="2010-07-26 12:33:50 +1000" MODIFIED_BY="Melina Willson" NAME="Loprinzi 2000" YEAR="">
<REFERENCE MODIFIED="2010-07-26 12:33:50 +1000" MODIFIED_BY="Melina Willson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, et al</AU>
<TI>Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>356</VL>
<NO>9247</NO>
<PG>2059-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-03-02 20:52:38 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>O'Connell MJ</AU>
<TI>Phase III randomised study of venlafaxine for hot flashes in women with prior breast cancer</TI>
<SO>Physician Data Query (PDQ)</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loprinzi-2002" MODIFIED="2010-07-26 12:34:03 +1000" MODIFIED_BY="Melina Willson" NAME="Loprinzi 2002" YEAR="">
<REFERENCE MODIFIED="2010-07-26 12:34:03 +1000" MODIFIED_BY="Melina Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loprinzi CL, Quella SK, Sloan JA, Perez EA, Fitch TR, Rummans TA, et al</AU>
<TI>Preliminary data from a randomized evaluation of fluoxetine (Prozac) for treating hot flashes in breast cancer survivors</TI>
<SO>Breast Cancer Research and Treatment</SO>
<YR>1999</YR>
<VL>57</VL>
<NO>1</NO>
<PG>34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-06-20 17:21:25 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA</AU>
<TI>Phase III evaluation of fluoxetine for treatment of hot flashes</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>6</NO>
<PG>1578-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pandya-2000" MODIFIED="2010-07-26 12:34:12 +1000" MODIFIED_BY="Melina Willson" NAME="Pandya 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-07-26 12:34:12 +1000" MODIFIED_BY="Melina Willson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pandya KJ, Raubertas RF, Flynn PJ, Hynes HE, Rosenbluth RJ, Kirshner JJ, et al</AU>
<TI>Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2000</YR>
<VL>132</VL>
<NO>10</NO>
<PG>788-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pandya-2005" MODIFIED="2010-07-26 12:34:25 +1000" MODIFIED_BY="Melina Willson" NAME="Pandya 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-07-26 12:34:25 +1000" MODIFIED_BY="Melina Willson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pandya KJ, Morrow GR, Roscoe JA, Zhao H, Hickok JT, Pajon E, et al</AU>
<TI>Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>366</VL>
<NO>9488</NO>
<PG>818-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-03-02 20:55:01 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Pandya KJ</AU>
<TI>Randomized study of gabapentin for the control of hot flashes and other vasomotor symptoms in women with breast cancer</TI>
<SO>Physician Data Query (PDQ)</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-03-02 20:24:50 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Pandya KJ</AU>
<TI>Randomized study of gabapentin for the control of hot flashes and other vasomotor symptoms in women with breast cancer</TI>
<SO>Physician Data Query</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stearns-2005" MODIFIED="2010-07-26 12:34:35 +1000" MODIFIED_BY="Melina Willson" NAME="Stearns 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-07-26 12:34:35 +1000" MODIFIED_BY="Melina Willson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Stearns V, Slack R, Greep N, Henry-Tilman R, Osborne M, Bunnell C, et al</AU>
<TI>Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>28</NO>
<PG>6919-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-03-02 20:45:11 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Stearns V</AU>
<TI>Paroxetine: preliminary data on breast cancer survivors</TI>
<SO>Menopause</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thompson-2005" MODIFIED="2010-06-20 17:23:17 +1000" MODIFIED_BY="[Empty name]" NAME="Thompson 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-06-20 17:23:17 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Thompson EA, Montgomery A, Douglas D, Reilly D</AU>
<TI>A pilot, randomized, double-blinded, placebo-controlled trial of individualized homeopathy for symptoms of estrogen withdrawal in breast-cancer survivors</TI>
<SO>Journal of Alternative and Complementary Medicine</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>1</NO>
<PG>13-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-06-20 17:23:41 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ganz-2000" MODIFIED="2010-06-20 17:23:41 +1000" MODIFIED_BY="[Empty name]" NAME="Ganz 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-06-20 17:23:41 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ganz PA, Greendale GA, Petersen L, Zibecchi L, Kahn B, Belin TR</AU>
<TI>Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2000</YR>
<VL>92</VL>
<NO>13</NO>
<PG>1054-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Li-2006" MODIFIED="2008-10-12 19:30:40 +1100" MODIFIED_BY="[Empty name]" NAME="Li 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-10-12 19:30:35 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Li P</AU>
<TI>The assessment of randomized double blind clinical trial of Shugan-liangxue prescription used for the treatment of hot flashes in breast cancer patients</TI>
<SO>Abstract presentation from the 2006 ASCO Annual Meeting</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-08-03 09:25:09 +1000" MODIFIED_BY="Melina Willson">
<STUDY DATA_SOURCE="PUB" ID="STD-Dyer-2008" MODIFIED="2010-06-20 17:24:58 +1000" MODIFIED_BY="[Empty name]" NAME="Dyer 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-06-20 17:24:58 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dyer J, Ashley S, Shaw C</AU>
<TI>A study to look at the effects of a hydrolat spray on hot flushes in women being treated for breast cancer</TI>
<SO>Complementary Therapies in Clinical Practice</SO>
<YR>2008</YR>
<VL>14</VL>
<PG>273-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elkins-2008" MODIFIED="2010-06-20 17:25:20 +1000" MODIFIED_BY="[Empty name]" NAME="Elkins 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-06-20 17:25:20 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elkins G, Marcus J, Stearns V, Perfect M, Rajab MH, Ruud C et al</AU>
<TI>Randomised trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>31</NO>
<PG>5022-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-ISRCTN33947463" MODIFIED="2010-08-03 09:23:29 +1000" MODIFIED_BY="Melina Willson" NAME="ISRCTN33947463" YEAR="">
<REFERENCE MODIFIED="2010-08-03 09:23:07 +1000" MODIFIED_BY="Melina Willson" PRIMARY="NO" TYPE="OTHER">
<AU>ISRCTN33947463</AU>
<TI>A randomised trial of the use of hypnosis to affect menopausal vasomotor symptoms in women with early stage breast cancer, using a waiting list control</TI>
<SO>controlled-trials.com/ISRCTN33947463</SO>
<YR>(accessed 21 May 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loprinzi-2010" MODIFIED="2010-07-26 12:35:04 +1000" MODIFIED_BY="Melina Willson" NAME="Loprinzi 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-07-26 12:35:04 +1000" MODIFIED_BY="Melina Willson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loprinzi CL, Qin R, Bacleauva EP, Flynn KA, Rowland KM, Graham DL, et al</AU>
<TI>Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2010</YR>
<VL>28</VL>
<NO>4</NO>
<PG>641-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00425776" MODIFIED="2010-08-03 09:25:09 +1000" MODIFIED_BY="Melina Willson" NAME="NCT00425776" YEAR="2007">
<REFERENCE MODIFIED="2010-08-03 09:24:48 +1000" MODIFIED_BY="Melina Willson" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00425776</AU>
<TI>Treatment of hot flushes in breast cancer patients with acupuncture</TI>
<SO>clinicaltrials.gov/show/NCT00425776</SO>
<YR>(accessed 21 May 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2010-08-03 09:26:23 +1000" MODIFIED_BY="Melina Willson">
<STUDY DATA_SOURCE="UNPUB" ID="STD-ISRCTN13771934" MODIFIED="2010-08-03 09:26:23 +1000" MODIFIED_BY="Melina Willson" NAME="ISRCTN13771934" YEAR="2009">
<REFERENCE MODIFIED="2010-08-03 09:25:53 +1000" MODIFIED_BY="Melina Willson" PRIMARY="NO" TYPE="OTHER">
<AU>ISRCTN13771934</AU>
<TI>A trial of a non-medical treatment for menopausal symptoms in women with breast cancer</TI>
<SO>controlled-trials.com/ISRCTN13771934</SO>
<YR>(accessed 21 May 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00363909" MODIFIED="2010-08-03 09:19:01 +1000" MODIFIED_BY="Melina Willson" NAME="NCT00363909" YEAR="">
<REFERENCE MODIFIED="2010-08-03 09:18:16 +1000" MODIFIED_BY="Melina Willson" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00363909</AU>
<TI>Citalopram in treating postmenopausal women with hot flashes</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00363909</SO>
<YR>(accessed 21 May 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00582244" MODIFIED="2010-08-03 09:14:13 +1000" MODIFIED_BY="Melina Willson" NAME="NCT00582244" YEAR="">
<REFERENCE MODIFIED="2010-08-03 09:12:59 +1000" MODIFIED_BY="Melina Willson" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00582244</AU>
<TI>Cognitive Behavioral Therapy (CBT) and physical exercise for climacteric symptoms in breast cancer patients experiencing treatment-induced menopause: a multi-centre randomised trial (EVA project)</TI>
<SO>clinicaltrials.gov/show/NCT00582244</SO>
<YR>(accessed 21 May 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00641303" MODIFIED="2010-08-03 09:20:37 +1000" MODIFIED_BY="Melina Willson" NAME="NCT00641303" YEAR="2008">
<REFERENCE MODIFIED="2010-08-03 09:20:20 +1000" MODIFIED_BY="Melina Willson" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00641303</AU>
<TI>Acupuncture in reducing muscle and bone symptoms in women receiving letrozole, exemestane, anastrozole for stage 0, stage I, stage II, or stage III breast cancer</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00641303</SO>
<YR>(accessed 21 May 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00956813" MODIFIED="2010-08-03 09:21:49 +1000" MODIFIED_BY="Melina Willson" NAME="NCT00956813" YEAR="2009">
<REFERENCE MODIFIED="2010-08-03 09:21:38 +1000" MODIFIED_BY="Melina Willson" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00956813</AU>
<TI>Flaxseed in treating postmenopausal women with hot flashes who have a history of breast cancer or other cancer or who do not wish to take estrogen therapy</TI>
<SO>clinicaltrials.gov/ct2/show.NCT00956813</SO>
<YR>(accessed 21 May 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-07-26 12:38:21 +1000" MODIFIED_BY="Melina Willson">
<ADDITIONAL_REFERENCES MODIFIED="2010-07-26 12:38:21 +1000" MODIFIED_BY="Melina Willson">
<REFERENCE ID="REF-Allegra-1980" MODIFIED="2010-05-14 15:04:01 +1000" MODIFIED_BY="Melina Willson" NAME="Allegra 1980" TYPE="JOURNAL_ARTICLE">
<AU>Allegra JC, Lippman ME</AU>
<TI>Estrogen receptor status and the disease-free interval in breast cancer</TI>
<SO>Recent Results In Cancer Research</SO>
<YR>1980</YR>
<VL>71</VL>
<PG>20-5</PG>
<IDENTIFIERS MODIFIED="2010-05-14 15:04:01 +1000" MODIFIED_BY="Melina Willson"/>
</REFERENCE>
<REFERENCE ID="REF-Anderson-2004" MODIFIED="2010-07-26 12:35:18 +1000" MODIFIED_BY="Melina Willson" NAME="Anderson 2004" TYPE="JOURNAL_ARTICLE">
<AU>Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al</AU>
<TI>Effects of conjugated equine estrogen in postmenopausal women with hysterectomy</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>291</VL>
<PG>1701-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beral-2003" MODIFIED="2010-06-08 09:16:50 +1000" MODIFIED_BY="Melina Willson" NAME="Beral 2003" TYPE="JOURNAL_ARTICLE">
<AU>Beral V</AU>
<TI>Breast cancer and hormone-replacement therapy in the Million Women Study</TI>
<SO>Lancet</SO>
<YR>2003</YR>
<VL>362</VL>
<NO>9382</NO>
<PG>419-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bordeleau-2007" MODIFIED="2010-07-26 12:35:26 +1000" MODIFIED_BY="Melina Willson" NAME="Bordeleau 2007" TYPE="JOURNAL_ARTICLE">
<AU>Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J, et al</AU>
<TI>Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis</TI>
<SO>JAMA</SO>
<YR>2006</YR>
<VL>295</VL>
<NO>17</NO>
<PG>2057-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1998" MODIFIED="2010-07-26 12:35:38 +1000" MODIFIED_BY="Melina Willson" NAME="Carpenter 1998" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter JS, Andrykowski MA, Cordova M, Cunningham L, Studts J, McGrath P, et al</AU>
<TI>Hot flashes in postmenopausal women treated for breast carcinoma: prevalence, severity, correlates, management, and relation to quality of life</TI>
<SO>Cancer</SO>
<YR>1998</YR>
<VL>82</VL>
<NO>9</NO>
<PG>1682-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9576289"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cella-2008" MODIFIED="2010-05-14 15:06:03 +1000" MODIFIED_BY="Melina Willson" NAME="Cella 2008" TYPE="JOURNAL_ARTICLE">
<AU>Cella D, Fallowfield LJ</AU>
<TI>Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy</TI>
<SO>Breast Cancer Research and Treatment</SO>
<YR>2008</YR>
<VL>107</VL>
<NO>2</NO>
<PG>167-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cheema-2007" MODIFIED="2009-03-20 14:53:41 +1100" MODIFIED_BY="[Empty name]" NAME="Cheema 2007" TYPE="JOURNAL_ARTICLE">
<AU>Cheema D, Coomarasamy A, El-Toukhy T</AU>
<TI>Non-hormonal therapy of post-menopausal vasomotor symptoms: a structured evidence-based review</TI>
<SO>Archives of Gynecology and Obstetrics</SO>
<YR>2007</YR>
<VL>276</VL>
<NO>5</NO>
<PG>463-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chlebowski-2003" MODIFIED="2010-07-26 12:35:52 +1000" MODIFIED_BY="Melina Willson" NAME="Chlebowski 2003" TYPE="JOURNAL_ARTICLE">
<AU>Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al</AU>
<TI>Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>289</VL>
<NO>24</NO>
<PG>3243-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cochrane-Handbook" MODIFIED="2010-06-20 17:32:18 +1000" MODIFIED_BY="[Empty name]" NAME="Cochrane Handbook" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [September 2009]</TI>
<SO>The Cochrane Collaboration</SO>
<YR>2009. Available from www.cochrane-handbook.org</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cochrane-Handbook-5.0.2" MODIFIED="2010-02-01 22:12:04 +1100" MODIFIED_BY="[Empty name]" NAME="Cochrane Handbook 5.0.2" TYPE="BOOK_SECTION">
<AU>OConnor D, Green S, Higgins JPT (editors)</AU>
<TI>Chapter 5: Defining the review question and developing criteria for including studies</TI>
<SO>Cochrane Handbook of Systematic Reviews of Intervention. Version 5.0.2 (updated September 2009)</SO>
<YR>2009</YR>
<ED>Higgins JPT, Green S (editors)</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Daley-2007" MODIFIED="2008-12-19 07:47:39 +1100" MODIFIED_BY="[Empty name]" NAME="Daley 2007" TYPE="JOURNAL_ARTICLE">
<AU>Daley A, MacArthur C, Mutrie N, Stokes-Lampard H</AU>
<TI>Exercise for vasomotor menopausal symptoms</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<VL>4</VL>
<PG>CD006108</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deitcher-2004" MODIFIED="2008-12-16 23:14:58 +1100" MODIFIED_BY="[Empty name]" NAME="Deitcher 2004" TYPE="JOURNAL_ARTICLE">
<AU>Deitcher SR, Gomes MP</AU>
<TI>The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review</TI>
<SO>Cancer</SO>
<YR>2004</YR>
<VL>101</VL>
<NO>3</NO>
<PG>439-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Farquhar-2005" MODIFIED="2008-12-16 08:03:11 +1100" MODIFIED_BY="[Empty name]" NAME="Farquhar 2005" TYPE="JOURNAL_ARTICLE">
<AU>Farquhar CM, Marjoribanks J, Lethaby A, Lamberts Q, Suckling JA; Cochrane HT Study Group</AU>
<TI>Long term hormone therapy for perimenopausal and postmenopausal women</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>3</NO>
<PG>CD004143</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ferlay-2004" MODIFIED="2010-05-14 14:49:13 +1000" MODIFIED_BY="Melina Willson" NAME="Ferlay 2004" TYPE="BOOK">
<AU>Ferlay J, Bray F, Pisani P, Parkin DM</AU>
<SO>Cancer Incidence, Mortality and Prevalence Worldwide IARC CancerBase No. 5. version 2.0.</SO>
<YR>2004</YR>
<PB>IARCPress</PB>
<CY>Lyon</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fitzpatrick-2003" MODIFIED="2010-06-08 09:17:31 +1000" MODIFIED_BY="Melina Willson" NAME="Fitzpatrick 2003" TYPE="JOURNAL_ARTICLE">
<AU>Fitzpatrick LA</AU>
<TI>Alternatives to estrogen</TI>
<SO>Medical Clinics of North America</SO>
<YR>2003</YR>
<VL>87</VL>
<PG>1091-113</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Freedman-2005" MODIFIED="2010-06-20 17:33:46 +1000" MODIFIED_BY="[Empty name]" NAME="Freedman 2005" TYPE="JOURNAL_ARTICLE">
<AU>Freedman R</AU>
<TI>Hot flashes: behavioral treatments, mechanisms, and relation to sleep</TI>
<SO>The American Journal of Medicine</SO>
<YR>2005</YR>
<VL>118 Suppl</VL>
<PG>124-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gartlehner-2008" MODIFIED="2010-05-14 14:49:54 +1000" MODIFIED_BY="Melina Willson" NAME="Gartlehner 2008" TYPE="JOURNAL_ARTICLE">
<AU>Gartlehner G, Thieda P, Hansen RA, Gaynes BN, Deveaugh-Geiss A, Krebs EE et al</AU>
<TI>Comparative risk for harms of second-generation antidepressants : a systematic review and meta-analysis</TI>
<SO>Drug Safety</SO>
<YR>2008</YR>
<VL>31</VL>
<NO>10</NO>
<PG>851-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goodwin-2008" MODIFIED="2010-06-20 17:35:09 +1000" MODIFIED_BY="[Empty name]" NAME="Goodwin 2008" TYPE="JOURNAL_ARTICLE">
<AU>Goodwin JW, Green SJ, Moinpour CM, Bearden JD, Giguere JK, Jiang CS et al</AU>
<TI>Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>10</NO>
<PG>1650-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grady-2006" MODIFIED="2010-06-08 09:17:58 +1000" MODIFIED_BY="Melina Willson" NAME="Grady 2006" TYPE="JOURNAL_ARTICLE">
<AU>Grady D</AU>
<TI>Management of Menopausal Symptoms</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>22</VL>
<NO>355</NO>
<PG>2338-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gupta-2006" MODIFIED="2010-07-26 12:36:17 +1000" MODIFIED_BY="Melina Willson" NAME="Gupta 2006" TYPE="JOURNAL_ARTICLE">
<AU>Gupta P, Sturdee DW, Palin SL, Majumder K, Fear F, Marshall T, et al</AU>
<TI>Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life</TI>
<SO>Climacteric</SO>
<YR>2006</YR>
<VL>9</VL>
<NO>1</NO>
<PG>49-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hofseth-1999" MODIFIED="2010-05-14 15:08:34 +1000" MODIFIED_BY="Melina Willson" NAME="Hofseth 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ</AU>
<TI>Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast</TI>
<SO>The Journal of Clinical Endocrinology and Metabolism</SO>
<YR>1999</YR>
<VL>84</VL>
<NO>12</NO>
<PG>4559-65</PG>
<IDENTIFIERS MODIFIED="2010-05-14 15:08:34 +1000" MODIFIED_BY="Melina Willson"/>
</REFERENCE>
<REFERENCE ID="REF-Holmberg-2008" MODIFIED="2010-07-26 12:36:28 +1000" MODIFIED_BY="Melina Willson" NAME="Holmberg 2008" TYPE="JOURNAL_ARTICLE">
<AU>Holmberg L, Iversen OE, Rudenstam CM, Hammar M, Kumpulainen E, Jaskiewicz J, et al</AU>
<TI>Increased risk of recurrence after hormone replacement therapy in breast cancer survivors</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2008</YR>
<VL>100</VL>
<NO>7</NO>
<PG>475-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jin-2005" MODIFIED="2010-07-26 12:36:38 +1000" MODIFIED_BY="Melina Willson" NAME="Jin 2005" TYPE="JOURNAL_ARTICLE">
<AU>Jin Y, Desta Z, Stearns V, Ward B, Ho H, Kyung-Hoon L, et al</AU>
<TI>CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2005</YR>
<VL>97</VL>
<NO>1</NO>
<PG>30-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Loprinzi-2008" MODIFIED="2010-05-14 14:58:45 +1000" MODIFIED_BY="Melina Willson" NAME="Loprinzi 2008" TYPE="JOURNAL_ARTICLE">
<AU>Loprinzi CL, Wolf SL, Barton DL, Laack NN</AU>
<TI>Symptom management in premenopausal patients with breast cancer</TI>
<SO>Lancet Oncology</SO>
<YR>2008</YR>
<VL>9</VL>
<NO>10</NO>
<PG>993-1001</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Loprinzi-2009" MODIFIED="2009-01-19 22:56:42 +1100" MODIFIED_BY="[Empty name]" NAME="Loprinzi 2009" TYPE="JOURNAL_ARTICLE">
<AU>Loprinzi CL, Barton DL, Sloan JA, Novotny PJ, Wolf S</AU>
<TI>Newer antidepressants for hot flashes--should their efficacy still be up for debate?</TI>
<SO>Menopause</SO>
<YR>2009</YR>
<VL>16</VL>
<NO>1</NO>
<PG>184-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MacLennan-2004" MODIFIED="2008-12-10 01:38:44 +1100" MODIFIED_BY="[Empty name]" NAME="MacLennan 2004" TYPE="JOURNAL_ARTICLE">
<AU>MacLennan AH, Broadbent JL, Lester S, Moore V</AU>
<TI>Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<VL>4</VL>
<PG>CD002978</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McPhail-2000" MODIFIED="2010-05-14 15:10:41 +1000" MODIFIED_BY="Melina Willson" NAME="McPhail 2000" TYPE="JOURNAL_ARTICLE">
<AU>McPhail G, Smith LN</AU>
<TI>Acute menopause symptoms during adjuvant systemic treatment for breast cancer: a case-control study</TI>
<SO>Cancer Nursing</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>6</NO>
<PG>430-43</PG>
<IDENTIFIERS MODIFIED="2010-05-14 15:10:41 +1000" MODIFIED_BY="Melina Willson"/>
</REFERENCE>
<REFERENCE ID="REF-Nedrow-2006" MODIFIED="2010-01-27 06:14:18 +1100" MODIFIED_BY="[Empty name]" NAME="Nedrow 2006" TYPE="JOURNAL_ARTICLE">
<AU>Nedrow A, Miller J, Walker M, Nygren P, Huffman LH, Nelson HD</AU>
<TI>Complementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2006</YR>
<VL>166</VL>
<NO>14</NO>
<PG>1453-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nelson-2006" MODIFIED="2010-07-26 12:36:54 +1000" MODIFIED_BY="Melina Willson" NAME="Nelson 2006" TYPE="JOURNAL_ARTICLE">
<AU>Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J, et al</AU>
<TI>Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis</TI>
<SO>JAMA</SO>
<YR>2006</YR>
<VL>295</VL>
<NO>17</NO>
<PG>2057-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parkin-2005" MODIFIED="2010-05-14 15:14:26 +1000" MODIFIED_BY="Melina Willson" NAME="Parkin 2005" TYPE="JOURNAL_ARTICLE">
<AU>Parkin DM, Bray F, Ferlay J, Pisani P</AU>
<TI>Global cancer statistics, 2002</TI>
<SO>CA: a cancer journal for physicians</SO>
<YR>2005</YR>
<VL>55</VL>
<NO>2</NO>
<PG>74-108</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rossouw-2002" MODIFIED="2010-07-26 12:38:21 +1000" MODIFIED_BY="Melina Willson" NAME="Rossouw 2002" TYPE="JOURNAL_ARTICLE">
<AU>Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al</AU>
<TI>Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>288</VL>
<PG>321-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stein-2000" MODIFIED="2010-05-14 15:16:41 +1000" MODIFIED_BY="Melina Willson" NAME="Stein 2000" TYPE="JOURNAL_ARTICLE">
<AU>Stein KD, Jacobsen PB, Hann DM, Greenberg H, Lyman G</AU>
<TI>Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>6</NO>
<PG>436-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sturdee-2008" MODIFIED="2008-12-18 04:07:40 +1100" MODIFIED_BY="[Empty name]" NAME="Sturdee 2008" TYPE="JOURNAL_ARTICLE">
<AU>Sturdee DW</AU>
<TI>The menopausal hot flush--anything new?</TI>
<SO>Maturitas</SO>
<YR>2008</YR>
<VL>60</VL>
<NO>1</NO>
<PG>42-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1996" MODIFIED="2010-06-20 17:39:32 +1000" MODIFIED_BY="[Empty name]" NAME="WHO 1996" TYPE="JOURNAL_ARTICLE">
<AU>World Health Organization</AU>
<TI>Menopause</TI>
<SO>WHO Technical Report Series. World Health Organization Scientific Group</SO>
<YR>1996</YR>
<VL>7</VL>
<PG>236-42</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-08-03 09:13:27 +1000" MODIFIED_BY="Melina Willson">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-07-25 22:50:30 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-07-25 22:20:48 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barton-1998">
<CHAR_METHODS MODIFIED="2010-01-23 08:30:48 +1100" MODIFIED_BY="[Empty name]">
<P>Cross-over design.<BR/>Randomization with method of dynamic allocation. Stratified by age, current tamoxifen use, duration of hot flushes, average frequency of flushes, and current multivitamin use.<BR/>Described as double-blind.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-25 22:20:48 +1000" MODIFIED_BY="[Empty name]">
<P>Country: United States</P>
<P>Setting: not described.<BR/>
</P>
<P>Inclusion criteria:<BR/>Over 18 years with a history of breast cancer.<BR/>At least 14 episodes of hot flushes per week, for at least one month.<BR/>Life expectancy of six months.<BR/>Performance status of 0 or 1 on the Eastern Cooperative Oncology Group scale.<BR/>
</P>
<P>Exclusion criteria:<BR/>Current or planned therapy with chemotherapy, androgens, estrogens, progestational agents,corticosteroids, or other agents used for treating hot flushes.<BR/>Use of multivitamin tablets over two times per day or over 60 IU of vitamin E.<BR/>Pregnant or lactating women.<BR/>History of bleeding tendencies, immune deficiencies, or thrombophlebitis.</P>
<P>Characteristics of participants:<BR/>Age range or mean not described: 66% were older than 50 years.<BR/>Mean daily hot-flush frequency: 6.5 times per day.<BR/>60% on tamoxifen.<BR/>
</P>
<P>Number of participants/assessable participants: 120/105 for first period.<BR/>Numbers of assessable participants in treatment first/control first arms at the end of the study (not reported for the first period): 54/50<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-27 09:01:07 +1100" MODIFIED_BY="[Empty name]">
<P>Arm 1: Vitamin E succinate 800 IU daily<BR/>Arm 2: Identical-appearing placebo<BR/>
<BR/>Study duration: Four weeks for each period. No washout between cross-over periods.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-23 08:16:30 +1100" MODIFIED_BY="[Empty name]">
<P>Hot-flush frequency.<BR/>Hot-flush severity.<BR/>Hot-flush score (number of hot flushes per day x severity in a scale of 1 to 4, being 4 the maximum severity).<BR/>Patient preference during each period of the cross over.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-23 08:57:44 +1100" MODIFIED_BY="[Empty name]">
<P>5 of 125 participants were excluded after randomization, and before starting study medication.</P>
<P>Only the first period of the cross-over study analysed.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-20 17:47:14 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carpenter-2002">
<CHAR_METHODS MODIFIED="2010-01-20 05:17:30 +1100" MODIFIED_BY="[Empty name]">
<P>Cross-over design.<BR/>Method of randomization not described.<BR/>Patients blinded. Other participants not clear.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-20 17:46:53 +1000" MODIFIED_BY="[Empty name]">
<P>Country: United States</P>
<P>Setting: Cancer center.</P>
<P>Inclusion criteria:<BR/>Over 18 years of age with a first-time diagnosis of breast cancer experiencing daily hot flushes.<BR/>No history of other types of cancer.<BR/>Free of cancer or currently completing treatment for breast cancer.<BR/>Postmenopausal.</P>
<P>Exclusion criteria:<BR/>Contraindications for magnets (including presence of implanted devices).<BR/>Use of other hot flushes treatments.</P>
<P>Characteristics of participants:<BR/>Mean age 57 years.<BR/>Baseline hot flush frequency: mean 10 hot flushes per day.<BR/>55% on tamoxifen.<BR/>
<BR/>Number of participants/assessable participants: 15/11.<BR/>Numbers of assessable participants in treatment first/control first arms: 6/5.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-20 17:47:02 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: Six magnetic devices attached to participants skin placed over acupuncture/acupressure sites used to balance yin energy (female, calming) and treat hot flushes. Acupuncturists located the sites and a nurse installed the devices. Magnetic devices consisted of four separate magnets of alternating polarity.<BR/>Arm 2: Identical placebo devices.</P>
<P>Study duration: 72 hours for each period. Ten days washout between cross-over periods.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-20 17:47:14 +1000" MODIFIED_BY="[Empty name]">
<P>Frequency of hot flushes measured by sternal skin conductance.<BR/>Frequency, severity (from 0 to 10) and bothering (from 0 to 10) of hot flushes measured by hot flushes diary.<BR/>Hot Flash-related Daily Interference Scale (HFRDIS).<BR/>Acceptabiliy of the device.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-27 07:38:06 +1100" MODIFIED_BY="[Empty name]">
<P>Only the first period of the cross-over study analysed.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-20 17:50:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carpenter-2007a">
<CHAR_METHODS MODIFIED="2010-01-20 05:48:24 +1100" MODIFIED_BY="[Empty name]">
<P>Cross-over design.<BR/>Computer-generated randomization sequence (without blocking or stratification).<BR/>Participants, providers and investigators blinded.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-20 17:50:44 +1000" MODIFIED_BY="[Empty name]">
<P>Country: United States</P>
<P>Setting: Cancer center clinics</P>
<P>Inclusion criteria:<BR/>Adult women with a history of breast cancer, experiencing daily hot flushes (1 per day), disease-free and functioning, postmenopausal or using a method of birth control, nondepressed.</P>
<P>Exclusion criteria:<BR/>History of other cancer, tamoxifen or aromatase inhibitor use, antidepressants use, hot flush treatment within the past four weeks, pregnant or lactating.</P>
<P>Characteristics of participants:<BR/>mean age 50.5 years<BR/>51% taking endocrine therapy.<BR/>Baseline frequency of hot flushes: between 6 (written diary) and 7.7 (event marker associated with skin conductance monitor) per day.<BR/>
<BR/>Number of participants/assessable participants: 52/31.<BR/>Numbers of assessable women in treatment first/placebo first arms:16/15.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-20 17:48:35 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: Venlafaxine 37.5 mg daily (extended release formulations).<BR/>Arm 2: Identical-appearing placebo.</P>
<P>Study duration: Six weeks for each period. No washout between cross-over periods.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-20 17:49:00 +1000" MODIFIED_BY="[Empty name]">
<P>Frequency of hot flushes (24-hour ambulatory sternal skin conductance monitoring and written diaries once a week to tabulate electronic events).<BR/>Severity of hot flushes, rated from 0 (not at all) to 10 (extremely severe).<BR/>Bother of hot flushes, rated from 0 (not at all) to 10 (extremely bothersome).<BR/>Hot flush interference with daily activities, and quality of life (Hot Flash-Related Daily Interference Scale).<BR/>Depressive symptoms were evaluated through a Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders at week 6, and the 17-item Hamilton Rating Scale-Depression (Ham-D) at week 2, 4 and 6.<BR/>Negative affect index (combination of four questionnaires to measure anxiety, depression and other negative mood states).<BR/>Fatigue (Profile of Mood States Short Form fatigue subscale).<BR/>Sleep quality (The Pittsburgh Sleep Quality Index).<BR/>Quality of life (36-item Medical Outcomes Survey with its eight subscales).<BR/>Blood pressure and other side-effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-20 17:49:26 +1000" MODIFIED_BY="[Empty name]">
<P>Two studies described in the same article (Carpenter 2007a; Carpenter 2007b).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-20 17:50:34 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carpenter-2007b">
<CHAR_METHODS MODIFIED="2010-01-20 05:31:28 +1100" MODIFIED_BY="[Empty name]">
<P>Cross-over design.<BR/>Computer-generated randomization sequence (without blocking or stratification).<BR/>Participants and providers blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-20 17:50:34 +1000" MODIFIED_BY="[Empty name]">
<P>Country: United States</P>
<P>Setting: Cancer center clinics.</P>
<P>Inclusion criteria: Adult women with a history of breast cancer, experiencing daily hot flushes (1 per day), disease-free and functioning, postmenopausal or using a method of birth control, nondepressed.</P>
<P>Exclusion criteria: History of other cancer, tamoxifen or aromatase inhibitor use, antidepressants use, hot flush treatment within the past four weeks, pregnant or lactating.</P>
<P>Characteristics of participants:<BR/>mean age 53 years<BR/>63% taking endocrine therapy.<BR/>Baseline frequency of hot flushes: between 6 (written diary) and 7.7 (Event marker associated with skin conductance monitor) per day<BR/>
<BR/>Number of patients/assessable women: 18/15<BR/>Numbers of assessable women in treatment first/placebo first arms: 7/8</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-27 09:04:52 +1100" MODIFIED_BY="[Empty name]">
<P>Arm 1: venlafaxine 37.5 mg daily for one week, then venlafaxine 75 mg daily for four weeks, then venlafaxine 37.5 mg daily for one week (extended release formulations)<BR/>Arm 2: Identical-appearing placebo</P>
<P>Study duration: six weeks for each period. No washout between cross-over periods.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-27 08:20:43 +1100" MODIFIED_BY="[Empty name]">
<P>Frequency of hot flushes (24-hour ambulatory sternal skin conductance monitoring and written diaries once a week to tabulate electronic events).<BR/>Severity of hot flushes, rated from 0 (not at all) to 10 (extremely severe).<BR/>Bother of hot flushes, rated from 0 (not at all) to 10 (extremely bothersome).<BR/>Hot flush interference with daily activities, and quality of life (Hot Flash-Related Daily Interference Scale).<BR/>Deppresive symptoms were evaluated through a Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders at week 6, and the 17-item Hamilton Rating Scale-Depression (Ham-D) at week 2, 4 and 6.<BR/>Negative affect index (combination of four questionnaires to measure anxiety, depression and other negative mood states).<BR/>Fatigue (Profile of Mood States Short Form fatigue subscale).<BR/>Sleep quality (The Pittsburgh Sleep Quality Index).<BR/>Quality of life (36-item Medical Outcomes Survey with its eight subscales).<BR/>Blood pressure and other side-effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-20 05:16:41 +1100" MODIFIED_BY="[Empty name]">
<P>Two studies described in the same article (Carpenter 2007a; Carpenter 2007b)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-20 17:52:26 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Deng-2007">
<CHAR_METHODS MODIFIED="2010-01-27 09:05:31 +1100" MODIFIED_BY="[Empty name]">
<P>Cross-over design.<BR/>Randomization sequence generated by computer. Stratified by concurrent treatment, concurrent use of hot flush medication, baseline hot flushes, and menopausal status.<BR/>Participants, researchers and others involved in patient care were blinded. Acupuncturists and research assistant not blinded.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-20 17:51:47 +1000" MODIFIED_BY="[Empty name]">
<P>Country: United States</P>
<P>Setting: Cancer Center.</P>
<P>Inclusion criteria:<BR/>Women undergoing treatment for breast cancer with three or more hot flushes per day.<BR/>Karnofsky performance score over 60</P>
<P>Exclusion criteria:<BR/>Planned surgery, chemotherapy, radiotherapy or immunotherapy.<BR/>Initiation or cessation of hormonal therapy during the trial or within three weeks before the trial.<BR/>Pharmacologic treatment of hot flushes or any use of SSRIs.<BR/>Skin infection.<BR/>Acupuncture treatment in the six weeks prior to study.<BR/>Acupuncture treatment for hot flushes in the previous six months.</P>
<P>Characteristics of participants (Real/Sham):<BR/>Median age 55 years<BR/>Mean baseline hot flush frequency: 8.7/10<BR/>93% postmenopausal.<BR/>Tamoxifen (48/33%), aromatase Inhibitors (19/30%), SSRIs (38/30%).</P>
<P>Number of participants/assessable participants: 72/67.<BR/>Numbers of assessable participants in treatment first/control first arms: 39/28.<BR/>
<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-20 17:52:16 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: Real acupuncture.<BR/>Arm 2: Sham acupuncture.<BR/>
<BR/>Both treatments were administered twice-weekly (eight treatment sessions in weeks 1 through 4) in 19 points, for four weeks.<BR/>Sham and true acupuncture treatments were delivered by several licensed acupuncturists (not always by the same acupuncturist) with at least three years of formal postgraduate training, and 3 to 25 years of continuous practice.<BR/>Different needles in both group in order to provide real or sham acupuncture. No electrical stimulation or other interventions were applied.<BR/>The frequency and duration of the sham acupuncture intervention were identical to those of true acupuncture. External conditions were also identical (relaxation period before acupuncture, music and eye pillow).<BR/>
</P>
<P>Study duration: six weeks of treatment (only first period included in analysis).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-20 17:52:20 +1000" MODIFIED_BY="[Empty name]">
<P>Hot flush frequency (diary).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-20 17:52:26 +1000" MODIFIED_BY="[Empty name]">
<P>Only the participants in the sham acupuncture group were crossed over to the true acupuncture group at week seven. Only the first period of the cross-over study analysed.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-20 17:54:25 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fenlon-1999">
<CHAR_METHODS MODIFIED="2010-06-20 17:53:05 +1000" MODIFIED_BY="[Empty name]">
<P>Parallel-group design.<BR/>Method of randomization not described.<BR/>Participants and providers not blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-20 17:53:27 +1000" MODIFIED_BY="[Empty name]">
<P>Country: United Kingdom</P>
<P>Setting: Breast cancer follow-up clinic in a cancer hospital.</P>
<P>Inclusion criteria:<BR/>Women with a history of treated non metastatic breast cancer with hot flushes.</P>
<P>Exclusion criteria:<BR/>None described.</P>
<P>Characteristics of participants:<BR/>Mean age 49 (range 29 to 74).<BR/>Median daily hot flush frequency: 4 per day in treatment group and 5 in control.<BR/>79% on tamoxifen.</P>
<P>Number of participants/assessable participants: 24/16.<BR/>Numbers of assessable participants in treatment/control arms: 8/8.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-20 17:53:56 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: Occupational therapist-guided relaxation (deep breathing and guided imaginery).<BR/>Arm 2: No treatment.</P>
<P>Study duration: one month of treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-20 17:54:25 +1000" MODIFIED_BY="[Empty name]">
<P>Hot flush frequency.<BR/>General Health Questionnaire.<BR/>Distress (0-10 visual analogue scale).<BR/>Problem factor (0-10 visual analogue scale).<BR/>Interference (0-10 visual analogue scale).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-20 17:56:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fenlon-2008">
<CHAR_METHODS MODIFIED="2010-06-20 17:54:43 +1000" MODIFIED_BY="[Empty name]">
<P>Parallel-group design.<BR/>Computer-generated randomization list. Stratified according to clinic site and age.<BR/>Participants and providers not blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-20 17:55:24 +1000" MODIFIED_BY="[Empty name]">
<P>Country: United Kingdom</P>
<P>Study setting: Three breast cancer follow-up clinics in England.<BR/>
<BR/>Inclusion criteria:<BR/>Women with a history primary breast cancer with hot flushes described as troublesome by the patient.</P>
<P>Exclusion criteria:<BR/>Use of estrogen therapy, aromatase inhibitors, or any other hormone therapies except tamoxifen.<BR/>Use of remedies or prescription medicines likely to have an impact on hot flushes, such as acupuncture, venlafaxine, progesterones, or clonidine.</P>
<P>Characteristics of participants:<BR/>Mean age 55, range from 36 to 77 years.<BR/>Baseline hot-flush frequency: Mean 4.5 per day for treatment and 5.3 for control group.<BR/>55% on tamoxifen.<BR/>
</P>
<P>Number of participants/assessable participants: 150/104.<BR/>Numbers of assessable participants in treatment/control arms: 50/54.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-20 17:56:20 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: Relaxation therapy.<BR/>Arm 2: Control group.</P>
<P>Relaxation therapy consisted of: One-hour session of occupational therapist-guided relaxation (stress management; written information about stress; and a session  of relaxation using deep breathing techniques, muscle relaxation and guided imaginery). Audiotape to use at home for 20 minutes once per day for at least one month.<BR/>Control: One session with a specialist nurse to discuss hot flushes and menopause management.</P>
<P>Study duration: One month of treatment. Two months of additional follow up.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-20 17:56:41 +1000" MODIFIED_BY="[Empty name]">
<P>Hot flushes frequency and severity through self-administered diary.<BR/>Hot flushes score (number of hot flushes per day x severity in a scale of 1 to 4, being 4 the maximum severity).<BR/>Hunter menopause scale (distress caused by flushes).<BR/>Quality of life, using Functional Assessment of Cancer Therapy with the endocrine subscale (FACT-ES).<BR/>Anxiety, using the Spielberger State/Trait Anxiety Index (STAI).</P>
<P>All outcomes evaluated at months one and three.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-20 17:58:32 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goldberg-1994">
<CHAR_METHODS MODIFIED="2010-01-25 01:13:01 +1100" MODIFIED_BY="[Empty name]">
<P>Cross-over design.<BR/>Method of randomization not described. Stratified by age, duration of tamoxifen use, duration of hot-flush symptoms, and the average frequency and severity of hot flushes.<BR/>Described as double blind.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-20 17:57:59 +1000" MODIFIED_BY="[Empty name]">
<P>Country: United States</P>
<P>Setting: not described.</P>
<P>Inclusion criteria:<BR/>Adult women receiving tamoxifen for breast cancer.<BR/>At least seven episodes of hot flushes per week, for at least one month.<BR/>Life expectancy of six months.<BR/>Performance status of 0 or 1 on the Eastern Cooperative Oncology Group.</P>
<P>Exclusion criteria:<BR/>Use of chemotherapy, androgens, estrogens, progestational agents, corticosteroids, monoamine oxidase inhibitors, levodopa, piribedil, tricyclic antidepressants, or sedatives such as benzodiazepines or barbiturates.<BR/>Poorly controlled hypertension, coronary insufficiency, history of myocardial infarction, symptomatic coronary artery disease, peripheral or cerebral vascular disease, syncope, symptomatic hypotension, significant hepatic or renal dysfunction, a history of significant mental depression.<BR/>Widespread skin disease, or a history of allergic or adverse reactions to clonidine.<BR/>Pregnant or nursing patients.</P>
<P>Characteristics of participants:<BR/>Median age 54 years.<BR/>Baseline hot flushes: Median frequency (hot flush per day) 6.1 in clonidine first arm and 7.0 in placebo first arm.<BR/>
</P>
<P>Number of participants/assessable participants:110/89 (86 for severity of hot flushes).<BR/>Numbers of assessable participants in treatment first/control first arms: 42/47.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-20 17:58:06 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: Transdermal clonidine patch (equivalent to a daily oral dose of 0.1 mg). Patches changed weekly.<BR/>Arm 2: Identical-appearing placebo patches.<BR/>
<BR/>Study duration: four weeks for each period. No washout between cross-over periods.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-20 17:58:32 +1000" MODIFIED_BY="[Empty name]">
<P>- Average daily number of hot flushes and average daily score (number of hot flushes per day x severity in a scale of 1 to 4, being 4 the maximum severity). Severity was graded as mild, moderate, severe and very severe. A self-administered questionnaire was used to collect the information about hot flushes through a daily diary hot-flush questionnaire.<BR/>- Side-effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-25 22:50:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jacobs-2005">
<CHAR_METHODS MODIFIED="2010-06-20 17:58:49 +1000" MODIFIED_BY="[Empty name]">
<P>Parallel-group design.<BR/>Computer-generated randomization. Stratified by age, breast cancer staging and use of tamoxifen.<BR/>Participants and providers blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-25 22:50:30 +1000" MODIFIED_BY="[Empty name]">
<P>Country: United States</P>
<P>Setting: Not described.</P>
<P>Inclusion criteria:<BR/>Women with a history of breast cancer (carcinoma in situ and stages I to III).<BR/>At least three episodes of hot flushes per day for at least one month.</P>
<P>Exclusion criteria:<BR/>Use of other hot flushes treatments, including vitamin regimens, herbs, estrogen or progestational agents, antidepressants, or sleep medications.<BR/>Chronic health problems such as rheumatoid arthritis, asthma, heart disease and inflammatory bowel disease necessitating treatment with corticosteroids.<BR/>Chemotherapy or radiation therapy expected to be received in the next year.<BR/>Pregnant or planned to become pregnant in the next year.</P>
<P>Characteristics of participants:<BR/>Mean age 55.5 years.<BR/>Mean daily hot-flush frequency not mentioned.<BR/>58% on tamoxifen. Tamoxifen use was allowed, other drugs not mentioned but 65% were taking unspecified hormones.</P>
<P>Number of participants/assessable participants: 83/79.<BR/>Numbers of assessable participants in Arm 1/Arm 2/control arm: 24/29/26.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-20 17:59:48 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: Single homeopathic remedy.<BR/>Arm 2: Combination homeopathic remedy (Hyland's menopause).<BR/>Arm 3: Identical-appearing placebo.</P>
<P>Study duration: One year.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-20 17:59:59 +1000" MODIFIED_BY="[Empty name]">
<P>Total number of hot flushes.<BR/>Hot flush score (number of hot flushes per day x severity in a scale of 1 to 4, being 4 the maximum severity).<BR/>Kupperman Menopausal Index.<BR/>SF-36 Quality of Life Score.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-20 18:00:09 +1000" MODIFIED_BY="[Empty name]">
<P>28 withdrawals. Not clear if considered for calculations.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-20 18:01:50 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kimmick-2006">
<CHAR_METHODS MODIFIED="2010-01-19 23:01:56 +1100" MODIFIED_BY="[Empty name]">
<P>Cross-over design.<BR/>Method of randomization not described. Stratified by menopausal status and average number of hot flushes per day.<BR/>Described as double blind.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-20 18:01:10 +1000" MODIFIED_BY="[Empty name]">
<P>Country: United States</P>
<P>Setting: Not described.</P>
<P>Inclusion criteria:<BR/>Women over 18 years with localized breast cancer (including stages 0&#8211;IIIB; American Joint Committee on Cancer, version 5), receiving adjuvant tamoxifen therapy.<BR/>At least one hot flush per day (or more than seven hot flushes per week).</P>
<P>Exclusion criteria:<BR/>Pregnant or breastfeeding.<BR/>History of seizure disorder or hepatic or renal insufficiency.<BR/>Use of estrogen, progestational agents, corticosteroids, androgens, or other antidepressants.</P>
<P>Characteristics of participants:<BR/>Mean age 54 (range 36 to 77 years).<BR/>Baseline hot flush frequency was 5.8 and score 11.5.<BR/>
</P>
<P>Number of participants/assessable participants: 62/39.<BR/>Numbers of assessable participants in treatment first/control first arms: 20/19.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-20 18:01:19 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: Sertraline 50 mg daily.<BR/>Arm 2: Placebo.<BR/>Study duration: six weeks for each period. No washout between cross-over periods.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-20 18:01:50 +1000" MODIFIED_BY="[Empty name]">
<P>- Hot flush self-assessment diary, frequency and intensity, score (number of hot flushes per day x severity in a scale of 1 to 4, being 4 the maximum severity).<BR/>- Questionnaires for mood status, the Center for Epidemiologic Studies depression (CES-D).<BR/>- Functional Assessment of Cancer Therapy-Breast (FACT-B) for quality of life in cancer patients.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-24 16:39:45 +1100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-20 18:03:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Loprinzi-2000">
<CHAR_METHODS MODIFIED="2010-01-23 08:08:32 +1100" MODIFIED_BY="[Empty name]">
<P>Parallel-group design.<BR/>Randomization with method of dynamic allocation. Stratified according to age, current tamoxifen use, duration of symptoms, and average frequency of hot flushes per day.<BR/>Participants and providers blinded. Statisticians not blinded to treatment assignment.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-20 18:03:10 +1000" MODIFIED_BY="[Empty name]">
<P>Country: United States</P>
<P>Setting: Not described.</P>
<P>Inclusion criteria:<BR/>Women with a history of breast cancer or concerned about taking estrogens for fear of breast cancer.<BR/>Troublesome hot flushes, at least 14 times per week for at least a month.<BR/>Life expectancy at least six months; performance status of 0&#8211;1 on the Eastern Cooperative Oncology Group scale.</P>
<P>Exclusion criteria: use of venlafaxine in the past; use of antidepressants within preceding two years; pregnancy; breastfeeding; use of hot flushes treatment within two weeks; uncontrolled hypertension.</P>
<P>Characteristics of participants:<BR/>Mean age not reported.<BR/>Tamoxifen use 69%.<BR/>Baseline hot flushes: Mean frequency 8.0, mean score 13.3.</P>
<P>Number of participants/assessable participants: 221/191.<BR/>Numbers of assessable participants in arm 1/arm 2/arm 3/arm 4 (placebo): 49/43/49/50.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-20 18:03:23 +1000" MODIFIED_BY="[Empty name]">
<P>Venlafaxine (extended release) vs placebo (identical appearance):<BR/>Arm 1: 37.5 mg daily for 28 days;<BR/>Arm 2: 37.5 mg daily for 7 days, then 75 mg daily for 21 days;<BR/>Arm 3: 37.5 mg daily for 7 days, 75 mg daily for 7 days, then 150 mg daily for 14 days.<BR/>Arm 4: Placebo for 28 days.</P>
<P>Study duration: four weeks of treatment. Additional follow up for six months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-20 18:03:42 +1000" MODIFIED_BY="[Empty name]">
<P>- Average daily number of hot flushes and average daily score (number of hot flushes per day x severity in a scale of 1 to 4, being 4 the maximum severity). Severity was graded as mild, moderate, severe and very severe. A previously validated questionnaire was used to collect the information about hot flushes through a daily diary hot-flush questionnaire.<BR/>- Two single-item global quality-of-life questions.<BR/>- Beck depression inventory.<BR/>- Blood pressure and other side-effects.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-20 05:07:23 +1100" MODIFIED_BY="[Empty name]">
<P>8/229 participants were excluded after randomization, and before starting study medication.</P>
<P>Effect of missing data was analysed. Results were consistent.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-25 22:33:46 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Loprinzi-2002">
<CHAR_METHODS MODIFIED="2010-01-23 09:07:31 +1100" MODIFIED_BY="[Empty name]">
<P>Cross-over design.<BR/>Randomization with method of dynamic allocation. Stratified randomisation by age, tamoxifen use, duration and frequency of hot flushes.<BR/>Reported as double blind.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-25 22:33:46 +1000" MODIFIED_BY="[Empty name]">
<P>Country: United States</P>
<P>Setting: Not described.</P>
<P>Inclusion criteria:<BR/>Women with history of breast cancer or at increased risk.<BR/>At least 14 hot flushes per week for at least one month.<BR/>No evidence of malignant disease.</P>
<P>Exclusion criteria:<BR/>Use of antineoplastic chemotherapy, androgens, estrogens, progestational drugs, coumadin or substances for the treatment of hot flushes.<BR/>Previous use of fluoxetine or any other antidepressant for two years before study entry.</P>
<P>Characteristics of participants:<BR/>Mean age not described. 74% of participants over 50 years.<BR/>Tamoxifen use: 55%.<BR/>Baseline hot flushes: Mean frequency 7.9, mean score 13.4.<BR/>
</P>
<P>Number of participants/assessable participants: 81/68 for first period. <BR/>Numbers of assessable participants in treatment first/control first arms: 33/35.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-20 18:04:59 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: Fluoxetine 20 mg/day.<BR/>Arm 2: Identical-appearing placebo.<BR/>
</P>
<P>Study duration: four weeks for each period. No washout between cross-over periods.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-20 18:05:17 +1000" MODIFIED_BY="[Empty name]">
<P>- Average daily number of hot flushes and average daily score (number of hot flushes per day x severity in a scale of 1 to 4, being 4 the maximum severity). Severity was graded as mild, moderate, severe and very severe. A previously validated questionnaire was used to collect the information about hot flushes through a daily diary hot-flush questionnaire.<BR/>- Depression (Beck depression inventory).<BR/>- Quality of life (uniscale global QOL instrument).<BR/>- Side-effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-24 14:51:13 +1100" MODIFIED_BY="[Empty name]">
<P>6/87 participants were excluded after randomization, and before starting study medication.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-20 18:06:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pandya-2000">
<CHAR_METHODS MODIFIED="2010-01-19 10:30:07 +1100" MODIFIED_BY="[Empty name]">
<P>Parallel-group design.<BR/>Randomization by using a computer program via centralised office. Stratified by time since menopause, duration of tamoxifen therapy and baseline frequency of hot flushes.<BR/>Described as double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-20 18:06:18 +1000" MODIFIED_BY="[Empty name]">
<P>Country: United States</P>
<P>Setting: Clinical practice of medical oncologists.</P>
<P>Inclusion criteria: Women receiving tamoxifen for breast cancer. At least 1 hot flush per day for one month.</P>
<P>Exclusion criteria:<BR/>Premenopausal.<BR/>Use of chemotherapy or endocrine therapy for breast cancer.<BR/>Use of antihypertensive agents, monoamine oxidase inhibitors, L-dopa, piribedil, tricyclic antidepressants or sedatives.<BR/>Coronary insufficiency, recent history of myocardial infarction, symptomatic cardiac disease, peripheral or cerebrovascular disease, syncope or symptomatic hypotension.<BR/>Allergy or adverse reaction to clonidine.<BR/>Abnormal hepatic or renal function.</P>
<P>Characteristics of participants:<BR/>Mean age 54 (range 35 to 75 years).<BR/>Baseline hot flushes: Mean frequency 7.7, mean severity 2.2.</P>
<P>Number of participants/assessable participants: 198/149.<BR/>Numbers of assessable participants at week 8 in treatment/control arms: 84/79.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-20 18:06:29 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: Oral clonidine 0.1 mg at bedtime.<BR/>Arm 2: Placebo.</P>
<P>Study duration: eight weeks of treatment. Four weeks of additional follow up.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-20 18:06:41 +1000" MODIFIED_BY="[Empty name]">
<P>- Hot flushes frequency and severity score (number of hot flushes per day x severity in a scale of 1 to 4, being 4 the maximum severity). A self-report questionnaire was used to collect the information through a daily diary.<BR/>- Quality of life (1-10 scale).<BR/>- Side-effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-27 04:10:00 +1100" MODIFIED_BY="[Empty name]">
<P>Effect of missing data was analysed. Results were consistent.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-20 18:08:25 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pandya-2005">
<CHAR_METHODS MODIFIED="2010-06-20 18:07:11 +1000" MODIFIED_BY="[Empty name]">
<P>Parallel-group design.<BR/>Computer-generated sequence. Stratified by site and duration of hot flushes.<BR/>Participants and providers blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-20 18:08:06 +1000" MODIFIED_BY="[Empty name]">
<P>Country: United States</P>
<P>Setting: Oncology clinic.</P>
<P>Inclusion criteria:<BR/>Adult women with a history of breast cancer, experiencing two or more hot flushes per day.</P>
<P>Exclusion criteria:<BR/>Use of chemotherapy, steroidal contraception, venlafaxine, clonidine or anticonvulsants.<BR/>Pregnancy or breastfeeding.<BR/>Coronary insufficiency, recent history of myocardial infarction, symptomatic cardiac disease, peripheral or cerebrovascular disease, stroke, syncope, or symptomatic hypotension.<BR/>Hepatic or renal dysfunction.<BR/>Allergy to gabapentin.</P>
<P>Characteristics of participants:<BR/>Mean age 55 years.<BR/>Baseline hot flush frequency: Mean 8.6 (range 2 to 54).<BR/>71% on tamoxifen.<BR/>
</P>
<P>Number of participants/assessable participants: 420/347.<BR/>Numbers of assessable participants in 300 mg arm/ 900 mg arm/placebo: 114/120/113.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-20 18:08:14 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: Gabapentin 300mg/day (orally, three times a day).<BR/>Arm 2: Gabapentin 900mg/day (orally, three times a day).<BR/>Arm 3: Identical-appearing placebo.</P>
<P>Study duration: eight weeks of treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-20 18:08:25 +1000" MODIFIED_BY="[Empty name]">
<P>- Hot flushes frequency and severity score (number of hot flushes per day x severity in a scale of 1 to 4, being 4 the maximum severity). A self-report questionnaire was used to collect the information through a daily diary.<BR/>- Patient-reported symptoms inventory (11 point scale on fatigue, pain, nausea, sleep disturbance, shortness of breath, memory, appetite, drowsiness, vomiting and distress).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-20 18:10:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stearns-2005">
<CHAR_METHODS MODIFIED="2010-06-20 18:08:59 +1000" MODIFIED_BY="[Empty name]">
<P>Cross-over design.<BR/>Computer-generated sequence. Stratified by age and anti-estrogen use.<BR/>Participants were blinded, not known if providers, assessors or analysts were blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-20 18:09:50 +1000" MODIFIED_BY="[Empty name]">
<P>Country: United States</P>
<P>Setting: Six cancer clinics.</P>
<P>Inclusion criteria:<BR/>Over 18 years with or without a history of breast cancer.<BR/>At least 14 episodes of hot flushes per week, for at least one month.<BR/>Life expectancy of 6 months.<BR/>Performance status of 0 or 2 on the Eastern Cooperative Oncology Group scale.<BR/>Creatinine and bilirubin less than two times normal level.</P>
<P>Exclusion criteria:<BR/>Use of other treatments for hot flushes.<BR/>Use of chemotherapy, radiation therapy, HT (estrogen and/or progestin), antidepressants, and monoamine oxidase inhibitors.</P>
<P>Characteristics of participants:<BR/>81% with a history of breast cancer.<BR/>Age range 27 to 76 years.<BR/>Mean daily hot-flush frequency: 7.9 times per day.<BR/>64% on anti-estrogen therapy.</P>
<P>Number of participants/assessable participants: 151/107.<BR/>Numbers of assessable participants in arm 1/arm 2/placebo arm: 28/23/56.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-20 18:09:59 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: Paroxetine 10mg/day.<BR/>Arm 2: Paroxetine 20mg/day.<BR/>Arm 3: Identical-appearing placebo.</P>
<P>Study duration: four weeks for each period. No washout between cross-over periods.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-20 18:10:17 +1000" MODIFIED_BY="[Empty name]">
<P>- Average daily number of hot flushes and average daily score (number of hot flushes per day x severity in a scale of 1 to 4, being 4 the maximum severity). Severity was graded as mild, moderate, severe and very severe. A previously validated questionnaire was used to collect the information about hot flushes through a daily diary hot-flush questionnaire.<BR/>- Kupperman Menopausal Index.<BR/>- Patient preference during each period of the cross-over.<BR/>- Center for Epidemiologic Studies Depression Scale.<BR/>- Hospital Anxiety and Depression Scale.<BR/>- Medical Outcomes Study Sleep Problem Index.<BR/>- Medical Outcomes Study Sexual Problem Index.<BR/>- EuroQOL Linear Rating Scale.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-24 15:40:47 +1100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-20 18:11:51 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thompson-2005">
<CHAR_METHODS MODIFIED="2010-06-20 18:10:42 +1000" MODIFIED_BY="[Empty name]">
<P>Parallel-group design.<BR/>Randomization through random numbers table kept by the pharmacy.<BR/>All participants blinded.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-20 18:11:11 +1000" MODIFIED_BY="[Empty name]">
<P>Country: United Kingdom</P>
<P>Setting: Outpatient department of a homeopathic hospital. Recruited from oncology center, surgical breast units, and community (through poster advertising).</P>
<P>Inclusion criteria:<BR/>Women with breast cancer with more than 3 hot flushes per day.</P>
<P>Exclusion criteria:<BR/>Metastatic disease.<BR/>Use of other treatments for hot flushes.<BR/>Severe concurrent illness.<BR/>Undergoing or about to receive adjuvant chemotherapy.</P>
<P>Characteristics of participants:<BR/>Mean age 52 years.<BR/>80% on tamoxifen.<BR/>Baseline hot flush frequency: 7.5 per day.</P>
<P>Number of participants/assessable participants: 53/45.<BR/>Numbers of assessable participants in treatment/control arms: 23/22.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-20 18:11:33 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: Homeopathic medicines (in tablet, granule or liquid form).<BR/>Arm 2: Identical placebo preparation.<BR/>All prescriptions made by the same doctor. Homeopathy and placebo prepared by a single pharmacy.<BR/>Study duration: 16 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-20 18:11:51 +1000" MODIFIED_BY="[Empty name]">
<P>Activity score.<BR/>Profile score (MYMOP) that includes symptom scores, dalily living disruption and general well-being.<BR/>Frequency and severity of hot flushes.<BR/>Quality of life (EORTC QLC-C30).<BR/>Hospital anxiety and depression scale.<BR/>Overall satisfaction with homeopathy.<BR/>Impact on daily living.<BR/>Side-effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-27 09:56:45 +1100" MODIFIED_BY="[Empty name]">
<P>Eight withdrawals. Not clear if considered for calculations.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-12-17 23:00:40 +1100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-01-23 08:08:40 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ganz-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-23 08:08:40 +1100" MODIFIED_BY="[Empty name]">
<P>Intervention consists of a program that may include some drugs with possible hormonal action. Data do not allow to discriminate which participants received different drugs.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-12 19:37:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-12 19:37:41 +1100" MODIFIED_BY="[Empty name]">
<P>Even though the abstract reports that Shugan-liangxue compound contains no phytoestrogen, there is too little information to be sure of its non-hormonal mechanism. We didn't find published literature to support the inclusion of this compound.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-08-02 16:43:31 +1000" MODIFIED_BY="Melina Willson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2010-06-20 18:13:49 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dyer-2008">
<CHAR_METHODS MODIFIED="2010-06-07 12:21:58 +1000" MODIFIED_BY="Melina Willson">
<P>Randomised controlled cross-over trial<BR/>Participants blinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-20 18:13:49 +1000" MODIFIED_BY="[Empty name]">
<P>Country: United Kingdom</P>
<P>Setting: Out-patient clinics at both sites of the hospital<BR/>
</P>
<P>Inclusion criteria:<BR/>Women suffering from hot flushes as a result of treatment for breast cancer</P>
<P>Exclusion criteria:<BR/>Any woman suffering from adverse reactions to cosmetics, perfumes or menthol, already currently using a cooling spray for hot flushes or unable to attend hospital to collect spray bottles and diaries<BR/>
</P>
<P>Characteristics of participants:<BR/>Median age: water = 52 years (33-69); hydrolats = 52 years (35-70)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-07 12:30:01 +1000" MODIFIED_BY="Melina Willson">
<P>Arm 1: Spray A (peppermint and neroli) for month 1, then Spray B (water) for month 2, then choose Spray A or B<BR/>Arm 2: Spray B (water) for month 1, then Spray A (peppermint and neroli) for month 2, then choose Spray A or B</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-07 12:31:29 +1000" MODIFIED_BY="Melina Willson">
<P>Number of women choosing hydrolat spray in preference to water spry to palliate hot flushes<BR/>Level of hot flush annoyance for each woman (descriptive purposes)<BR/>Visual Anaologue Scale (VAS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 12:32:57 +1000" MODIFIED_BY="Melina Willson">
<P>4/44 dropped out</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-06-20 18:14:51 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Elkins-2008">
<CHAR_METHODS MODIFIED="2010-06-20 18:14:09 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>All participants unblinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-04 14:06:53 +1000" MODIFIED_BY="Melina Willson">
<P>Country: United States</P>
<P>Setting: Unknown recruitment setting. Hypnosis undertaken by clinician with 40 hours training</P>
<P>Inclusion criteria:<BR/>Women &gt; 18 years old with a history of breast cancer and more than 14 hot flashes per week </P>
<P>Exclusion criteria:<BR/>Use of other treatments (i.e. chemotherapy, androgens, estrogens, progestational drugs) or any treatment for hot flashes<BR/>Use of antihormonal agents for breast cancer at variable dose<BR/>No participation in other mind-body therapy (i.e. relaxation therapy, biofeedback, yoga)</P>
<P>Characteristics of participants:<BR/>Mean age: control = 58 years ± 2 months; hypnosis = 55 years ± 10 months<BR/>Baseline hot flush frequency: control = 7.52; hypnosis = 7.77<BR/>Numbers of assessable participants in control/hypnosis arms: 24/27</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-04 14:11:54 +1000" MODIFIED_BY="Melina Willson">
<P>Arm 1: hypnosis intervention (5 weekly session each lasting approximately 50 minutes with a trained clinician and participants were given instructions in self hypnosis for at-home practice)<BR/>Arm 2: no treatment</P>
<P>Study duration: five weeks of treatment or remained on a no-treatment waiting list for 5 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-07 11:29:07 +1000" MODIFIED_BY="Melina Willson">
<P>-Daily number of hot flashes (frequency)<BR/>-Hot flash severity score (1 point equalled mild hot flash, two points equalled moderate hot flash, three points equalled severe hot flash and four points equalled very severe hot flash). Hot flash score equalled severity average for one week x hot flash frequency for that one week<BR/>-HFRDIS (Hot Flash Related Daily Interference Scale)<BR/>-Centre for Epidemiologic Studies Depression Scale (CEDS-D)<BR/>-Hospital Anxiety and Depression Scale - Anxiety Subscale (HADS-A)<BR/>-Medical Outcomes Study Sleep Scale (MOS-Sleep Scale)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-20 18:14:51 +1000" MODIFIED_BY="[Empty name]">
<P>9/60 participants were lost to follow up or withdrew post-randomisation<BR/>Effect of missing data was analysed. Results were consistent</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-06-20 18:16:13 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ISRCTN33947463">
<CHAR_METHODS MODIFIED="2010-06-20 18:15:58 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial (with waiting list control)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-20 18:16:13 +1000" MODIFIED_BY="[Empty name]">
<P>Country: United Kingdom</P>
<P>Setting: Unknown recruitment setting</P>
<P>Inclusion criteria:<BR/>Women who have had stage1/II breast cancer with no clinical evidence of recurrence<BR/>Have been amenorrhoeic for 36 months irrespective of menopausal status at time of diagnosis or have had a surgical bilateral oophorectomy<BR/>Are experiencing vasomotor symptoms (i.e. hot flushes or night sweats) with or without vaginal dryness<BR/>
</P>
<P>Exclusion criteria:<BR/>Currently taking HRT or have received oral or transdermal HRT within the last 3 months or have received HRT implant within the last 5 years<BR/>Receiving chemotherapy<BR/>Receiving gonadotrophin-releasing hormone e.g. Zoladex<BR/>Are pregnant<BR/>
</P>
<P>Characteristics of participants:<BR/>Unknown<BR/>
</P>
<P>Number of participants/assessable participants: Unknown<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-07 11:44:50 +1000" MODIFIED_BY="Melina Willson">
<P>Arm 1: 3 sessions of hypnosis over 3 weeks<BR/>Arm 2: control arm, similar treatment but delayed for 3 weeks<BR/>
</P>
<P>Study duration: both groups to keep diaries of vasomotor events and complete Quality of Life questionnaires at strategic points through a 16 week period</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-07 11:46:59 +1000" MODIFIED_BY="Melina Willson">
<P>-Reduction in frequency or intensity of flushing compared with waiting list control<BR/>-Treatment effects and improvements maintained for over 3 months<BR/>-Sustained effect passed 4 months <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-08 09:12:13 +1000" MODIFIED_BY="Melina Willson"/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-06-24 17:12:01 +1000" MODIFIED_BY="Melina Willson" STUDY_ID="STD-Loprinzi-2010">
<CHAR_METHODS MODIFIED="2010-06-20 18:15:25 +1000" MODIFIED_BY="[Empty name]">
<P>Placebo-controlled, randomized trial design<BR/>Participants stratified by age (&gt; or &lt; 50 years), use of tamoxifen, raloxifene or aromatase inhibitor (yes versus no), duration of hot flashes (&gt; or &lt; 9 months) and estimated daily frequency of hot flashes (4 to 9 versus &gt;9)<BR/>Randomization through a dynamic allocation procedure (by the North Central Cancer Treatment Group (NCCTG))<BR/>All participants blinded until study completion</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-04 14:54:24 +1000" MODIFIED_BY="Melina Willson">
<P>Country: United States</P>
<P>Setting: Unknown recruitment setting</P>
<P>Inclusion criteria:<BR/>Women with more than 28 hot flashes per week. Hot flashes must be present for at least one month prior to study entry<BR/>Participants able to complete questionnaires by themselves or with assistance</P>
<P>Exclusion criteria:<BR/>Receiving antineoplastic chemotherapy, androgens, progestogen agents, estrogens<BR/>Use of gabapentin or pregabalin in the past<BR/>Current or planned use of other agents for hot flashes (exception being stable doses of vitamin E, soy products and/or antidepressants)<BR/>Concurrent history of renal insufficiency or child bearing potential</P>
<P>Characteristics of participants:<BR/>Percentage 18 - 49 years of age: 21%; &gt; 50 years of age: 79%<BR/>Breast cancer history: 40%<BR/>Baseline hot flush frequency: 4 - 9 hot flashes = 57%; 10+ = 43%<BR/>Concurrent aromatase inhibitor = 21%, raloxifene = 2%, tamoxifen = 11%<BR/>
</P>
<P>Number of participants/assessable participants:191/163<BR/>Numbers of assessable participants in placebo/pregabalin 75 mg BD arm/pregabalin 150 mg BD arm: 51/56/56<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-04 15:11:14 +1000" MODIFIED_BY="Melina Willson">
<P>Pregabalin versus placebo (identical appearance):<BR/>Arm 1: Placebo for 6 weeks;<BR/>Arm 2: 50 mg for 1st week, 50 mg BD for 2nd week, 75 mg BD for 4 additional weeks;<BR/>Arm 3: 50 mg for 1st week, 50 mg BD for 2nd week, 75 mg BD for 3rd week, 150 mg BD for 3 additional weeks<BR/>
</P>
<P>Study duration: six weeks of treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-24 17:12:01 +1000" MODIFIED_BY="Melina Willson">
<P>-Change-from-baseline hot flash score during treatment week 6 between pregabalin 150 mg BD and placebo. Hot flash score was calculated by combining severity (i.e. mild, moderate, severe and very severe) and frequency of hot flash from average across each study week<BR/>-Change-from-baseline hot flash score during treatment week 6 between pregabalin 75 mg BD and placebo<BR/>-Change-from-baseline hot flash score during treatment week 6 between pregabalin 150 mg BD and pregabalin 75 mg BD versus placebo<BR/>-Toxicity profiles<BR/>-Moods (from POMS)<BR/>-HFRDIS scores between either treatment arms and placebo</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-20 18:15:53 +1000" MODIFIED_BY="[Empty name]">
<P>44/207 participants were excluded after randomisation, due to cancelling, drop-out for toxicities and failing to complete or return study diary forms</P>
<P>No mention of missing data</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-06-20 18:13:18 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00425776">
<CHAR_METHODS MODIFIED="2010-06-20 18:12:50 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled double-blinded trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-20 18:13:00 +1000" MODIFIED_BY="[Empty name]">
<P>Country: Denmark</P>
<P>Setting: Unknown recruitment setting</P>
<P>Inclusion criteria:<BR/>Women &gt; 35 years old treated for breast cancer, have hot flushes and sleeping disturbances</P>
<P>Exclusion criteria:<BR/>Any use of estrogen as tablets or plaster</P>
<P>Characteristics of participants:<BR/>Unknown<BR/>
</P>
<P>Number of participants/assessable participants:<BR/>Unknown</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-20 18:13:18 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: Active comparator (real acupuncture)<BR/>Arm 2: Sham comparator (sham acupuncture)<BR/>Arm 3: No intervention (no kind of acupuncture)<BR/>
<BR/>Acupuncture occurs once a week for 5 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-07 15:57:38 +1000" MODIFIED_BY="Melina Willson">
<P>-Hot flushes rating scale<BR/>-Sleep disturbances (yes or no)<BR/>-Measure of se-estrogen and se-endorphin before and after acupuncture<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 15:57:54 +1000" MODIFIED_BY="Melina Willson"/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2010-08-03 09:13:27 +1000" MODIFIED_BY="Melina Willson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2010-06-07 14:59:47 +1000" MODIFIED_BY="Melina Willson" STUDY_ID="STD-ISRCTN13771934">
<CHAR_STUDY_NAME MODIFIED="2010-06-07 12:03:23 +1000" MODIFIED_BY="Melina Willson">
<P>A trial of a non-medical treatment for menopausal symptoms in women with breast cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-06-07 12:03:47 +1000" MODIFIED_BY="Melina Willson">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-07 14:59:47 +1000" MODIFIED_BY="Melina Willson">
<P>-Aged 18 and older and have had early stage breast cancer<BR/>-Have completed radiotherapy and chemotherapy<BR/>-No evidence of distant metastatic disease<BR/>-May have had ductal carcinoma in situ<BR/>-Experience hot flushes/night sweats for at least 2 months<BR/>-Completed active treatment and in remission<BR/>-Prior medical treatment for hot flushes/night sweats will be recorded</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-07 12:08:19 +1000" MODIFIED_BY="Melina Willson">
<P>Arm 1: Cognitive behavioural therapy (61.5 hour sessions for 6 weeks). <BR/>Arm 2: Usual care<BR/>
<BR/>Duration: 3 months assessment and treatment, and 6 months follow-up post-randomisation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-07 12:09:41 +1000" MODIFIED_BY="Melina Willson">
<P>Problem rating of hot flushes and night sweats (measured at 12 weeks post-randomisation)<BR/>Frequency of hot flushes and night sweats (physiologically measured and self reported)<BR/>Mood, sleep and quality of life<BR/>Treatment cost-effectiveness</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2010-06-07 12:09:53 +1000" MODIFIED_BY="Melina Willson">
<P>September 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-06-07 12:13:32 +1000" MODIFIED_BY="Melina Willson">
<P>Myra Hunter (myra.hunter@kcl.ac.uk)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2010-06-07 12:14:37 +1000" MODIFIED_BY="Melina Willson">
<P>Anticipated end date: December 2011</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-06-04 15:50:42 +1000" MODIFIED_BY="Melina Willson" STUDY_ID="STD-NCT00363909">
<CHAR_STUDY_NAME MODIFIED="2010-06-04 15:32:18 +1000" MODIFIED_BY="Melina Willson">
<P>Citalopram in treating postmenopausal women with hot flashes</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-06-04 15:33:17 +1000" MODIFIED_BY="Melina Willson">
<P>Randomised, placebo-controlled, double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-04 15:34:49 +1000" MODIFIED_BY="Melina Willson">
<P>Postmenopausal women with a history of breast cancer (no current malignant disease) or no history of breast cancer and refused estrogen replacement therapy due to perceived increased risk of breast cancer</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-04 15:50:42 +1000" MODIFIED_BY="Melina Willson">
<P>Arm 1: 3 different doses (i.e. low, medium or high) of citalopram hydrobromide<BR/>Arm 2: placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-04 15:37:58 +1000" MODIFIED_BY="Melina Willson">
<P>Different in average hot flash score from baseline until week 7 of treatment<BR/>Toxicity<BR/>Mood and hot flash related daily interference with activities</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2010-06-04 15:38:25 +1000" MODIFIED_BY="Melina Willson">
<P>November 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-06-04 15:39:02 +1000" MODIFIED_BY="Melina Willson">
<P>Debra Barton (Mayo Clinic), Beth La Vasseur (Saint Joseph Mercy Cancer Center), Charles L Loprinzi (Mayo Clinic)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-06-20 18:19:35 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00582244">
<CHAR_STUDY_NAME MODIFIED="2010-06-20 18:17:26 +1000" MODIFIED_BY="[Empty name]">
<P>Cognitive behavioral therapy (CBT) and physical exercise for climacteric symptoms in breast cancer patients experiencing treatment-induced menopause: a multicenter randomised trial (EVA project)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-06-20 18:17:34 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>Intervention model: factorial assignment<BR/>Open label</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-20 18:19:35 +1000" MODIFIED_BY="[Empty name]">
<P>-Women 30 - 50 years old with histologically confirmed primary breast cancer<BR/>-All women will have been premenopausal at the time of diagnosis, have completed adjuvant chemotherapy (with the exception of trastuzumab (Herceptin)) a minimum of 4 months and a maximum of 5 years prior to study entry<BR/>-Women may currently be receiving adjuvant hormonal therapy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-07 11:59:37 +1000" MODIFIED_BY="Melina Willson">
<P>Arm 1: Experimental CBT and relaxation <BR/>Arm 2: Experimental physical activity<BR/>Arm 3: Experiimental CBT and physical activity<BR/>Arm 4: No intervention control group<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-07 12:00:18 +1000" MODIFIED_BY="Melina Willson">
<P>Menopausal symptoms<BR/>Vasomotor symptoms, urinary symptoms, sexuality, body- and self image, psychological distress, quality of life<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2010-06-07 12:01:02 +1000" MODIFIED_BY="Melina Willson">
<P>January 2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-06-07 12:01:30 +1000" MODIFIED_BY="Melina Willson">
<P>Saskia Duijts (s.duijts@nki.nl)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2010-06-07 12:01:08 +1000" MODIFIED_BY="Melina Willson">
<P>Anticipated end date: December 2010</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-06-20 18:20:34 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00641303">
<CHAR_STUDY_NAME MODIFIED="2010-06-07 14:55:05 +1000" MODIFIED_BY="Melina Willson">
<P>Acupuncture in reducing muscle and bone symptoms in women receiving letrozole, exemestane, or anastrozole for stage 0, stage 1, stage 11, or stage III breast cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-06-20 18:20:04 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled double-blind trial<BR/>Stratified according to participation in the aromatase inhibitor trial "A multicenter randomised clinical trial correlating the effects of 24 months of exemestane or letrozole on surrogate markers of response with aromatase polymorphism"</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-07 15:06:58 +1000" MODIFIED_BY="Melina Willson">
<P>-Women &gt;18 years old with histologically confirmed invasive carcinoma of the breast (stage 0-III disease)<BR/>-Estrogen receptor and/or progesterone receptor positive immunohistochemical staining<BR/>-Must be receiving a standard dose of aromatase inhibitor therapy<BR/>-No known metastatic (stage IV) breast cancer<BR/>-No prior acupuncture for any reason<BR/>-No other concurrent systemic therapy (i.e. chemotherapy, biologic therapy or radiotherapy)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-20 18:20:34 +1000" MODIFIED_BY="[Empty name]">
<P>Arm 1: Control (sham comparator) - patients receive 8 weekly sessions of acupuncture treatment<BR/>Arm 2: Treatment (experimental) - patients receive 8 weekly sessions of acupuncture treatment<BR/>
<BR/>Patients followed for 24 weeks. Patients in Arm 1 may receive 4 free acupuncture sessions (not sham) after the 24 week follow-up visit</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-07 15:06:22 +1000" MODIFIED_BY="Melina Willson">
<P>Health Assessment Questionnaire Disability Index (HAQ-DI) score<BR/>Pain scores on visual analog scale (VAS)<BR/>Change in amount and/or frequency of oral analgesic use<BR/>Number of patients who discontinue aromatase inhibitor therapy<BR/>Change in menopausal symptoms (NSABP revised), hot flash frequency (HFRDIS), sleep quality (PSQI), depression score (CESD), and overall quality of life (EuroQOL) in patients at weeks 4, 8, and 24 vs week 0 of acupuncture treatment<BR/>Change in plasma estrogen concentrations, beta endorphin concentration and cytokine profile from week 0 to week 8</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2010-06-07 15:06:41 +1000" MODIFIED_BY="Melina Willson">
<P>May 2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-06-07 15:07:15 +1000" MODIFIED_BY="Melina Willson">
<P>Vered Stearns (Sidney Kimmel Comprehensive Cancer Centre)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2010-06-07 15:07:30 +1000" MODIFIED_BY="Melina Willson">
<P>Anticipated end date: April 2010</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-06-04 16:28:16 +1000" MODIFIED_BY="Melina Willson" STUDY_ID="STD-NCT00956813">
<CHAR_STUDY_NAME MODIFIED="2010-06-04 15:57:26 +1000" MODIFIED_BY="Melina Willson">
<P>Flaxseed in treating postmenopausal women with hot flashes who have a history of breast cancer or other cancer or who do not wish to take estrogen therapy</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-06-04 16:25:32 +1000" MODIFIED_BY="Melina Willson">
<P>Randomised, placebo-controlled, double-blind<BR/>Stratified according to:<BR/>-age (18-49 years versus &gt;50 years)<BR/>-treatment with tamoxifen citrate, selective estrogen receptor modulators or aromatase inhibitors (yes versus no)<BR/>-duration of hot flashes (&lt;9 months versus &gt;9 months)<BR/>-daily frequency of hot flashes (4-9 versus &gt;10)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-04 16:28:16 +1000" MODIFIED_BY="Melina Willson">
<P>-Women &gt;18 years old with a history of breast cancer or other cancer (without malignant disease) or no history of breast cancer and wishes to avoid estrogen due to perceived increase breast cancer risk</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-04 16:07:28 +1000" MODIFIED_BY="Melina Willson">
<P>Arm 1: Oral flaxseed in the form of a bar similar to a granola bar once daily<BR/>Arm 2: Oral placebo bar once daily<BR/>Treatment continues for 6 - 12 weeks; patients in Arm 2 may cross-over to receive treatment as in Arrm I after 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-04 16:08:39 +1000" MODIFIED_BY="Melina Willson">
<P>Hot flash score at week 7<BR/>Toxicity as measured by CTCAE v3.0<BR/>Mood<BR/>General menopausal symptoms<BR/>Hot flash-related daily interference on activities</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2010-06-04 16:08:51 +1000" MODIFIED_BY="Melina Willson">
<P>October 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-06-04 16:09:17 +1000" MODIFIED_BY="Melina Willson">
<P>Debra Barton (Mayo Clinic)</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2010-06-04 16:09:03 +1000" MODIFIED_BY="Melina Willson">
<P>Anticipated end date: October 2010</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-06-20 18:12:09 +1000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-06-20 18:10:31 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-20 17:45:11 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barton-1998">
<DESCRIPTION>
<P>Stratified randomization with method of dynamic allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-07 08:45:27 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carpenter-2002">
<DESCRIPTION>
<P>Method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-20 17:49:42 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carpenter-2007a">
<DESCRIPTION>
<P>Computer-generated sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-20 05:32:43 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carpenter-2007b">
<DESCRIPTION>
<P>Computer generated sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-20 17:52:39 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Deng-2007">
<DESCRIPTION>
<P>Computer-generated sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-11 23:22:58 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fenlon-1999">
<DESCRIPTION>
<P>Method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-20 17:56:59 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fenlon-2008">
<DESCRIPTION>
<P>Computer-generated sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-11 23:23:18 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goldberg-1994">
<DESCRIPTION>
<P>Method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-20 18:00:17 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jacobs-2005">
<DESCRIPTION>
<P>Computer-generated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-11 23:24:31 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kimmick-2006">
<DESCRIPTION>
<P>Method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-23 10:18:55 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loprinzi-2000">
<DESCRIPTION>
<P>Stratified randomization by a method of dynamic allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-11 23:32:45 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loprinzi-2002">
<DESCRIPTION>
<P>Stratified randomisation by a method of dynamic allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-20 18:06:56 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pandya-2000">
<DESCRIPTION>
<P>Computer-generated sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-20 18:08:37 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pandya-2005">
<DESCRIPTION>
<P>Computer-generated sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-20 18:10:31 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stearns-2005">
<DESCRIPTION>
<P>Computer-generated sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-23 10:25:13 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thompson-2005">
<DESCRIPTION>
<P>Randomization through random numbers table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-06-20 18:12:09 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-20 17:45:13 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barton-1998">
<DESCRIPTION>
<P>B - Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-20 17:47:23 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carpenter-2002">
<DESCRIPTION>
<P>B - Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-20 17:49:37 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carpenter-2007a">
<DESCRIPTION>
<P>A - Clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-20 05:32:29 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carpenter-2007b">
<DESCRIPTION>
<P>A- Clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-20 17:52:44 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Deng-2007">
<DESCRIPTION>
<P>A - Clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-20 17:54:29 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fenlon-1999">
<DESCRIPTION>
<P>A - Adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-20 17:57:02 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fenlon-2008">
<DESCRIPTION>
<P>A - Adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-20 17:58:39 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goldberg-1994">
<DESCRIPTION>
<P>B - Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-20 18:00:18 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jacobs-2005">
<DESCRIPTION>
<P>A - Adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-20 18:02:03 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kimmick-2006">
<DESCRIPTION>
<P>B - Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-20 18:03:51 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loprinzi-2000">
<DESCRIPTION>
<P>B - Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-20 18:05:22 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loprinzi-2002">
<DESCRIPTION>
<P>B - Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-20 18:06:58 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pandya-2000">
<DESCRIPTION>
<P>A - Adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-20 18:08:39 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pandya-2005">
<DESCRIPTION>
<P>B - Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-20 18:10:27 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stearns-2005">
<DESCRIPTION>
<P>A - Adequate (consecutively numbered sealed envelopes).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-20 18:12:09 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thompson-2005">
<DESCRIPTION>
<P>A - Adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-06-20 18:08:40 +1000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-23 08:47:38 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barton-1998">
<DESCRIPTION>
<P>Described as double-blind, but not clear if assessors or researchers are blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-01-23 08:06:28 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carpenter-2002">
<DESCRIPTION>
<P>Participants blinded. Other participants not clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-22 23:46:02 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carpenter-2007a">
<DESCRIPTION>
<P>Participants, providers and investigators blinded. Verification of blinding at the end of the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-22 23:46:17 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carpenter-2007b">
<DESCRIPTION>
<P>Participants, providers and investigators blinded. Verification of blinding at the end of the study. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-20 17:52:48 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Deng-2007">
<DESCRIPTION>
<P>Acupuncturist and research assistant not blinded. All other participants blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-01-23 08:07:05 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fenlon-1999">
<DESCRIPTION>
<P>Participants and providers not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-18 22:26:29 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fenlon-2008">
<DESCRIPTION>
<P>Participants and providers not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-07 09:08:00 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goldberg-1994">
<DESCRIPTION>
<P>Described as double blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-01-23 08:07:26 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jacobs-2005">
<DESCRIPTION>
<P>Participants and providers blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-11 22:55:41 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kimmick-2006">
<DESCRIPTION>
<P>Described as double blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-20 04:29:13 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loprinzi-2000">
<DESCRIPTION>
<P>Participants and physicians blinded. Blinding of other participants not explicit but likely, except for statisticians.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-06 04:21:27 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loprinzi-2002">
<DESCRIPTION>
<P>Reported as double blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-20 18:06:59 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pandya-2000">
<DESCRIPTION>
<P>Described as double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-20 18:08:40 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pandya-2005">
<DESCRIPTION>
<P>Participants and providers blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-01-23 08:08:27 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stearns-2005">
<DESCRIPTION>
<P>Participants were blinded. Not clear if providers were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-13 10:01:13 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thompson-2005">
<DESCRIPTION>
<P>All participants blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-06-20 18:08:43 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-23 08:41:50 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barton-1998">
<DESCRIPTION>
<P>15 of 120 (12.5%) of women did not provide data for the first period. The analyses followed the intention-to-treat principle, except for five patients on the placebo arm who withdrew before starting study medication, and were excluded from analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-23 08:06:33 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carpenter-2002">
<DESCRIPTION>
<P>4 of 15 (27%) of women did not provide data. The analyses followed the intention-to-treat principle.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-22 23:51:08 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Carpenter-2007a">
<DESCRIPTION>
<P>21 of 52 (40%) women did not provide data. The analyses followed the intention-to-treat principle.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-22 23:51:38 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carpenter-2007b">
<DESCRIPTION>
<P>3 of 18 (16%) women did not provide data. The analyses followed the intention-to-treat principle.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-14 14:03:40 +1000" MODIFIED_BY="Melina Willson" RESULT="UNKNOWN" STUDY_ID="STD-Deng-2007">
<DESCRIPTION>
<P>5 of 72 (7%) did not provide data, withdrew or were excluded. Two participants in the real acupuncture group were not treated according to allocated and were excluded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-23 08:07:09 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fenlon-1999">
<DESCRIPTION>
<P>8 of 24 (33%) of women did not provide complete data. The analyses followed the intention-to-treat principle.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-03-18 22:28:54 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fenlon-2008">
<DESCRIPTION>
<P>46 of 150 (31%) of women did not complete the study or provide complete data at one month. The analyses followed the intention-to-treat principle.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-25 01:23:00 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goldberg-1994">
<DESCRIPTION>
<P>21/110 (19%) and 24/110 (22% ) of women did not provide complete data for hot flushes frequency and hot flushes severity, respectively. Losses unequally balanced between groups. The analyses followed the intention-to-treat principle.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-23 08:07:29 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jacobs-2005">
<DESCRIPTION>
<P>Only 4 of 83 women lost to follow up (5%). Intention-to-treat analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-24 16:44:10 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kimmick-2006">
<DESCRIPTION>
<P>23 of 62 (37%) of the originally randomized women did not provide baseline data or withdrew. Potential bias introduced for substantial number of incomplete data was not assessed. Intention-to-treat analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-06-20 18:03:59 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loprinzi-2000">
<DESCRIPTION>
<P>30 of 221 (14%) were not assessable at the end of the study. Analyses following the intention-to-treat principle (with the exception of 8 participants excluded after randomization).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-06-20 18:05:32 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Loprinzi-2002">
<DESCRIPTION>
<P>13 of 81 (19%) of the originally randomized women did not take the drug or provide data for analyses. Potential bias introduced for substantial number of incomplete data was not assessed. Analyses following the intention-to-treat principle (with the exception of six participants excluded after randomization).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-14 14:09:36 +1000" MODIFIED_BY="Melina Willson" RESULT="UNKNOWN" STUDY_ID="STD-Pandya-2000">
<DESCRIPTION>
<P>49 of 198 (25%) did not provide data at the end of the study. Potential bias introduced for substantial number of incomplete data was assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-06-20 18:08:43 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pandya-2005">
<DESCRIPTION>
<P>73 of 420 (17%) were not evaluable by the end of the follow up. Potential bias introduced for substantial number of incomplete data was not assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-05-13 10:00:18 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stearns-2005">
<DESCRIPTION>
<P>44 of 151 (29%) were not included in analyses. Potential bias introduced for substantial number of incomplete data was not assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-27 10:00:00 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thompson-2005">
<DESCRIPTION>
<P>8 of 53 (15%) were lost to follow up. All randomized women were analysed, but not clear if withdrawals considered for calculations.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-05-14 04:42:41 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-07 08:40:50 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barton-1998">
<DESCRIPTION>
<P>Main outcomes are reported. There is no reason to suspect selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-07 08:47:00 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carpenter-2002">
<DESCRIPTION>
<P>Main outcomes are reported. There is no reason to suspect selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-20 06:26:06 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carpenter-2007a">
<DESCRIPTION>
<P>Main outcomes reported. There is no reason to suspect selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-20 06:26:17 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carpenter-2007b">
<DESCRIPTION>
<P>Main outcomes reported. There is no reason to suspect selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-20 06:25:05 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Deng-2007">
<DESCRIPTION>
<P>Main outcomes reported. There is no reason to suspect selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-20 06:25:14 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fenlon-1999">
<DESCRIPTION>
<P>Main outcomes reported. There is no reason to suspect selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-20 06:25:19 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fenlon-2008">
<DESCRIPTION>
<P>Main outcomes reported. There is no reason to suspect selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-20 06:25:28 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goldberg-1994">
<DESCRIPTION>
<P>Main outcomes reported. There is no reason to suspect selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 09:25:16 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jacobs-2005">
<DESCRIPTION>
<P>Main outcomes reported. There is no reason to suspect selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-11 23:57:08 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kimmick-2006">
<DESCRIPTION>
<P>Main outcomes reported. There is no reason to suspect selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 09:30:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loprinzi-2000">
<DESCRIPTION>
<P>Main outcomes reported. There is no reason to suspect selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 09:31:16 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loprinzi-2002">
<DESCRIPTION>
<P>Main outcomes reported. There is no reason to suspect selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 09:45:24 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pandya-2000">
<DESCRIPTION>
<P>Main outcomes reported. There is no reason to suspect selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 09:54:29 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pandya-2005">
<DESCRIPTION>
<P>Main outcomes reported. There is no reason to suspect selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 10:00:31 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stearns-2005">
<DESCRIPTION>
<P>Main outcomes reported. There is no reason to suspect selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 10:02:42 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thompson-2005">
<DESCRIPTION>
<P>Main outcomes reported. There is no reason to suspect selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-05-14 04:42:41 +1000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-07 08:40:33 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barton-1998">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-07 08:47:04 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carpenter-2002">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-22 23:47:06 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carpenter-2007a">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-22 23:51:17 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carpenter-2007b">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-27 07:56:39 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Deng-2007">
<DESCRIPTION>
<P>Baseline differences in baseline symptoms, and use of tamoxifen, aromatase Inhibitors and SSRIs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-07 09:06:58 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fenlon-1999">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-18 22:30:51 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fenlon-2008">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 09:21:02 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goldberg-1994">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 09:25:19 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jacobs-2005">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-11 23:57:24 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kimmick-2006">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 09:30:45 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loprinzi-2000">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 09:31:19 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loprinzi-2002">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 09:45:29 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pandya-2000">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 09:54:31 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pandya-2005">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 10:00:34 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stearns-2005">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 10:02:46 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thompson-2005">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2010-06-20 18:21:29 +1000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2010-06-20 18:21:09 +1000" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2010-06-20 18:21:09 +1000" MODIFIED_BY="[Empty name]">SoF vitamin E versus placebo</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TD COLSPAN="7">
<P>
<B>Vitamin E compared to Placebo for hot flushes in women with a history of breast cancer</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with hot flushes in women with a history of breast cancer</P>
<P>
<B>Settings:</B>
</P>
<P>
<B>Intervention:</B> Vitamin E</P>
<P>
<B>Comparison: </B>Placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Placebo</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Vitamin E</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Frequency of hot flushes</B>
<BR/>Number of hot flushes per day<BR/>(follow-up: 4 weeks)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean frequency of hot flushes in the control groups was<BR/>
<B>6.6 HF per day</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean Frequency of hot flushes in the intervention groups was<BR/>
<B>0.15 lower</B>
<BR/>(2.45 lower to 2.16 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>104<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Hot flushes score</B>
<BR/>Number of HF x severity (from 1 to 4)<BR/>(follow-up: 4 weeks)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean hot flushes score in the control groups was<BR/>
<B>14.4 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean Hot flushes score in the intervention groups was<BR/>
<B>0.82 lower</B>
<BR/>(4.68 lower to 3.05 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>104<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: Confidence interval;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidance<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2010-06-20 18:21:29 +1000" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2010-06-20 18:21:29 +1000" MODIFIED_BY="[Empty name]">SoF gabapentin versus placebo</TITLE>
<TABLE COLS="7" ROWS="4">
<TR>
<TD COLSPAN="7">
<P>
<B>Gabapentin compared to Placebo for hot flushes in women with a history of breast cancer</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B> Patient or population:</B> patients with hot flushes in women with a history of breast cancer</P>
<P>
<B> Settings:</B> Ambulatory clinic</P>
<P>
<B> Intervention:</B> Gabapentin</P>
<P>
<B>Comparison: </B>Placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Placebo</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Gabapentin</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Frequency of hot flushes</B>
<BR/>Number of hot flushes per day<BR/>(follow-up: 8 weeks)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean frequency of hot flushes in the control groups was<BR/>
<B>8.8 HF per day</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean Frequency of hot flushes in the intervention groups was<BR/>
<B>4.21 lower</B>
<BR/>(5 to 3.42 lower)<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>233<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Hot flushes score</B>
<BR/>Number of HF x severity (from 1 to 4)<BR/>(follow-up: 8 weeks)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean hot flushes score in the control groups was<BR/>
<B>19.9 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean Hot flushes score in the intervention groups was<BR/>
<B>9.94 lower</B>
<BR/>(12.02 to 7.86 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>233<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: Confidence interval; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidance<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Effect estimates correspond to data for 900 mg dose</P>
<P>
<SUP>2</SUP> Allocation concealment unclear. A large proportion of patients were not assessable at the end of the study.</P>
<P>
<SUP>3</SUP> 900 mg dose achieved a larger effect than 300 mg dose.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2010-06-04 15:41:35 +1000" MODIFIED_BY="Melina Willson"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-05-13 22:35:53 +1000" MODIFIED_BY="[Empty name]"/>
<FIGURES MODIFIED="2010-01-24 16:21:09 +1100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Quorum210110.JPG" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2010-01-24 16:21:09 +1100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Quorum flow diagram</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-07-12 12:06:39 +1000" MODIFIED_BY="Melina Willson">
<APPENDIX ID="APP-01" MODIFIED="2010-06-20 17:40:26 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-06-20 17:40:26 +1000" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-01-23 08:46:30 +1100" MODIFIED_BY="[Empty name]">
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P>Host: Wiley<BR/>Date of search: 19 July 2008<BR/>
</P>
</TH>
</TR>
<TR>
<TD>
<P>1. randomised controlled trial.pt.<BR/>2. controlled clinical trial.pt.<BR/>3. randomised controlled trials/<BR/>4. random allocation/<BR/>5. double-blind method/<BR/>6. single-blind method/<BR/>7. or/1-6<BR/>8. clinical trial.pt.<BR/>9. exp clinical trials<BR/>10. (clin$ adj25 trial$).tw.<BR/>11. ((singl$ or doubl$ or treb$ or tripl$) adj25 (blind$ or mask$)).tw.<BR/>12. placebos/<BR/>13. placebo$.tw.<BR/>14. random$.tw.<BR/>15. research design/<BR/>16. or/8-15<BR/>17. animal/ not (human/ and animal/)<BR/>18. 7 or 16<BR/>19. 18 not 17<BR/>20. exp breast neoplasms/<BR/>21. exp "neoplasms, ductal, lobular, and medullary"/<BR/>22. exp fibrocystic disease of breast/<BR/>23. or/20-22<BR/>24. exp breast/<BR/>25. breast.tw.<BR/>26. 24 or 25<BR/>27. (breast adj milk).mp.<BR/>28. (breast adj tender$).mp.<BR/>29. or/27-28<BR/>30. 26 not 29<BR/>31. exp neoplasms/<BR/>32. 30 and 31<BR/>33. exp lymphedema/<BR/>34. 33 and 30<BR/>35. (breast adj25 neoplasm$).mp.<BR/>36. (breast adj25 cancer$).mp.<BR/>37. (breast adj25 tumour$).mp.<BR/>38. (breast adj25 tumor$).mp.<BR/>39. (breast adj25 carcinoma$).mp.<BR/>40. (breast adj25 adenocarcinoma$).mp.<BR/>41. (breast adj25 sarcoma$).mp.<BR/>42. (breast adj50 dcis).mp.<BR/>43. (breast adj25 ductal).mp.<BR/>44. (breast adj25 infiltrating).mp.<BR/>45. (breast adj25 intraductal).mp.<BR/>46. (breast adj25 lobular).mp.<BR/>47. (breast adj25 medullary).mp.<BR/>48. or/35-47<BR/>49. 23 or 32 or 34 or 48<BR/>50. exp mastectomy/<BR/>51. 49 or 50<BR/>52. exp "Analytical, Diagnostic and Therapeutic Techniques and Equipment (Non MeSH)"/<BR/>53. 52 and 30<BR/>54. 53 or 51<BR/>55. exp mammary neoplasms/<BR/>56. (mammary adj25 neoplasm$).mp.<BR/>57. (mammary adj25 cancer$).mp.<BR/>58. (mammary adj25 tumour$).mp.<BR/>59. (mammary adj25 tumor$).mp.<BR/>60. (mammary adj25 carcinoma$).mp.<BR/>61. (mammary adj25 adenocarcinoma$).mp.<BR/>62. (mammary adj25 sarcoma$).mp.<BR/>63. (mammary adj50 dcis).mp.<BR/>64. (mammary adj25 ductal).mp.<BR/>65. (mammary adj25 infiltrating).mp.<BR/>66. (mammary adj25 intraductal).mp.<BR/>67. (mammary adj25 lobular).mp.<BR/>68. (mammary adj25 medullary).mp.<BR/>69. or/55-68<BR/>70. 54 or 69<BR/>71. exp breast self-examination/<BR/>72. (breast adj25 self$).mp.<BR/>73. (breast adj25 screen$).mp.<BR/>74. exp mammography/<BR/>75. or/70-74<BR/>76. mammograph$.tw.<BR/>77. 76 and 30<BR/>78. 75 or 77<BR/>79. Flushing/<BR/>80. flush$.mp.<BR/>81. flash$.mp.<BR/>82. Vasomotor.mp.<BR/>83. Vasomotor$.mp.<BR/>84. or/79-83<BR/>85. non hormonal therapy.mp.<BR/>86. "not hormonal therapy".mp.<BR/>87. "therapy not hormonal".mp.<BR/>88. serotonin uptake inhibitors.mp.<BR/>89. (Serotonin and norepinephrine reuptake inhibitors).mp.<BR/>90. fluoxetine.mp.<BR/>91. sertraline.mp.<BR/>92. paroxetine.mp.<BR/>93. citalopram.mp.<BR/>94. serotonin antagonists.mp.<BR/>95. Venlafaxine.mp.<BR/>96. Mirtazapine.mp.<BR/>97. trazodone.mp.<BR/>98. Gabapentin.mp.<BR/>99. clonidine.mp.<BR/>100. Veralipride.mp.<BR/>101. methyldopa.mp.<BR/>102. vitamin E.mp.<BR/>103. Bellergal.mp.<BR/>104. (ergotamine and phenobarbital and belladonna).mp.<BR/>105. exp Acupuncture/<BR/>106. Acupuncture.mp.<BR/>107. exp Complementary therapies/<BR/>108. thinking/<BR/>109. odors/<BR/>110. oils, volatile/<BR/>111. Magnetic therapy.mp.<BR/>112. Exercise/<BR/>113. Physical fitness/<BR/>114. or/85-113<BR/>115. 19 and 78 and 84 and 114</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2010-06-20 17:40:45 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-06-20 17:40:45 +1000" MODIFIED_BY="[Empty name]">CINAHL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-03-20 08:34:08 +1100" MODIFIED_BY="[Empty name]">
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P>Host: EBSCO<BR/>1981 to August 2008</P>
</TH>
</TR>
<TR>
<TD>
<P>1. MH "Random Assignment"<BR/>2. MH "Random Sample+"<BR/>3. MH "Crossover Design"<BR/>4. MH "Clinical Trials+"<BR/>5. MH "Comparative Studies"<BR/>6. MH "Control (Research)+"<BR/>7. MH "Control Group"<BR/>8. MH "Factorial Design"<BR/>9. MH "Quasi-Experimental Studies+"<BR/>10. MH "Placebos"<BR/>11. MH "Meta Analysis"<BR/>12. MH "Sample Size"<BR/>13. MH "Research, Nursing"<BR/>14. MH "Research Question"<BR/>15. MH "Research Methodology+"<BR/>16. MH "Evaluation Research+"<BR/>17. MH "Concurrent Prospective Studies"<BR/>18. MH "Prospective Studies"<BR/>19. MH "Nursing Practice, Research-Based"<BR/>20. MH "Solomon Four-Group Design"<BR/>21. MH "One-Shot Case Study"<BR/>22. MH "Pretest-Posttest Design+"<BR/>23. MH "Static Group Comparison"<BR/>24. MH "Study Design"<BR/>25. MH "Clinical Research+"<BR/>26. clinical nursing research or random* or cross?over or placebo* or control* or factorial or sham* or meta?analy* or systematic review* or blind* or mask* or trial*<BR/>27. or/1-26<BR/>28. MH "Breast Neoplasms"<BR/>29. MH "Fibrocystic Disease of Breast"<BR/>30. MH "Breast"<BR/>31. TX breast<BR/>32. or/28-31<BR/>33. TI breast N6 milk or AB breast N6milk or MW breast N6 milk<BR/>34. TI breast N6 tender* or AB breast N6 tender* or MW breast N6 tender*<BR/>35. or/32-33<BR/>36. 32 not 35<BR/>37. MH "Neoplasms+"<BR/>38. 36 and 37<BR/>39. MH "Lymphedema+"<BR/>40. 39 and 36<BR/>41. TI breast N25 neoplasm* or AB breast N25 neoplasm* or MW breast N25 neoplasm<BR/>42. TI breast N25 cancer* or AB breast N25 cancer* or MW breast N25 cancer*<BR/>43. TI breast N25 tumour* or AB breast N25 tumour* or MW breast N25 tumour*<BR/>44. TI breast N25 tumor* or AB breast N25 tumor* or MW breast N25 tumor*<BR/>45. TI breast N25 carcinoma* or AB breast N25 carcinoma* or MW breast N25 carcinoma*<BR/>46. TI breast N25 adenocarcinoma* or AB breast N25 adenocarcinoma* or MW breast N25 adenocarcinoma*<BR/>47. TI breast N25 sarcoma* or AB breast N25 sarcoma* or MW breast N25 sarcoma*<BR/>48. TI breast N50 dcis or AB breast N50 dcis or MW breast N50 dcis<BR/>49. TI breast N25 ductal or AB breast N25 ductal or MW breast N25 ductal<BR/>50. TI breast N25 infiltrating or AB breast N25 infiltrating or MW breast N25 infiltrating<BR/>51. TI breast N25 intraductal or AB breast N25 intraductal or MW breast N25 intraductal<BR/>52. TI breast N25 lobular or AB breast N25 lobular or MW breast N25 lobular<BR/>53. TI breast N25 medullary or AB breast N25 medullary or MW breast N25 medullary<BR/>54. or/41-53<BR/>55. 38 or 40 or 54<BR/>56. MH "Mastectomy+"<BR/>57. 55 or 56<BR/>58. TI mammary N25 neoplasm* or AB mammary N25 neoplasm* or MW mammary N25 neoplasm*<BR/>59. TI mammary N25 cancer* or AB mammary N25 cancer* or MW mammary N25 cancer*<BR/>60. TI mammary N25 tumour* or AB mammary N25 tumour* or MW mammary N25 tumour*<BR/>61. TI mammary N25 tumor* or AB mammary N25 tumor* or MW mammary N25 tumor*<BR/>62. TI mammary N25 carcinoma* or AB mammary N25 carcinoma* or MW mammary N25 carcinoma*<BR/>63. TI mammary N25 adenocarcinoma* or AB mammary N25 adenocarcinoma* or MW mammary N25 adenocarcinoma* <BR/>64. TI mammary N25 sarcoma* or AB mammary N25 sarcoma* or MW mammary N25 sarcoma*<BR/>65. TI mammary N50 dcis or AB mammary N50 dcis or MW mammary N50 dcis<BR/>66. TI mammary N25 ductal or AB mammary N25 ductal or MW mammary N25 ductal<BR/>67. TI mammary N25 infiltrating or AB mammary N25 infiltrating or MW mammary N25 infiltrating<BR/>68. TI mammary N25 intraductal or AB mammary N25 intraductal or MW mammary N25 intraductal<BR/>69. TI mammary N25 lobular or AB mammary N25 lobular or MW mammary N25 lobular<BR/>70. TI mammary N25 medullary or AB mammary N25 medullary or MW mammary N25 medullary<BR/>71. or/58-70<BR/>72. 57 or 71<BR/>73. MH "Breast Self-Examination"<BR/>74.TI breast N25 self* or AB breast N25 self* or MW breast N25 self*<BR/>75.TI breast N25 screen* or AB breast N25 screen* or MW breast N25 screen*<BR/>76. MH "Mammography"<BR/>77. or/72-76<BR/>78. TX mammograph*<BR/>79. 78 and 36<BR/>80. 77 or 79<BR/>81. TI flush* or AB flush* or MW flush*<BR/>82. TI flash* or AB flash* or MW flash*<BR/>83.TI vasomotor* or AB vasomotor* or MW vasomotor*<BR/>84. or/81-83<BR/>85. 27 and 80 and 84</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2010-06-20 17:41:12 +1000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-06-20 17:41:12 +1000" MODIFIED_BY="[Empty name]">PsycINFO search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-03-20 08:35:02 +1100" MODIFIED_BY="[Empty name]">
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P>Host: EBSCO<BR/>1887 to August 2008</P>
</TH>
</TR>
<TR>
<TD>
<P>1. MH "Random Assignment"<BR/>2. MH "Random Sample+"<BR/>3. MH "Crossover Design"<BR/>4. MH "Clinical Trials+"<BR/>5. MH "Comparative Studies"<BR/>6. MH "Control (Research)+"<BR/>7. MH "Control Group"<BR/>8. MH "Factorial Design"<BR/>9. MH "Quasi-Experimental Studies+"<BR/>10. MH "Placebos"<BR/>11. MH "Meta Analysis"<BR/>12. MH "Sample Size"<BR/>13. MH "Research, Nursing"<BR/>14. MH "Research Question"<BR/>15. MH "Research Methodology+"<BR/>16. MH "Evaluation Research+"<BR/>17. MH "Concurrent Prospective Studies"<BR/>18. MH "Prospective Studies"<BR/>19. MH "Nursing Practice, Research-Based"<BR/>20. MH "Solomon Four-Group Design"<BR/>21. MH "One-Shot Case Study"<BR/>22. MH "Pretest-Posttest Design+"<BR/>23. MH "Static Group Comparison"<BR/>24. MH "Study Design"<BR/>25. MH "Clinical Research+"<BR/>26. clinical nursing research or random* or cross?over or placebo* or control* or factorial or sham* or meta?analy* or systematic review* or blind* or mask* or trial*<BR/>27. or/1-26<BR/>28. MH "Breast Neoplasms"<BR/>29. MH "Fibrocystic Disease of Breast"<BR/>30. MH "Breast"<BR/>31. TX breast<BR/>32. or/28-31<BR/>33. TI breast N6 milk or AB breast N6milk or MW breast N6 milk<BR/>34. TI breast N6 tender* or AB breast N6 tender* or MW breast N6 tender*<BR/>35. or/32-33<BR/>36. 32 not 35<BR/>37. MH "Neoplasms+"<BR/>38. 36 and 37<BR/>39. MH "Lymphedema+"<BR/>40. 39 and 36<BR/>41. TI breast N25 neoplasm* or AB breast N25 neoplasm* or MW breast N25 neoplasm<BR/>42. TI breast N25 cancer* or AB breast N25 cancer* or MW breast N25 cancer*<BR/>43. TI breast N25 tumour* or AB breast N25 tumour* or MW breast N25 tumour*<BR/>44. TI breast N25 tumor* or AB breast N25 tumor* or MW breast N25 tumor*<BR/>45. TI breast N25 carcinoma* or AB breast N25 carcinoma* or MW breast N25 carcinoma*<BR/>46. TI breast N25 adenocarcinoma* or AB breast N25 adenocarcinoma* or MW breast N25 adenocarcinoma*<BR/>47. TI breast N25 sarcoma* or AB breast N25 sarcoma* or MW breast N25 sarcoma*<BR/>48. TI breast N50 dcis or AB breast N50 dcis or MW breast N50 dcis<BR/>49. TI breast N25 ductal or AB breast N25 ductal or MW breast N25 ductal<BR/>50. TI breast N25 infiltrating or AB breast N25 infiltrating or MW breast N25 infiltrating<BR/>51. TI breast N25 intraductal or AB breast N25 intraductal or MW breast N25 intraductal<BR/>52. TI breast N25 lobular or AB breast N25 lobular or MW breast N25 lobular<BR/>53. TI breast N25 medullary or AB breast N25 medullary or MW breast N25 medullary<BR/>54. or/41-53<BR/>55. 38 or 40 or 54<BR/>56. MH "Mastectomy+"<BR/>57. 55 or 56<BR/>58. TI mammary N25 neoplasm* or AB mammary N25 neoplasm* or MW mammary N25 neoplasm*<BR/>59. TI mammary N25 cancer* or AB mammary N25 cancer* or MW mammary N25 cancer*<BR/>60. TI mammary N25 tumour* or AB mammary N25 tumour* or MW mammary N25 tumour*<BR/>61. TI mammary N25 tumor* or AB mammary N25 tumor* or MW mammary N25 tumor*<BR/>62. TI mammary N25 carcinoma* or AB mammary N25 carcinoma* or MW mammary N25 carcinoma*<BR/>63. TI mammary N25 adenocarcinoma* or AB mammary N25 adenocarcinoma* or MW mammary N25 adenocarcinoma* <BR/>64. TI mammary N25 sarcoma* or AB mammary N25 sarcoma* or MW mammary N25 sarcoma*<BR/>65. TI mammary N50 dcis or AB mammary N50 dcis or MW mammary N50 dcis<BR/>66. TI mammary N25 ductal or AB mammary N25 ductal or MW mammary N25 ductal<BR/>67. TI mammary N25 infiltrating or AB mammary N25 infiltrating or MW mammary N25 infiltrating<BR/>68. TI mammary N25 intraductal or AB mammary N25 intraductal or MW mammary N25 intraductal<BR/>69. TI mammary N25 lobular or AB mammary N25 lobular or MW mammary N25 lobular<BR/>70. TI mammary N25 medullary or AB mammary N25 medullary or MW mammary N25 medullary<BR/>71. or/58-70<BR/>72. 57 or 71<BR/>73. MH "Breast Self-Examination"<BR/>74.TI breast N25 self* or AB breast N25 self* or MW breast N25 self*<BR/>75.TI breast N25 screen* or AB breast N25 screen* or MW breast N25 screen*<BR/>76. MH "Mammography"<BR/>77. or/72-76<BR/>78. TX mammograph*<BR/>79. 78 and 36<BR/>80. 77 or 79<BR/>81. TI flush* or AB flush* or MW flush*<BR/>82. TI flash* or AB flash* or MW flash*<BR/>83.TI vasomotor* or AB vasomotor* or MW vasomotor*<BR/>84. or/81-83<BR/>85. 27 and 80 and 84</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2010-06-20 17:41:35 +1000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2010-06-20 17:41:28 +1000" MODIFIED_BY="[Empty name]">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-06-20 17:41:35 +1000" MODIFIED_BY="[Empty name]">
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P>Host: BIREME (www.bireme.br/bvs/I/ibd.htm)<BR/>1986 to August 2008</P>
</TH>
</TR>
<TR>
<TD>
<P>1. sofoco$<BR/>2. hot flush$<BR/>3. hot flash$<BR/>4. Bochorn$<BR/>5. Vasomoto$<BR/>6. flash$<BR/>7. flush$<BR/>8. fogacho$<BR/>9. OR/1-8</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2010-06-20 17:42:09 +1000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2010-06-20 17:42:09 +1000" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-06-20 17:41:58 +1000" MODIFIED_BY="[Empty name]">
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P>Host: Ovid<BR/>January 1966 to December 2005<BR/>
</P>
</TH>
</TR>
<TR>
<TD>
<P>1. randomised controlled trial.pt.<BR/>2. controlled clinical trial.pt.<BR/>3. randomised controlled trials/<BR/>4. random allocation/<BR/>5. double-blind method/<BR/>6. single-blind method/<BR/>7. or/1-6<BR/>8. ANIMALS.sh. not HUMAN.sh.<BR/>9. 7 not 8<BR/>10. clinical trial.pt.<BR/>11. exp clinical trials/<BR/>12. (clin$ adj25 trial$).tw.<BR/>13. ((singl$ or doubl$ or treb$ or tripl$) adj25 (blind$ or mask$)).tw.<BR/>14. placebos.sh<BR/>15. placebo$.ti,ab.<BR/>16. random$.ti,ab.<BR/>17. RESEARCH DESIGN.sh.<BR/>18. or/10 17<BR/>19. 18 not 8<BR/>20. 19 not 9<BR/>21. 9 or 20<BR/>22. exp breast neoplasms/<BR/>23. exp "neoplasms, ductal, lobular, and medullary"/<BR/>24. exp fibrocystic disease of breast/<BR/>25. or/22-24<BR/>26. exp breast/<BR/>27. breast.tw.<BR/>28. 26 or 27<BR/>29. (breast adj milk).ti,ab,sh.<BR/>30. (breast adj tender$).ti,ab,sh.<BR/>31. or/29-30<BR/>32. 28 not 31<BR/>33. exp neoplasms/<BR/>34. 32 and 33<BR/>35. exp lymphedema/<BR/>36. 35 and 32<BR/>37. (breast adj25 neoplasm$).ti,ab,sh.<BR/>38. (breast adj25 cancer$).ti,ab,sh.<BR/>39. (breast adj25 tumour$).ti,ab,sh.<BR/>40. (breast adj25 tumor$).ti,ab,sh.<BR/>41. (breast adj25 carcinoma$).ti,ab,sh.<BR/>42. (breast adj25 adenocarcinoma$).ti,ab,sh.<BR/>43. (breast adj25 sarcoma$).ti,ab,sh.<BR/>44. (breast adj50 dcis).ti,ab,sh.<BR/>45. (breast adj25 ductal).ti,ab,sh.<BR/>46. (breast adj25 infiltrating).ti,ab,sh.<BR/>47. (breast adj25 intraductal).ti,ab,sh.<BR/>48. (breast adj25 lobular).ti,ab,sh.<BR/>49. (breast adj25 medullary).ti,ab,sh.<BR/>50. or/37-49<BR/>51. 25 or 34 or 36 or 50<BR/>52. exp mastectomy/<BR/>53. 51 or 52<BR/>54. exp "Analytical, Diagnostic and Therapeutic Techniques and Equipment"/<BR/>55. 54 and 32<BR/>56. 55 or 53<BR/>57. exp mammary neoplasms/<BR/>58. (mammary adj25 neoplasm$).ti,ab,sh.<BR/>59. (mammary adj25 cancer$).ti,ab,sh.<BR/>60. (mammary adj25 tumour$).ti,ab,sh.<BR/>61. (mammary adj25 tumor$).ti,ab,sh.<BR/>62. (mammary adj25 carcinoma$).ti,ab,sh.<BR/>63. (mammary adj25 adenocarcinoma$).ti,ab,sh.<BR/>64. (mammary adj25 sarcoma$).ti,ab,sh.<BR/>65. (mammary adj50 dcis).ti,ab,sh.<BR/>66. (mammary adj25 ductal).ti,ab,sh.<BR/>67. (mammary adj25 infiltrating).ti,ab,sh.<BR/>68. (mammary adj25 intraductal).ti,ab,sh.<BR/>69. (mammary adj25 lobular).ti,ab,sh.<BR/>70. (mammary adj25 medullary).ti,ab,sh.<BR/>71. or/57-70<BR/>72. 56 or 71<BR/>73. exp breast self-examination/<BR/>74. (breast adj25 self$).ti,ab,sh.<BR/>75. (breast adj25 screen$).ti,ab,sh.<BR/>76. exp mammography/<BR/>77. or/72-76<BR/>78. mammograph$.tw.<BR/>79. 78 and 32<BR/>80. 77 or 79<BR/>81. Flushing/<BR/>82. flush$.ti,ab,sh.<BR/>83. flash$.ti,ab,sh.<BR/>84. Vasomotor.mp.<BR/>85. Vasomotor$.ti,ab,sh.<BR/>86. or/81-85<BR/>87. non hormonal therapy.mp.<BR/>88. "not hormonal therapy".mp.<BR/>89. (therapy not hormonal).mp.<BR/>90. "therapy not hormonal".mp.<BR/>91. serotonin uptake inhibitors/<BR/>92. (Serotonin and norepinephrine reuptake inhibitors).mp.<BR/>93. fluoxetine/<BR/>94. Phenyl Ethers.mp.<BR/>95. limit 94 to yr=1974-1978<BR/>96. propylamines/<BR/>97. limit 96 to yr=1966-1978<BR/>98. sertraline/<BR/>99. sertraline.mp.<BR/>100. limit 99 to yr=1983-1998<BR/>101. 11-Naphythylamine.mp.<BR/>102. limit 101 to yr=1983-1998<BR/>103. paroxetine/<BR/>104. Paroxetine.mp.<BR/>105. limit 104 to yr=1980-1992<BR/>106. Dioxolanes/<BR/>107. limit 106 to yr=1978-1982<BR/>108. Piperidines/<BR/>109. limit 108 to yr=1982-1992<BR/>110. citalopram/<BR/>111. antidepressive agents/<BR/>112. limit 111 to yr=1977-1988<BR/>113. propylamines/<BR/>114. limit 113 to yr=1977-1988<BR/>115. serotonin antagonists/<BR/>116. limit 115 to yr=1978-1988<BR/>117. Venlafaxine.mp.<BR/>118. Mirtazapine.mp.<BR/>119. trazodone/<BR/>120. piperazines/<BR/>121. limit 120 to yr=1971-1974<BR/>122. pyridines/<BR/>123. limit 122 to yr=1971-1974<BR/>124. Triazoles/<BR/>125. limit 124 to yr=1971-1974<BR/>126. Gabapentin.mp.<BR/>127. clonidine/<BR/>128. Antihypertensive agents/<BR/>129. limit 128 to yr=1966-1971<BR/>130. Imidazoles/<BR/>131. limit 130 to yr=1966-1971<BR/>132. Veralipride.mp.<BR/>133. methyldopa/<BR/>134. vitamin E/<BR/>135. Bellergal.mp.<BR/>136. ergotamine-phenobarbital-belladonna.mp.<BR/>137. exp Acupuncture/<BR/>138. exp Complementary therapies/<BR/>139. thinking/<BR/>140. limit 139 to yr=1970-1974<BR/>141. odors/<BR/>142. limit 141 to yr=1986-1995<BR/>143. oils, volatile/<BR/>144. limit 143 to yr=1986-1996<BR/>145. Magnetic therapy/<BR/>146. Exercise/<BR/>147. excertion/<BR/>148. limit 147 to yr=1966-1988<BR/>149. Physical fitness/<BR/>150. limit 149 to yr=1966-1988<BR/>151. or/87-150<BR/>152. 21 and 80 and 86 and 151</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2010-06-20 17:42:25 +1000" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2010-06-20 17:42:25 +1000" MODIFIED_BY="[Empty name]">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-05 17:33:24 +1100" MODIFIED_BY="[Empty name]">
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P>Host: OVID<BR/>1974 to April 2005</P>
</TH>
</TR>
<TR>
<TD>
<P>1. exp breast cancer/<BR/>2. exp neoplasms/ and medullary.mp.<BR/>3. exp fibrocystic disease of breast/<BR/>4. or/1-3<BR/>5. exp breast/<BR/>6. breast.tw.<BR/>7. 5 or 6<BR/>8. (breast adj milk).ti,ab,sh.<BR/>9. (breast adj tender$).ti,ab,sh.<BR/>10. or/8-9<BR/>11. 7 not 10<BR/>12. exp neoplasms/<BR/>13. 11 and 12<BR/>14. exp lymphedema/<BR/>15. 14 and 11<BR/>16. (breast adj25 neoplasm$).ti,ab,sh.<BR/>17. (breast adj25 cancer$).ti,ab,sh.<BR/>18. (breast adj25 tumour$).ti,ab,sh.<BR/>19. (breast adj25 tumor$).ti,ab,sh.<BR/>20. (breast adj25 carcinoma$).ti,ab,sh.<BR/>21. (breast adj25 adenocarcinoma$).ti,ab,sh.<BR/>22. (breast adj25 sarcoma$).ti,ab,sh.<BR/>23. (breast adj25 dcis).ti,ab,sh.<BR/>24. (breast adj25 ductal).ti,ab,sh.<BR/>25. (breast adj25 infiltrating).ti,ab,sh.<BR/>26. (breast adj25 intraductal).ti,ab,sh.<BR/>27. (breast adj25 lobular).ti,ab,sh.<BR/>28. (breast adj25 medullary).ti,ab,sh.<BR/>29. or/16-28<BR/>30. 4 or 13 or 15 or 29<BR/>31. exp mastectomy/<BR/>32. 30 or 31<BR/>33. exp mammary neoplasms/<BR/>34. (mammary adj25 neoplasm$).ti,ab,sh.<BR/>35. (mammary adj25 cancer$).ti,ab,sh.<BR/>36. (mammary adj25 tumour$).ti,ab,sh.<BR/>37. (mammary adj25 tumor$).ti,ab,sh.<BR/>38. (mammary adj25 carcinoma$).ti,ab,sh.<BR/>39. (mammary adj25 adenocarcinoma$).ti,ab,sh.<BR/>40. (mammary adj25 sarcoma$).ti,ab,sh.<BR/>41. (mammary adj25 dcis).ti,ab,sh.<BR/>42. (mammary adj25 ductal).ti,ab,sh.<BR/>43. (mammary adj25 infiltrating).ti,ab,sh.<BR/>44. (mammary adj25 intraductal).ti,ab,sh.<BR/>45. (mammary adj25 lobular).ti,ab,sh.<BR/>46. (mammary adj25 medullary).ti,ab,sh.<BR/>47. or/33-46<BR/>48. 32 or 47<BR/>49. exp breast self-examination/<BR/>50. (breast adj25 self$).ti,ab,sh.<BR/>51. (breast adj25 screen$).ti,ab,sh.<BR/>52. exp mammography/<BR/>53. or/48-52<BR/>54. mammograph$.tw.<BR/>55. 54 and 11<BR/>56. 53 or 55<BR/>57. exp clinical trial/<BR/>58. comparative study/<BR/>59. drug comparison/<BR/>60. major clinical study/<BR/>61. randomization/<BR/>62. crossover procedure/<BR/>63. double blind procedure/<BR/>64. single blind procedure/<BR/>65. placebo/<BR/>66. prospective study/<BR/>67. ((clinical or controlled or comparative or placebo or prospective or randomi#ed) adj3 (trial or study)).ti,ab.<BR/>68. (random$ adj7 (allocat$ or allot$ or assign$ or basis$ or divid$ or order$)).ti,ab.<BR/>69. ((singl$ or doubl$ or trebl$ or tripl$) adj7 (blind$ or mask$)).ti,ab.<BR/>70. (cross?over$ or (cross adj1 over$)).ti,ab.<BR/>71. or/57-70<BR/>72. 56 and 71<BR/>73. limit 72 to human<BR/>74. flushing/<BR/>75. hot flush/<BR/>76. flush$.ti,ab,sh.<BR/>77. flash$.ti,ab,sh.<BR/>78. vasomotor.mp.<BR/>79. vasomotor$.ti,ab,sh.<BR/>80. or/74-79<BR/>81. non hormonal therapy.mp.<BR/>82. (therapy not hormonal).mp.<BR/>83. exp serotonin uptake inhibitors/<BR/>84. serotonin reuptake inhibitors.mp.<BR/>85. norepinephrine reuptake inhibitors.mp.<BR/>86. fluoxetine/<BR/>87. sertraline/<BR/>88. paroxetine/<BR/>89. citalopram/<BR/>90. venlafaxine/<BR/>91. mirtazapine/<BR/>92. trazodone/<BR/>93. gabapentin/<BR/>94. clonidine/<BR/>95. veralipride/<BR/>96. methyldopa/<BR/>97. alpha tocopherol/<BR/>98. bellergal/<BR/>99. ergotamine-phenobarbital-belladonna.mp.<BR/>100. alternative medicine/<BR/>101. meditation/<BR/>102. yoga/<BR/>103. ayurvedic drug/<BR/>104. ayurvedic.mp.<BR/>105. acupuncture/<BR/>106. magnetic therapy.mp.<BR/>107. leisure/<BR/>108. relaxation.mp.<BR/>109. feedback system/<BR/>110. hypnosis/<BR/>111. behaviour therapy/<BR/>112. exp exercise/<BR/>113. or/81-112<BR/>114. 73 and 80 and 113</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2010-07-12 12:06:39 +1000" MODIFIED_BY="Melina Willson" NO="7">
<TITLE MODIFIED="2010-06-08 09:20:23 +1000" MODIFIED_BY="Melina Willson">WHO ICTRP Search Portal</TITLE>
<APPENDIX_BODY MODIFIED="2010-07-12 12:06:39 +1000" MODIFIED_BY="Melina Willson">
<P>
<B>Host: http://apps.who.int/trialsearch/<BR/>21 May 2010</B>
</P>
<P>Advanced search (with Recruitment set at ALL):</P>
<P>Search 1. <BR/>Condition field: breast cancer AND flush<BR/>Intervention field: hormone<BR/>Search 2. <BR/>Condition field: flush<BR/>Intervention field: hormone<BR/>Search 3. <BR/>Condition field: hot<BR/>Intervention field: hormone<BR/>Search 4. <BR/>Intervention field: breast cancer AND hot flash<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2010-03-02 07:34:57 +1100" MODIFIED_BY="[Empty name]"/>
</COCHRANE_REVIEW>